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Abstract 
Deep brain stimulation (DBS) is an established surgical therapy for movement 
disorders. The mechanisms of action of DBS remain unclear, and selection of stimulation 
parameters is a clinical challenge and can result in sub-optimal outcomes. Closed-loop 
DBS systems would use a feedback control signal for automatic adjustment of DBS 
parameters and improved therapeutic effectiveness. We hypothesized that evoked 
compound action potentials (ECAPs), generated by activated neurons in the vicinity of 
the stimulating electrode, would reveal the type and spatial extent of neural activation, 
as well as provide signatures of clinical effectiveness. The objective of this dissertation 
was to record and characterize the ECAP during DBS to determine its suitability as a 
feedback signal in closed-loop systems. The ECAP was investigated using computer 
simulation and in vivo experiments, including the first preclinical and clinical ECAP 
recordings made from the same DBS electrode implanted for stimulation.  
First, we developed DBS-ECAP recording instrumentation to reduce the stimulus 
artifact and enable high fidelity measurements of the ECAP at short latency. In vitro and 
in vivo validation experiments demonstrated the capability of the instrumentation to 
suppress the stimulus artifact, increase amplifier gain, and reduce distortion of short 
latency ECAP signals. 
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Second, we characterized ECAPs measured during thalamic DBS across 
stimulation parameters in anesthetized cats, and determined the neural origin of the 
ECAP using pharmacological interventions and a computer-based biophysical model of 
a thalamic network. This model simulated the ECAP response generated by a 
population of thalamic neurons, calculated ECAPs similar to experimental recordings, 
and indicated the relative contribution from different types of neural elements to the 
composite ECAP. Signal energy of the ECAP increased with DBS amplitude or pulse 
width, reflecting an increased extent of activation. Shorter latency, primary ECAP 
phases were generated by direct excitation of neural elements, whereas longer latency, 
secondary phases were generated by post-synaptic activation. 
Third, intraoperative studies were conducted in human subjects with thalamic 
DBS for tremor, and the ECAP and tremor responses were measured across stimulation 
parameters. ECAP recording was technically challenging due to the presence of a wide 
range of stimulus artifact magnitudes across subjects, and an electrical circuit equivalent 
model and finite element method model both suggested that glial encapsulation around 
the DBS electrode increased the artifact size. Nevertheless, high fidelity ECAPs were 
recorded from acutely and chronically implanted DBS electrodes, and the energy of 
ECAP phases was correlated with changes in tremor.  
Fourth, we used a computational model to understand how electrode design 
parameters influenced neural recording. Reducing the diameter or length of recording 
  
vi 
contacts increased the magnitude of single-unit responses, led to greater spatial 
sensitivity, and changed the relative contribution from local cells or passing axons. The 
effect of diameter or contact length varied across phases of population ECAPs, but 
ECAP signal energy increased with greater contact spacing, due to changes in the spatial 
sensitivity of the contacts. In addition, the signal increased with glial encapsulation in 
the peri-electrode space, decreased with local edema, and was unaffected by the 
physical presence of the highly conductive recording contacts. 
 It is feasible to record ECAP signals during DBS, and the correlation between 
ECAP characteristics and tremor suggests that this signal could be used in closed-loop 
DBS. This was demonstrated by implementation in simulation of a closed-loop system, 
in which a proportional-integral-derivative (PID) controller automatically adjusted DBS 
parameters to obtain a target ECAP energy value, and modified parameters in response 
to disturbances. The ECAP also provided insight into neural activation during DBS, with 
the dominant contribution to clinical ECAPs derived from excited cerebellothalamic 
fibers, suggesting that activation of these fibers is critical for DBS therapy. 
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1. Introduction: Recording neural activity to understand 
the mechanisms of deep brain stimulation and develop 
closed-loop control systems 
Deep brain stimulation (DBS) is an established surgical therapy for movement 
disorders (Benabid et al., 1991, Limousin et al., 1995, Gross and Lozano, 2000, Krauss et 
al., 2004), and is being investigated as a therapy for other neurological disorders. DBS is 
FDA-approved for treatment of the symptoms of Parkinson's disease (PD), which 
include tremor, rigidity, bradykinesia, and postural instability, essential tremor (ET), 
and dystonia. Patients may chose to undergo surgery to receive a DBS system if they 
suffer long-term complications from pharmacological treatments, such as dyskinesias, 
on-off fluctuations, or a loss of effectiveness with levodopa therapy for PD (Chou, 2007), 
or if they have treatment-resistant ET (Lyons and Pahwa, 2004). An electrode is 
implanted into a targeted region of the brain and connected via a subcutaneous wire to 
an implanted pulse generator (IPG), which delivers electrical stimulation through the 
electrode. The DBS electrode is typically implanted in the subthalamic nucleus (STN) or 
globus pallidus internus (GPi) for PD, GPi for dystonia, and the ventral intermediate 
(Vim) nucleus of the thalamus for ET. DBS is also a promising therapy for treatment of 
epilepsy (Hodaie et al., 2002), obsessive-compulsive disorder (Nuttin et al., 2003), pain 
(Kumar et al., 1997, Owen et al., 2006), and depression (Mayberg et al., 2005).  
The origins of DBS (Hariz et al., 2010) date back to the 1950s, at which time 
intraoperative electrical stimulation was used to explore brain targets prior to lesioning 
 2 
(Gildenberg, 2005). Subsequently, chronic subcortical stimulation was tested for 
treatment of psychosis (Delgado et al., 1952), then chronic pain (Hosobuchi et al., 1973, 
Mazars, 1975), epilepsy (Cooper et al., 1980, Upton et al., 1985), and finally movement 
disorders (Bechtereva et al., 1975, Cooper et al., 1980, 1982). The modern form of DBS, as 
a first-hand alternative procedure to lesioning, was introduced by Benabid and 
colleagues, who in 1987 demonstrated the efficacy of chronic DBS in the thalamus for 
patients with tremor (Benabid et al., 1987), and in 1993 used STN-DBS for PD (Pollak et 
al., 1993). The FDA approved Medtronic's DBS system for tremor in 1997, for PD in 2002, 
and for dystonia in 2003, and its long-term therapeutic effectiveness was demonstrated 
(Pahwa et al., 2006, Blomstedt et al., 2007, Hariz et al., 2008). DBS systems have now 
been implanted in over 100,000 patients worldwide. 
Despite the clinical efficacy of DBS for movement disorders, there remains a lack 
of understanding of its mechanisms of action (Grill and McIntyre, 2001, McIntyre et al., 
2004b), which limits the full development and optimization of this treatment. A better 
understanding of DBS could enhance the clinical implementation of this therapy in at 
least four ways. First, by understanding which neural elements are activated by 
stimulation and contribute to symptom reduction or side effects, the tuning of 
stimulation parameters could be optimized. Recording neural activity from the brain 
could provide insight into neural activation and therefore guide the rational selection of 
stimulation parameters. Second, an improved understanding of DBS would enable the 
 3 
design of new technologies, such as novel stimulation waveforms and electrode shapes, 
which selectively activate the neural elements that generate clinical benefit. Third, 
understanding of mechanisms could enable identification of alternative brain targets for 
treatment of movement disorders, such as the pedunculopontine (PPT) nucleus, 
peripeduncular (PPD) nucleus (Mazzone et al., 2005, Zrinzo et al., 2007), or zona incerta 
(Kitagawa et al., 2005, Plaha et al., 2006) for PD. These alternative brain targets may 
provide greater benefit or be more surgically accessible than the current targets. Finally, 
a better understanding of DBS mechanisms could accelerate the application of DBS to 
other neurological disorders beyond movement disorders. 
The purpose of the work described in this dissertation was to record and analyze 
evoked compound action potentials (ECAPs) during DBS. Such signals may have utility 
for programming stimulation parameters and provide insight to understand better the 
mechanisms of action of DBS. The approach was to record ECAPs in preclinical and 
clinical studies across stimulation parameters, use pharmacological manipulation and 
computational modeling to identify the neural origin of the recorded signal, and 
correlate the characteristics of the ECAP with the symptom response. This first chapter 
includes a summary of current approaches to parameter selection, a discussion of 
methodologies used to understand the mechanisms of DBS or to investigate rational 
selection of stimulation parameters, and an outline of the approaches used in this 
dissertation. 
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1.1 DBS parameter selection: current methods and limitations 
Following implantation of the DBS system, stimulation parameters are selected 
to meet the following three goals: 1) maximize symptom suppression, 2) minimize side 
effects, and 3) maximize the battery life of the IPG (Volkmann et al., 2002). Stimulation 
parameters include DBS amplitude, pulse duration, frequency, and contact polarity, and 
these are adjusted by an external programmer that communicates with the IPG via 
telemetry. There are over 25,000 available combinations of parameters in a typical IPG, 
but few data describing the relationships between these parameters and clinical 
outcomes (Kuncel and Grill, 2004). Consequently, the selection of stimulation 
parameters is an ad hoc process that requires a great deal of clinical expertise and often 
deprives patients of the optimal benefits of DBS. 
Guidelines have been suggested to assist programmers in selecting DBS 
parameters (Volkmann et al., 2002, Kuncel and Grill, 2004, Volkmann et al., 2006). The 
current-distance relationship states that neural activation thresholds increase with 
distance from the electrode (Ranck, 1975), and governs selection of DBS amplitude. 
Appropriate selection of DBS amplitude will activate a sufficient volume of the targeted 
brain region to generate a clinical response while minimizing spread to adjacent regions 
that can cause side effects, with a typical therapeutic range of 1-3.5 V (Volkmann et al., 
2002). Pulse width is selected on the basis of the current-duration relationship, in which 
longer pulse widths reduce activation thresholds (Ranck, 1975). The typical therapeutic 
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range is 60-210 μs/phase, and exceeding 210 μs/phase results in thresholds that are close 
to rheobase and reduces the size of the therapeutic window (Volkmann et al., 2002). 
Moreover, using a shorter pulse width is preferable to minimize charge delivery at 
threshold and thereby reduce the likelihood of electrode and tissue damage (Merrill et 
al., 2005). Medtronic IPGs deliver charge-balanced, biphasic pulses, which minimizes the 
risk of electrode and tissue damage that could result from accumulation of charge at the 
electrode-tissue interface (Kuncel and Grill, 2004). These biphasic pulses use a low-
amplitude, long-duration recharge phase so as to avoid affecting the neural excitation 
that was generated by the primary phase. For selection of DBS frequency, maximum 
clinical benefit is obtained between 130-185 Hz for PD (Limousin et al., 1995, Moro et al., 
2002, Timmermann et al., 2004, Fogelson et al., 2005) and at frequencies greater than 90 
Hz for ET (Benabid et al., 1991, Grill et al., 2004, Ushe et al., 2004, Kuncel et al., 2007), 
whereas symptoms may be exacerbated at frequencies less than 50 Hz (Birdno and Grill, 
2008). Generally, the DBS frequency is set to 130 Hz, and increased only if the patient 
has an unsatisfactory response and further increases in DBS amplitude or pulse width 
generate side effects (Volkmann et al., 2002). Finally, the contact(s) that are selected for 
stimulation generally have the best efficacy, largest therapeutic window, and lowest 
threshold for clinical benefit, which maximizes battery life (Volkmann et al., 2002, 
Volkmann et al., 2006). Monopolar stimulation is preferred due to lower thresholds 
(Pollak et al., 1998), but bipolar configurations are used to reduce current spread when 
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side effects are observed at relatively low DBS amplitudes (Volkmann et al., 2002, 
Kuncel and Grill, 2004). Finally, additional contacts are used for stimulation when a 
broader current distribution is required to generate a sufficient volume of activated 
tissue for therapeutic benefit. 
Power consumption is proportional to the product of DBS pulse width, 
frequency, and the square of the applied voltage. To extend battery life, these DBS 
parameters should be minimized, although not at the expense of therapeutic benefit. 
Importantly, older IPG models, such as Medtronic's Itrel II and Soletra, used a voltage 
doubler and tripler circuit above 3.6 V and 7.3 V, and exceeding these voltages led to a 
significant reduction in the battery life (Volkmann et al., 2002, Kuncel and Grill, 2004). 
Despite these general guidelines, the selection of stimulation parameters remains 
an empirical process that requires significant clinical expertise. DBS settings are 
programmed both after surgery and at follow-up visits (Ondo and Bronte-Stewart, 
2005), and it can take at least 3-6 months to obtain the best therapeutic outcomes 
(Bronstein et al., 2011) due to the transient micro-lesion effect (Volkmann et al., 2006), as 
well as concomitant adjustments of medications. During the first 6 months following 
implantation, patients require an average of almost 6 parameters adjustment sessions, 
and an additional 5 sessions during the subsequent 18 months (Ondo and Bronte-
Stewart, 2005). Further, each programming session takes substantial time, with the initial 
programming session typically taking 1-2 hours, and subsequent sessions 30-60 minutes. 
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Since over 40% of programmers are physicians, the need for repeated programming is 
both inconvenient and costly. 
 Furthermore, the current approach to parameter selection can deprive patients 
of the optimal benefits of stimulation. If symptom suppression is not satisfactory, simply 
increasing amplitude, pulse width, or frequency can produce delayed exacerbation of 
symptoms or side effects, and cause more rapid battery depletion (Moro et al., 2002, 
Kuncel et al., 2006, Volkmann et al., 2006, Kuncel et al., 2007). Conversely, measuring the 
steady state symptom response across a range of parameters is not feasible because 
symptoms do not respond immediately or uniformly to DBS. While the response time is 
only on the order of seconds for tremor (Beuter and Titcombe, 2003), it is on the order of 
minutes for bradykinesia and hours for gait and postural instability in PD (Temperli et 
al., 2003). Moreover, it is unclear how to program parameters when there are no overt 
responses to DBS, such as in epilepsy. Consequently, there is sub-optimal management 
of motor symptoms in movement disorders, with decreased symptom fluctuations in the 
DBS on state of only approximately 60% in PD (Witjas et al., 2007). Further, if not 
programmed correctly, side effects can result, including paresthesias (Pahwa et al., 
2006), dyskinesias (Hamani et al., 2005), hemiballism (Limousin et al., 1995, Limousin et 
al., 1996), stimulation-induced muscle contractions (Ashby et al., 1999), and cognitive 
and behavioral adverse effects (Romito and Albanese, 2010, Bronstein et al., 2011). The 
therapeutic outcome of DBS can be improved with expert reprogramming in many 
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patients (37%) complaining of sub-optimal results (Okun et al., 2005) and a majority of 
patients (55%) with long-term stable responses (Moro et al., 2006). Although patients are 
aware of the need for periodic readjustment of parameters, one study found that a 
majority (70%) was frustrated with the decreasing effectiveness of DBS prior to 
readjustment and anxious that full clinical benefit would not be restored (Perozzo et al., 
2001). 
1.2 Patient-specific models of DBS may guide parameter 
selection 
Computational modeling software (Cicerone) was developed to help guide DBS 
parameter selection, and thereby reduce the clinical burden of the current programming 
approach and optimize outcomes for patients. Cicerone estimates the volume of tissue 
activated (VTA) during DBS across stimulation parameters in a patient-specific manner, 
and identifies parameters that best localize activation to the targeted brain region 
(Frankemolle et al., 2010). This software package integrates patients' MRI and CT 
images, microelectrode recording data, and a three-dimensional brain atlas to build a 
model representing the DBS electrode within the brain. It then calculates the VTA using 
the finite element method and biophysical cable models of neural elements (Butson and 
McIntyre, 2005, Chaturvedi et al., 2010). The Cicerone-identified parameters were as 
effective in reducing PD symptoms as those identified by a clinician and reduced power 
consumption by over 50%. Further, the model parameters may have reduced cognitive 
and cognitive-motor side effects that were present with the clinically-identified 
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parameters. This patient-specific modeling platform could be used to suggest an initial 
parameter set that is modified by the clinician as necessary, and could thereby maximize 
clinical outcomes and minimize the amount of time required for parameter selection. 
However, it is unclear if this system could be used to update parameter settings after 
changes in either the disease state or the response to DBS over time. 
1.3 Recorded neural activity: improving the understanding of the 
mechanisms of DBS and potential use as a feedback control 
signal 
Neural recordings from the brain have been used to study pathological activity 
in movement disorders with and without DBS, and are being explored as feedback 
control signals for DBS implantation and parameter selection. These include single-unit 
recordings, local field potentials (LFPs), evoked compound action potentials (ECAPs), 
and neurochemical recordings. One potential use of these measurements is to 
understand which neural elements are activated during effective DBS or result in side 
effects. Second, these recordings could provide a feedback signal to assist in localizing 
the DBS electrode relative to brain structures during implantation surgery. Finally, these 
feedback signals may reflect the clinical state and help guide DBS programming, 
preferably without requiring additional hardware or changes to neurosurgery. These 
signals could be used in a closed-loop DBS system that provides automatic adjustment 
of stimulation parameters as the disease progresses (Krack et al., 2003, Deuschl et al., 
2006, Hariz et al., 2008, Weaver et al., 2012) or the response to stimulation changes over 
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time (Blomstedt et al., 2007, Priori et al., 2012, Rosa et al., 2012). The benefits of such a 
system include an elimination of the need for repeated programming sessions (Priori et 
al., 2012), improvement in clinical outcomes due to frequent parameter adjustments 
(Moro et al., 2006, Yu and Neimat, 2008, Bronstein et al., 2011), and identification of 
parameters that extend battery life (Priori et al., 2012).  
1.3.1 The theoretical basis of recording extracellular fields 
Interpretation of neural signals requires an understanding of their origin and of 
the effect of recording conditions on the measured waveforms. The extracellular fields 
measured from the brain are generated by neuronal transmembrane currents, and the 
recorded waveform is determined by the relative position of the electrode with respect 
to neuronal geometry. Neural excitation is associated with action potential propagation 
along the axon or dendrites, with an outward passive current at the leading edge, 
followed by inward Na+ current, and subsequently by outward K+ current at the trailing 
edge (Plonsey and Barr, 2007). This generates an extracellular current loop, in which 
current flows into the cell at the site of the action potential (sink), travels along the core 
of the cell, and exits at various, adjacent regions (sources) to return to the sink 
(Humphrey and Schmidt, 1991).  
Current source density (CSD) analysis can be used to understand better the 
contribution to recorded field potentials of transmembrane currents generated by a 
neuronal population (Mitzdorf, 1985). Extracellular potentials ( ) are generated by the 
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sum of contributions from current sources and sinks, and are governed by the Poisson 
equation: 
 VI )(      (Equation 1.1)
where σ is the conductivity of the extracellular medium and IV is the CSD (Plonsey and 
Barr, 2007). The sources can be represented using monopole or dipole approximations, 
for which the solution to Equation 1.1 is given by the following: 
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where Ij is the current from the source j, and rj is the distance from source j to the 
recording site (Plonsey and Barr, 2007). For the dipole source, dj is the distance 
separating the dipole sources and θ is the polar angle of the recording site relative to the 
vector formed by the dipole sources. Therefore, the recorded waveform shape is 
determined both by distance to the cell and by the location relative to neural 
morphology, varying with positioning near currents sources or sinks in the dendrites, 
axon, or soma (Holt and Koch, 1999). 
CSD analysis suggests that spatial alignment of neurons and temporal synchrony 
of their firing leads to higher amplitude extracellular potentials (Buzsaki et al., 2012, 
Lempka and McIntyre, 2013). In structures that have cytoarchitecturally regular 
structures, such as cortical pyramidal neurons whose apical dendrites lie in parallel, 
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superposition of activity is maximized and field potentials are strongest. Temporal 
synchrony is more likely to occur for relatively slow-acting events such as synaptic 
activity, so LFPs are generally thought to arise from dendritic synaptic currents. 
Moreover, it is thought that excitatory post-synaptic potentials (EPSPs) generate field 
potentials with amplitudes that are an order of magnitude greater than those of 
inhibitory post-synaptic potentials (IPSPs), due to the more shallow changes in 
transmembrane potential associated with the latter (Mitzdorf, 1985). Action potentials 
generate strong currents, but generally lead to smaller field potentials due to temporal 
dispersion, unless there is synchronous action potential generation in many neurons 
(Buzsaki et al., 2012). 
The recorded field potentials are also modulated by properties of the volume 
conductor and electrode. First, the recording electrode captures the spatial average of 
biopotentials that are present across the uninsulated contact surface (Plonsey, 1965). 
Second, low-pass filtering by dendrites and by the capacitive and inductive properties of 
the extracellular medium (Bedard et al., 2004, 2006, Buzsaki et al., 2012) results in an 
inverse relationship between the magnitude of power in recorded field potentials and 
temporal frequency. Additionally, this relationship is a consequence of there being a 
longer time window for neuronal contributions to lower frequency field potentials. 
Third, the measured waveform is high-pass filtered by the electrode-tissue interface 
(Wise and Angell, 1975). Nevertheless, a computational modeling study demonstrated 
 13 
that the interface impedance and the capacitive properties of the brain tissue had a 
negligible effect on LFPs recorded from a DBS electrode, although the former can have a 
more significant effect when recording with high impedance microelectrodes (Lempka 
and McIntyre, 2013). 
Experimental and theoretical studies have investigated the spatial limit of 
detection for different neural signals. Several studies have demonstrated that single-unit 
activity can be detected up to 100-200 µm from a neuron (Henze et al., 2000, Moffitt and 
McIntyre, 2005). Similarly, neuronal contributions to stimulus evoked field potentials in 
the 3-100 Hz band were up to 250 um from the electrode (Katzner et al., 2009). It remains 
unclear whether LFPs extend only a few hundred micrometers (Liu and Newsome, 2006, 
Katzner et al., 2009, Xing et al., 2009) or several millimeters from the source (Kreiman et 
al., 2006, Kajikawa and Schroeder, 2011, Lempka and McIntyre, 2013), and the spatial 
reach appears to depend on the neuron morphology, synapse distribution, and 
correlation in synaptic activity (Linden et al., 2011). 
1.3.2 Single-unit activity 
Pathological motor symptoms associated with PD and ET are accompanied by 
changes in neuronal activity that can be observed at the single-unit level. In addition to 
firing rate, functional brain processes are mediated by firing patterns (Bevan et al., 2002, 
Terman et al., 2002) and oscillations (Gatev et al., 2006, Uhlhaas and Singer, 2006, Wilke 
et al., 2006). Pathological increases in bursting and lower frequency oscillations in the 
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basal ganglia and thalamus (Bergman et al., 1994, Nini et al., 1995, Vitek et al., 1999, 
Deuschl et al., 2001, Levy et al., 2002, Tang et al., 2005, Hammond et al., 2007) may lead 
to inferior information processing (Rosin et al., 2011) and the manifestation of motor 
symptoms in movement disorders (Bergman et al., 1998, Wichmann et al., 1999, Magnin 
et al., 2000, Deuschl et al., 2001, Amirnovin et al., 2004). Specifically, increased tonic and 
phasic activity in the basal ganglia increases inhibition of thalamocortical neurons and 
results in akinesia and rigidity in PD (Bergman et al., 1994, Bergman et al., 1998). 
Moreover, thalamic cell bursting activity was correlated with EMG measurements 
during periods of tremor in ET and PD patients, and therefore, may drive generation of 
tremor (Lenz et al., 1988, Hua et al., 1998, Magnin et al., 2000). 
Single-unit recordings have helped to elucidate changes in network activity 
generated by DBS, and consequently, improved our understanding of the mechanisms 
of action of this therapy. The effect of single stimulation pulses on neural activity varies 
based on the region stimulated, with short duration (25 ms) neural inhibition in GPi and 
substantia nigra pars reticulata (SNr), no apparent effect in STN, and neural excitation in 
the Vim thalamus (Dostrovsky and Lozano, 2002). However, high-frequency stimulation 
in these target nuclei was consistently found to produce inhibition in recorded cell 
bodies (Dostrovsky et al., 2000, Welter et al., 2004, Meissner et al., 2005). Cellular 
inhibition was proposed to occur through activation of inhibitory afferent inputs 
(McIntyre et al., 2004b), depression of excitatory afferent input terminals (Anderson et 
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al., 2006), and/or depolarization blockade (Beurrier et al., 2001, Bikson et al., 2001). This 
result suggested that DBS generates therapeutic benefit through a lesion-like inhibitory 
effect. Conversely, other investigators demonstrated that axons were activated by high-
frequency stimulation (Hashimoto et al., 2003, Hershey et al., 2003, Zhao et al., 2004), 
and that this activity was propagated to downstream nuclei (Jech et al., 2001, Anderson 
et al., 2003, Hashimoto et al., 2003, Windels et al., 2003, Degos et al., 2005, Phillips et al., 
2006). These seemingly contradictory results were resolved by modeling studies that 
suggested the occurrence of both cell body inhibition and axonal activation (Grill and 
McIntyre, 2001, McIntyre et al., 2004b).  
Based on the strong dependence of clinical effectiveness on regularized, high 
frequency stimulation trains (Birdno et al., 2007, Birdno and Grill, 2008), an 
informational lesion hypothesis was suggested to underlie the clinical response to DBS 
(Grill et al., 2004, Kuncel et al., 2007). This theory suggests that DBS overrides 
pathological firing and replaces it with non-physiological but less pathological 
regularized firing, which gets propagated to downstream nuclei. High-frequency 
stimulation led to a reduction in the number of neurons with oscillatory behavior 
(Meissner et al., 2005), a decrease in the coefficient of variation of the cellular firing rate 
(Grill et al., 2004), and a disruption of intrinsic bursting in the basal ganglia and 
thalamus (Anderson et al., 2003, Degos et al., 2005, Birdno et al., 2007). The 
pathologically intrinsic patterns of activity were replaced by neuronal firing that was 
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regularized and time-locked to the stimulus pulse train (Hashimoto et al., 2003, Bar-Gad 
et al., 2004, Dorval et al., 2008, Xu et al., 2008, McConnell et al., 2012). Although high-
frequency stimulation can also drive somatic bursting (Welter et al., 2004) with 
interspike intervals phase-locked to the stimulation frequency or its subharmonics 
(Garcia et al., 2003, Garcia et al., 2005), this may not reach downstream nuclei due to 
collision block with antidromic action potentials generated in the axon (Johnson et al., 
2008). 
Single-unit recordings have been used successfully as a feedback control signal 
in closed-loop DBS. Rosin and colleagues recorded neuronal activity in the primary 
motor cortex (M1) of MPTP-treated primates, and delivered GPi stimulation pulses with 
80 ms latency following each neural spike (Rosin et al., 2011). In comparison to 
continuous, open-loop stimulation, closed-loop DBS more effectively alleviated 
parkinsonian motor symptoms. Further, closed-loop stimulation disrupted tremor-
related oscillatory activity in the GPi and M1 to a greater extent than continuous 
stimulation. While stimulating and recording from the same brain region would reduce 
surgical complexity in clinical translation, it was found that using GPi recordings as a 
feedback for GPi-DBS worsened motor symptoms, although adjustment of the post-
spike stimulation delay may have improved the outcome. 
Although initial results are encouraging, there exist several potential shortfalls to 
the use of single-unit recordings in closed-loop DBS systems. First, the long-term 
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stability of microelectrode recordings may be inadequate for human use (Williams et al., 
1999). Second, chronic microelectrode recording would require implantation of 
additional hardware during neurosurgery, thereby increasing surgical complexity. 
Third, chronic implantation of microelectrodes is not currently FDA-approved for 
patients with movement disorders, although microelectrode recordings are a routine 
part of the DBS electrode implant procedure to identify the targeted brain region. 
Conversely, macroelectrodes, such as contacts on the DBS electrode, are generally not 
suitable for recording activity from individual neurons. However, even it were 
technically feasible to record multi-unit spiking activity from macroelectrodes 
(Winestone et al., 2012), measuring the activity of cell bodies within the implanted 
nucleus may not be indicative of network activity during DBS (Grill and McIntyre, 2001, 
McIntyre et al., 2004b) or provide a suitable feedback signal (Rosin et al., 2011). 
1.3.3 Local field potentials 
LFPs also provide insight into brain processes under normal and pathological 
conditions, and have been investigated as a feedback control signal for DBS. The LFP 
reflects synchronous oscillatory activity from a large population of neurons (Brown and 
Williams, 2005), and may provide a surrogate marker of oscillatory activity at the single-
unit level (Creutzfeldt et al., 1966, Frost, 1968). Indeed, single-unit recordings were 
phase-locked with LFP oscillations, although not all neurons with oscillatory activity 
were coherent with the LFP (Kuhn et al., 2005, Weinberger et al., 2006). The magnitude 
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of the LFP reflects the number of oscillatory neurons and the degree of their 
synchronization (Kuhn et al., 2005, Weinberger et al., 2006, Linden et al., 2011). It is 
thought that these oscillations are pathologically elevated in PD and other neurological 
disorders (Llinas et al., 1999), and that high-frequency DBS disrupts these oscillations 
(Brown et al., 2004, Meissner et al., 2005, Silberstein et al., 2005a, Wingeier et al., 2006, 
Rosa et al., 2011) and restores more physiological firing patterns (Silberstein et al., 
2005b). 
LFP analysis is generally separated into distinct frequency bands that provide 
insight into brain function under physiological and pathological conditions, and the 
effect of DBS on these brain rhythms. Neural synchronization at low frequencies 
(approximately 4-10 Hz and including the theta band) recorded from the STN or GPi 
may be associated with dystonia (Liu et al., 2002, Silberstein et al., 2003) and tremor in 
PD (Brown et al., 2001, Brown, 2003), and thalamic oscillations may be related to tremor 
in ET and PD (Kane et al., 2009, Pedrosa et al., 2012). Further, basal ganglia activity in 
this band was elevated in PD during dyskinesias (Foffani et al., 2005, Alonso-Frech et al., 
2006, Rodriguez-Oroz et al., 2011). It has been hypothesized that low frequency basal 
ganglia activity holds the cortex in a low frequency, anti-kinetic state in PD and 
generates the muscle contractions that result in tremor (Brown, 2003). However, tremor-
related oscillations were not always observed or the most prominent feature within 
these LFPs (Brown and Williams, 2005). Furthermore, low-frequency oscillations 
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increased after administration of levodopa (Silberstein et al., 2003, Priori et al., 2004) or 
DBS (Giannicola et al., 2012a), and the extent of increase was correlated to clinical 
improvement, which contradicts the hypothesis that these oscillations are an anti-kinetic 
phenomenon. One group found that very low-frequency (1-2 Hz) oscillations increased 
in the STN after DBS was applied for a period sufficient to generate clinical 
improvement, and that this was persistent for several minutes after DBS was turned off 
(Priori et al., 2006, Rossi et al., 2008). However, rather than resulting from changes to 
network activity, this may have been caused by a reduction in the impedance of the 
electrode-tissue interface after stimulation, and a corresponding increase in the 
contribution of blood pressure-related tissue pulsation to the measured signal (Priori et 
al., 2006, Rosa et al., 2010). 
The most commonly studied LFPs are in the beta band (13-35 Hz) due to their 
seemingly close reflection of the PD motor state, including dyskinesias (Silberstein et al., 
2005a), bradykinesia, and rigidity (Kuhn et al., 2006, Ray et al., 2008, Kuhn et al., 2009, 
Pogosyan et al., 2010). Beta oscillations appear to reflect an anti-kinetic state, as beta 
power decreased in the STN and GPi during movement preparation and execution 
(Cassidy et al., 2002, Levy et al., 2002, Priori et al., 2002, Kuhn et al., 2004, Williams et al., 
2005). In patients with PD, beta synchronization in the STN was elevated (Bronte-
Stewart et al., 2009), particularly the low beta band (13-20 Hz) in the absence of 
dopamine (Priori et al., 2004, Marceglia et al., 2007), and which may have been driven by 
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the cortex (Marsden et al., 2001, Levy et al., 2002, Williams et al., 2002). Short intervals of 
STN-DBS reduced beta activity immediately after stimulation (Brown et al., 2004, 
Wingeier et al., 2006, Bronte-Stewart et al., 2009), similar to the effect of dopaminergic 
therapy (Brown et al., 2001, Silberstein et al., 2003, Priori et al., 2004, Alonso-Frech et al., 
2006, Ray et al., 2008, Kuhn et al., 2009). However, prolonged delivery of DBS sufficient 
to generate clinical improvement that was sustained for several minutes after DBS was 
turned off did not produce significant changes in beta after DBS (Foffani et al., 2006). 
Additionally, STN beta oscillations were not well correlated to tremor scores (Kuhn et 
al., 2006, Weinberger et al., 2009), although 8-27 Hz LFP oscillations in the Vim thalamus 
were coherent with oscillatory muscle contractions in subjects with tremor (Marsden et 
al., 2000). Other disadvantages of using the beta band as the only marker of the PD 
motor state include the fact that these oscillations were not easily detectable in all PD 
patients (Giannicola et al., 2010), and were expressed differently across genders despite 
similar clinical manifestations of the disease (Marceglia et al., 2006). Alternatively, the 
ratio of low frequency power to beta band power may be a more useful indicator of 
pathological STN activity in PD (Giannicola et al., 2012b). 
Two other LFP bands that have been investigated are gamma (60-80 Hz) and 
very high frequencies (around 250-350 Hz) (Priori et al., 2012). Gamma synchronization 
within the STN-GPi-cortical structural loop was observed in PD after dopaminergic 
treatment (Brown et al., 2001, Cassidy et al., 2002, Williams et al., 2002). Activity in this 
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band appears to be pro-kinetic, increasing before and during voluntary movement 
(Cassidy et al., 2002), and increasing gamma activity was correlated with greater PD 
symptom reduction following dopaminergic treatment (Kuhn et al., 2006). There is a 
reciprocal relationship between beta and gamma frequencies (Cassidy et al., 2002), and 
in untreated PD the beta activity may suppress gamma activity in the basal ganglia and 
contribute to the manifestation of bradykinesia (Brown and Marsden, 1998, Brown, 
2003). Lastly, very high frequency LFP activity can be recorded from the STN in persons 
with and without PD (Danish et al., 2007), and increases in amplitude during voluntary 
movement (Foffani et al., 2003) and following administration of levodopa (Foffani et al., 
2003, Lopez-Azcarate et al., 2010). It has been proposed that very high frequency 
oscillations are required for functional brain processes within the basal ganglia, and that 
high frequency stimulation could serve as a sub-harmonic drive of this activity (Foffani 
et al., 2003). 
LFPs can be recorded from the DBS electrode, and their long-term stability was 
investigated. In the acute stage after DBS implantation, the peri-electrode space is filled 
with extracellular fluid (Yousif et al., 2008b), and in the chronic stage 6-8 weeks post-
implantation this gets replaced with a glial scar (Griffith and Humphrey, 2006, Nielsen 
et al., 2007, Sun et al., 2008). The corresponding transition at the electrode-tissue 
interface led to reductions in the amplitude of the low frequency LFP band over the first 
30 days (Yousif et al., 2008b, Rosa et al., 2010), although this was stabilized by 7 years 
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(Giannicola et al., 2012b). Conversely, beta band LFPs recorded at 30 days and 7 years 
after implant were similar to those recorded in the acute stage, and had comparable 
responses to DBS (Rosa et al., 2010, Rosa et al., 2011, Giannicola et al., 2012b).  
There exist potential applications in functional neurosurgery and closed-loop 
DBS systems for LFP signal recordings. During DBS electrode implantation in the STN, 
the contact pair with the greatest beta activity was typically well-positioned within the 
STN, and this pair was independently chosen for chronic stimulation (Chen et al., 2006, 
Miyagi et al., 2009, Holdefer et al., 2010, Yoshida et al., 2010). Further, the therapeutic 
stimulation voltage was correlated with the distance between the contact used for 
stimulation and the depth of peak beta activity (Yoshida et al., 2010), and improvements 
in clinical symptoms with STN-DBS were inversely related to beta power in the off 
condition (Ray et al., 2008). A commercial, implantable interface was developed that 
enables simultaneous stimulation and recording of LFPs (Rouse et al., 2011) to explore 
the feasibility of a closed-loop DBS system for PD (Stanslaski et al., 2009) and epilepsy 
(Stanslaski et al., 2012). One LFP-based closed-loop approach entails triggering 
stimulation to changes to LFP bands, which were significantly different under tremulous 
and non-tremulous conditions and could be differentiated from movement-related 
changes (Burgess et al., 2010). This triggered stimulation system could conserve battery 
life compared to continuous stimulation. The feasibility of LFP-based closed-loop 
systems was demonstrated in computational models using an adaptive minimum 
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variance controller (Santaniello et al., 2011) or variations of the proportional-integral-
derivative (PID) controller (Guo and Rubin, 2011, Gorzelic et al., 2013). 
There are at least two underlying limitations to LFP-based closed-loop systems 
that still need to be addressed. First, a direct causality between LFP activity and clinical 
symptoms must be identified (Brown and Williams, 2005). These pathological 
oscillations may not provide a bidirectional relationship with clinical symptoms if they 
are instead an epiphenomenon reflective of the movement disorder (Priori et al., 2012). 
However, recent work demonstrated linear and non-linear causal relationships between 
tremor and both theta and broadband (>2 Hz) LFPs in the STN and Vim (Smirnov et al., 
2008, Tass et al., 2010). Second, it is possible that LFPs recorded from the DBS electrode 
may not have a local origin, but instead result from volume conduction (Wennberg and 
Lozano, 2003, Brown and Williams, 2005, Linden et al., 2011). Although the use of 
differential recording can minimize the amplitude of non-local sources (Brown and 
Williams, 2005), the local nature of the LFP signal must be verified by establishing 
relationships between LFPs and local neuronal activity (Buzsaki et al., 2012). 
1.3.4 Evoked compound action potentials 
Measurement of ECAPs during electrical stimulation was used to probe neural 
circuitry and has been proposed as an intraoperative method to localize the DBS 
electrode. This response is generated by the synchronous activation of a population of 
neurons near the recording electrode, resulting in the generation of transmembrane 
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currents in activated neurons that create recordable voltages. ECAP recordings have 
been used to investigate connections within the Papez circuit and to explore the 
feasibility of modulating activity in the hippocampus (HC) with delivery of DBS in the 
anterior nucleus (AN) of the thalamus for the treatment of epilepsy (Stypulkowski et al., 
2011). Using reciprocal stimulation and recording in the HC and AN thalamus, it was 
found that the characteristics of the ECAPs were dependent on the location of the 
stimulating electrode as well as the DBS amplitude and frequency. In another 
application, cortico-STN pathways were probed through measurement of EEG-based 
ECAPs from the frontocentral cortex during STN stimulation (Rosa et al., 2012). Studies 
have shown that these cortical responses were not simply DBS-related epiphenomena, 
but instead reflected changes in cortical excitability (Pierantozzi et al., 1999, Airaksinen 
et al., 2011, Devergnas and Wichmann, 2011). 
Somatosensory evoked potentials (SEPs) were recorded during stimulation of the 
median, tibial, or digital nerves and may provide clinical utility (Valls-Sole et al., 2008). 
It is thought that SEPs recorded from DBS electrodes in the Vim were generated by 
EPSPs in the ventral caudal (Vc) nucleus of the thalamus (Hanajima et al., 2004), and that 
those recorded from the STN resulted either from volume conduction from non-local 
sources (Hanajima et al., 2004, Valls-Sole et al., 2008), muscle afferent inputs, or thalamo-
STN projections (Pesenti et al., 2003). SEPs could be recorded during intraoperative DBS 
electrode implantation within the thalamus to enable determination of the electrode 
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position relative to the sensory pathway, where the response would be maximal (Valls-
Sole et al., 2008). The electrode could also be localized with respect to the horizontal 
position about the posterior commissure, at which there is a polarity phase reversal of 
the SEP response (Hanajima et al., 2004). 
1.3.5 Neurochemical recordings 
Another neural signal demonstrating potential for use in closed-loop DBS 
systems is derived from neurochemical recordings. The wireless instantaneous 
neurotransmitter concentration sensor system allows for electrochemical dopamine and 
glutamate measurement using amperometry and fast-scan cyclic voltammetry (Lee et al., 
2009). A probe was designed with interleaved stimulation and glutamate recording 
electrodes near the electrode tip for implantation into the STN, and dopamine recording 
electrodes located more dorsally on the electrode shaft for implantation in the striatum. 
In addition to providing guidance on DBS placement within the STN, which receives 
glutamatergic inputs from the cortex and PPT, neurochemical feedback from the STN 
and striatum could provide guidance for parameter adjustment to maintain optimal 
neurotransmitter levels. The basis for this feedback system is the dopamine release 
hypothesis, which asserts that the clinical benefit of STN-DBS is derived from activation 
of surviving nigrostriatal dopaminergic neurons, generating striatal dopamine release 
and reversing motor deficits. However, this theory has not yet been fully validated, and 
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the proposed neurotransmitter recording methodology and electrode design have not 
been approved for clinical use. 
1.4 A non-neuronal feedback signal: application of symptomatic 
surface tremor recordings in closed-loop DBS 
The use of surface EMG or accelerometry recordings also shows promise as a 
biophysical feedback signal for closed-loop systems (Shukla et al., 2012). Low frequency 
EMG activity was used to reliably predict the onset of tremor prior to its visual 
manifestation (Graupe et al., 2010, Basu et al., 2011). A 20 s stimulation train was 
triggered by the presence of EMG activity, resulting in a mean tremor-free period of 20 s 
after DBS was turned off (Graupe et al., 2010). This technique could potentially result in 
stimulation being off for almost half the time compared to continuous stimulation, which 
would extend battery life considerably. The disadvantage of this approach is that the 
patient would need to continuously wear a surface EMG electrode or accelerometer, or 
additional hardware would need to be surgically implanted to obtain these 
measurements. 
1.5 Investigating ECAPs as a feedback control signal for 
selection of stimulation settings 
While ECAPs have been recorded previously from the DBS electrode, they have 
not been explored as a feedback control signal for programming stimulation parameters 
in DBS systems. Nevertheless, they have been used for this purpose in cochlear 
implants, where ECAPs were recorded from non-stimulating contacts on the electrode 
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(Brown and Abbas, 1990, Miller et al., 2008). Taking a similar recording approach with 
the four-contact DBS lead, the measured signal would be a spatial average of the 
potentials generated by individual neurons near the electrode. It was therefore expected 
that the ECAP generated during DBS could provide a population view of the number 
and type of activated neural elements. 
1.5.1 Use of ECAPs in cochlear implants 
Cochlear implants are a treatment option for persons with sensorineural hearing 
loss, in which cochlear hair cells die due to congenital or environmental factors 
(Ramsden, 2002, Rauschecker and Shannon, 2002, Zeng, 2004, Middlebrooks et al., 2005). 
A multi-contact electrode is inserted into the cochlea and rests along the cochlear nerve, 
applying stimulation in a tonotopic fashion according to the sounds recorded by an 
external microphone. Cochlear implants have demonstrated excellent clinical 
effectiveness (Bond et al., 2009), and recent work has focused on using recorded ECAPs 
to assist in programming stimulation parameters. 
The ECAP signal represents the summation of potentials generated by 
synchronous activation of nerve fibers within the cochlear nerve (Briaire and Frijns, 
2005), and can have amplitudes as large as 1.5 mV and latencies as short as 0.2-0.4 ms 
(Jeon et al., 2010). Computational models suggested that the ECAP magnitude increases 
with the number and size of single fiber action potentials (SFAPs), and to a lesser extent 
the synchrony of SFAPs, whereas the duration of the ECAP is determined by the 
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duration and synchrony of the SFAPs (Rubinstein, 2004, Briaire and Frijns, 2005). The 
amplitude can, to a first approximation, be assumed proportional to the number of 
activated nerve fibers, and the recorded waveform is weighted towards the closest fibers 
(Miller et al., 2008). Further, the ECAP magnitude was greatest when the recording 
contact was closest to the stimulation contact, although this also generated a large 
stimulus artifact that could overlap the ECAP and make signal analysis more difficult 
(Miller et al., 2008). Finally, the ECAP amplitude and the slope of the ECAP growth 
function (ECAP magnitude versus stimulation amplitude) are believed to depend on the 
size of the surviving neural population (Hall, 1990) and the position of the electrode 
relative to the nerve (Miller et al., 1998). 
The ECAP signal characteristics vary with the applied stimulation waveform 
shape, polarity, amplitude, and frequency. Charge-balanced, biphasic waveforms 
produced higher ECAP thresholds than monophasic waveforms (Miller et al., 2001b). 
This indicated that a high-amplitude recharge phase can affect activation of nerve fibers 
(van den Honert and Mortimer, 1979), and when possible should be distributed into 
several shorter duration pulses or delayed after the primary stimulation phase. The 
stimulation polarity also had an effect on the amplitude and latency of the ECAP 
response, although the direction of this effect varied with the species tested (Miller et al., 
1998). The effect of polarity may have resulted from the orientation of nerve fibers 
relative to the electrode and/or neural degeneration of peripheral processes (Macherey et 
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al., 2008, van Wieringen et al., 2008). Increasing stimulation amplitude initially 
generated increases in ECAP magnitude before eventually reversing (Miller et al., 1998, 
Matsuoka et al., 2001, Westen et al., 2011), possibly due to changes in the site of 
excitation of a sub-population of nerve fibers (Briaire and Frijns, 2005). Finally, 
increasing stimulation frequency reduced ECAP amplitudes, beginning at frequencies as 
low as 250 Hz, resulting from neural refractoriness or adaptation (Miller et al., 2008). 
The use of ECAPs has been successfully translated to the clinic for programming 
of stimulation parameters in cochlear implants. Neural response telemetry and neural 
response imaging, developed by Cochlear Ltd. and Advanced Bionics Corp., 
respectively, allow for easy acquisition of the ECAP signal in human patients. While 
statistically significant correlations were demonstrated between ECAP threshold and 
perceptional measures, such as the thresholds for an audible response, most comfortable 
level, and maximum comfortable level, these correlations were not strong (Miller et al., 
2008, Jeon et al., 2010). Therefore, their use has been limited to locating general 
stimulation level contours, and must still be supplemented by perceptional data 
measures to identify parameters that generate robust therapeutic results (Briaire and 
Frijns, 2005, Jeon et al., 2010). Further, the quality of the ECAP recording and the size of 
the stimulus artifact varied substantially across subjects (Miller et al., 2008). These issues 
have limited the development of a closed-loop system that uses ECAPs alone as the 
feedback control signal. Nevertheless, for infants or persons with physical or 
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developmental impairments where behavioral feedback is not available, the ECAP may 
provide the only reliable method to ensure that the stimulation level is perceptible 
(Hughes et al., 2000, Miller et al., 2008). Other clinical applications of the ECAP include 
testing the integrity of the implant (Rubinstein, 2004), identifying redundant or 
interacting electrodes (Boex et al., 2003), and comparing the effectiveness of novel 
stimulation paradigms (Miller et al., 2008). The ECAP can also be used to identify 
changes in neural responses (Miller et al., 2008), measure cell survival (Hall, 1990), and 
better understand cochlear neurophysiology, such as the refractory period (Miller et al., 
2001a). The former would be critical in providing continuing clinical benefit as the 
disease progressed over time. 
1.5.2 Application of ECAPs in DBS 
Full development of a closed-loop DBS system has not yet been accomplished, 
and the ECAP shows potential for use as a feedback control signal. Due to temporal 
synchronization of activity generated by each DBS pulse, we hypothesized that a robust 
ECAP response could be recorded near the electrode. Further, we hypothesized the 
presence of ECAP signatures of clinical effectiveness that would indicate sufficient 
activation of the appropriate types of neural elements necessary for therapeutic benefit. 
Recording ECAPs from non-stimulating contacts on the DBS electrode eliminates 
requirements for additional hardware or changes to the neurosurgical approach. 
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Therefore, the ECAP may provide a suitable feedback control signal for DBS parameter 
selection and in closed-loop DBS systems. 
1.6 Dissertation objectives and organization 
The data presented above suggest that neural activity recorded during DBS can 
be used to guide the selection of DBS settings, reducing the clinical burden of parameter 
selection and optimizing patient outcomes. The successful clinical implementation of 
ECAP recording in cochlear implants led us to posit that ECAPs could provide insight 
into neural activation during DBS and thereby assist in selection of stimulation 
amplitude, pulse width, frequency, and contact configuration. The purpose of this work 
was to explore the feasibility of ECAP recording and the suitability of this signal for 
parameter selection. The approach was to develop instrumentation to suppress the 
stimulus artifact and enable high-fidelity ECAP recording, understand the neural 
contribution to the ECAP through coupled preclinical experiments and computational 
models, establish correlations between signal characteristics and motor symptom 
responses in clinical experiments, and investigate the effect of the DBS electrode and 
recording conditions on the measured response. This work focused on ECAP recording 
during Vim-DBS for treatment of movement disorders, although this could be 
subsequently extended to other brain targets and neurological disorders. Results from 
these studies provide insight both into the potential use of ECAPs in DBS programming 
as well as the mechanisms of action of DBS. 
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The chapters of this dissertation are organized and formatted as publishable 
manuscripts, with each chapter addressing one of the following main objectives. 
1.6.1 Recording evoked potentials during deep brain stimulation: 
development and validation of instrumentation to suppress the 
stimulus artifact 
In Chapter 2, we discuss the development and validation of instrumentation 
used to record ECAPs during DBS. Our approach was to record ECAP signals using 
instrumentation designed to suppress the stimulus artifact. In a conventional amplifier 
system, the artifact can generate amplifier saturation at high gains and distort the ECAP 
signal. To prevent amplifier saturation, our recording instrumentation made use of a 
series of amplifier stages and several additional circuit elements. The performance of 
this instrumentation was assessed through in vitro experiments, in which mock ECAP 
signals were recorded in the presence of a stimulus artifact to characterize the input-
output fidelity of the recording instrumentation. We also assessed whether ECAPs could 
be recorded in vivo during thalamic DBS in the cat without contamination by the artifact. 
Finally, we used an electrical circuit equivalent model to understand better the sources 
of the artifact and its reduction by the instrumentation circuit elements. The results 
presented in this chapter were published (Kent and Grill, 2012). 
1.6.2 Neural origin of evoked potentials during deep brain stimulation 
The objectives of the experiments in Chapter 3 were to measure in vivo ECAP 
signals during thalamic DBS in the cat and to determine the neural origin of the signals 
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using pharmacological interventions and a computational model. We assessed how 
ECAP characteristics were dependent on stimulation parameters (amplitude, pulse 
width, frequency, and contact configuration), electrode position, and the presence of 
pharmacological blockers. In addition, we used a computational model of thalamic DBS 
to calculate an ECAP response, and compared this to the experimentally recorded signal. 
The model allowed us to investigate the contribution to the ECAP of different neural 
elements, including pre-synaptic axons, local cells, and passing axons, activated directly 
by stimulation or through post-synaptic mechanisms. This study demonstrated the 
insight provided by the ECAP signal into the type and extent of neural activation during 
DBS. The results presented in this chapter were published (Kent and Grill, 2013). 
1.6.3 Measurement of evoked potentials during thalamic deep brain 
stimulation 
The purpose of the experiments in Chapter 4 was to assess the feasibility of 
recording ECAPs in the clinical setting, identify the origin of the ECAP and any stimulus 
artifact, and correlate the ECAP characteristics with the efficacy of DBS treatment. We 
quantified both the ECAP response and tremor symptoms in human subjects with 
movement disorders as a function of the amplitude, frequency, and polarity of thalamic 
DBS. These experiments could not be accomplished with the clinically implanted pulse 
generator, and we used an intraoperative setting that allowed for direct connection of 
our recording instrumentation to the DBS brain lead during electrode implantation or 
IPG replacement surgeries. Additionally, we used computational models, including a 
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modified version of the thalamic DBS model from Chapter 3, to investigate the types of 
elements contributing to the ECAP and the role of local impedance on the size of the 
stimulus artifact. The results of this study allowed us to identify ECAP signatures of 
clinical effectiveness, evaluate the suitability of using ECAPs as a feedback signal for 
DBS programming, and understand better the mechanisms of action of DBS. 
1.6.4 Analysis of electrode characteristics for neural recording during 
deep brain stimulation 
In Chapter 5, we determined how single-unit evoked responses, as well as 
population ECAP and LFP signals, were affected by the presence and geometry of the 
DBS electrode, as well as changes in the composition of the peri-electrode space. First, 
the model from Chapter 4 was modified to determine how the signals were modulated 
by the high conductivity of the recording contacts. Second, we modified the model to 
analyze how the geometry of the electrode affected the recorded potentials. This allowed 
us to identify specifications for electrode designs with superior recording capabilities. 
Finally, we analyzed how signal characteristics would be expected to change under 
acute and chronic recording conditions by adjusting conductivity in the peri-electrode 
space. The results from this modeling study informed recording conditions and 
electrode design for improved neural recording fidelity. 
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1.6.5 Closed-loop deep brain stimulation based on evoked compound 
action potentials: a simulation analysis 
In Appendix A, we implemented in the computational model from Chapter 3 an 
ECAP-based closed-loop DBS system. We used a PID controller and its variants to adjust 
automatically DBS amplitude and/or pulse width and thereby maintain ECAP signal 
energy near a target value. The fraction of thalamocortical soma transmembrane 
potential power in the burst-driver band (4.8-6.8 Hz) served as a proxy for tremor 
magnitude (Birdno et al., 2012), and was used to select the target ECAP value. After 
steady-state was reached, disturbances were introduced that affected the bursting 
characteristics of thalamocortical neurons and the DBS-generated potentials via glial 
encapsulation, to investigate the response of this closed-loop system compared to 
continuous, open-loop DBS. This study enabled evaluation of the feasibility of an ECAP-
based closed-loop DBS system. 
1.6.6 Comparison of local field potential and tremor spectrograms  
In Appendix B, we compared theta and beta band LFPs recorded clinically from 
the DBS brain lead with the onset and amplitude of tremor. Based on literature, we 
hypothesized that an increase in theta band power or suppression of beta band power 
would be concurrent with tremor. LFPs and tremor were measured in the absence of 
stimulation using the same instrumentation and intraoperative clinical setup from 
Chapter 4, and with subjects holding their arm in different positions to evoke tremor 
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with various amplitudes and durations. We studied frequency-time spectrograms for 
temporal association analysis. 
1.6.7 Investigating a harmaline tremor model in anesthetized cats  
In Appendix C, we attempted to generate tremor in anesthetized cats via 
harmaline administration, for potential use in a preclinical study investigating the 
correlation between ECAP characteristics and motor symptoms during DBS. In 
literature, harmaline tremor was typically generated in awake or decerebrated animals. 
We tested different anesthesia regimens, harmaline formulations and dosages, and body 
positions for the manifestation of tremor. 
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2. Recording evoked potentials during deep brain 
stimulation: development and validation of 
instrumentation to suppress the stimulus artifact 
This chapter has been previously published and is used with permission (Kent 
and Grill, 2012). 
2.1 Introduction 
Deep brain stimulation (DBS) is a surgical therapy to treat medically refractory 
movement disorders, such as essential tremor (ET) (Benabid et al., 1991, Pahwa et al., 
2006) and Parkinson's disease (PD) (Benabid et al., 1994), as well as other neurological 
disorders including epilepsy (Hodaie et al., 2002). The DBS electrode is implanted in the 
ventral intermediate (Vim) nucleus of the thalamus for tremor and the subthalamic 
nucleus (STN) or internal segment of the globus pallidus (GPi) for PD. An implantable 
pulse generator (IPG) is connected to the electrode via a subcutaneous wire and delivers 
high frequency stimulation to the targeted brain region. Following implantation, the 
parameters of stimulation, including voltage, frequency, and pulse width are selected to 
produce symptom suppression (Kuncel and Grill, 2004). 
Current approaches to the selection of stimulation parameters are a significant 
clinical burden and improper programming may deprive patients of the optimal benefits 
of DBS. There are over 25,000 available combinations of stimulation voltage, frequency, 
and pulse width in a typical IPG (Medtronic Soletra 7426), but few data describing the 
relationships between stimulation parameters and clinical outcomes (Kuncel and Grill, 
 38 
2004). Further, because symptoms do not respond immediately or uniformly to DBS 
(Temperli et al., 2003), it is not feasible to measure the steady-state symptom response to 
a wide range of stimulation parameters, as required to identify the most effective 
settings. The time course of response to DBS is on the order of seconds for tremor 
(Beuter and Titcombe, 2003), but minutes for bradykinesia (Temperli et al., 2003), 
making programming more challenging for the latter. Moreover, it is unclear how to 
select parameters when there are no immediate or overt responses to stimulation, such 
as for epilepsy. Consequently, there are typically a large number of parameter 
adjustments necessary at follow-up visits, making programming time-consuming and 
costly (Ondo and Bronte-Stewart, 2005), and many patients spend appreciable time with 
sub-optimal DBS treatment (Okun et al., 2005, Moro et al., 2006). 
Measuring neural activity during DBS may provide a means for rational selection 
of stimulation parameters. One strategy records ongoing EEG-like brain rhythms known 
as local field potentials (LFPs), which are V-level signals reflecting synchronized neural 
activity (Marceglia et al., 2007). For example, elevated theta oscillations (4-7 Hz) are 
observed within the thalamus of ET subjects at the characteristic frequency of 
pathological tremor (Kane et al., 2009), and elevated beta frequency power (13-35 Hz) is 
present within the STN and GPi of PD subjects (Brown and Williams, 2005). LFPs are 
modulated following treatment with DBS, suggesting that clinical efficacy is dependent 
on the disruption of pathological synchronization (Rossi et al., 2008, Bronte-Stewart et 
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al., 2009). However, a direct causal link between LFP activity measured during DBS and 
the corresponding motor symptoms has not yet been identified (Brown and Williams, 
2005). 
We propose to record electrically evoked compound action potentials (ECAPs) 
during DBS, providing insight into the activity of neurons directly affected by 
stimulation. Each DBS pulse activates an ensemble of neurons near the electrode. 
Transmembrane currents generated during activation of individual neural elements 
create voltages that can be recorded from non-stimulating contacts on the DBS electrode. 
The characteristics of the ECAP are expected to depend on the type and spatial extent of 
neural element activation during DBS. The ECAP could thus provide signatures of 
clinical effectiveness that correspond to sufficient activation of the appropriate type(s) of 
neural elements (Kuncel et al., 2007), and could be used to tune stimulation parameters 
during DBS programming sessions. An analogous ECAP recording strategy has been 
used during cochlear nerve stimulation as a feedback signal for programming cochlear 
implants (Miller et al., 2008, Jeon et al., 2010). The ECAP could also be used as a 
feedback control signal in closed-loop DBS systems that provide automated, periodic 
tuning of stimulation parameters to respond to patient needs. 
The purpose of this study was to develop and evaluate instrumentation to record 
ECAPs during DBS. Recording the ECAP is challenging due to the large stimulus artifact 
that can cause amplifier saturation and mask the ECAP signal (McGill et al., 1982, Rossi 
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et al., 2007). Available techniques to remove the stimulus artifact are inadequate for 
ECAP recording during DBS. Several techniques rely on signal processing strategies, 
including curve fitting (Wagenaar and Potter, 2002), template subtraction (Hashimoto et 
al., 2002), polarity averaging (Brown and Abbas, 1990), and masker-probe paradigms 
(Miller et al., 2000). Although several of these strategies have been used with some 
success in cochlear nerve ECAP recordings (Miller et al., 1999, Miller et al., 2000, Alvarez 
et al., 2007), they are performed after the amplification stage and thus limit the gain that 
can be used without amplifier saturation. Hardware methods are also used to reduce the 
artifact, including signal filtering for DBS LFP recordings (Rossi et al., 2007), but this 
requires separation of the artifact and physiological signal in the frequency domain. 
Alternatively, sample-and-hold amplifiers (Babb et al., 1978) have enabled artifact-free 
recording from stimulating electrodes within 2 ms after the stimulation pulse (Jimbo et 
al., 2003, Blum et al., 2007), though have exhibited inconsistent performance (Grumet et 
al., 2000). 
We sought to develop instrumentation that could reduce the artifact during the 
amplification stage and thereby enable high gain recording of ECAPs. The performance 
of this instrumentation was assessed through in vitro experiments, in which mock 
ECAPs were recorded in the presence of a stimulus artifact to characterize the input-
output fidelity of the system. The instrumentation was then used to demonstrate that 
ECAPs could be recorded in vivo from the thalamus of the cat, with signal characteristics 
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dependent on stimulation parameters. Finally, an electrical circuit equivalent model was 
developed to determine both the sources of the stimulus artifact recorded during the in 
vitro and in vivo experiments and the mechanisms of artifact reduction by the 
instrumentation. Preliminary results of this study were presented in a conference paper 
(Kent and Grill, 2011).  
2.2 Methods 
The design objective for the instrumentation was to make high fidelity ECAP 
recordings in the presence of a stimulus artifact. We used differential recordings from 
non-stimulating contacts on the DBS electrode to eliminate the need for additional 
recording electrodes and ensure that the recording contacts were near the neurons 
activated by stimulation. We sought to limit the artifact magnitude such that sufficient 
amplifier gain could be used without saturation, and to limit the artifact duration to 
avoid distorting short latency ECAPs. The instrumentation combined battery-powered 
biopotential amplifiers in a serial configuration with diode clamps, amplifier blanking, 
and a relay at the stimulator. In vitro and in vivo experiments were conducted to 
characterize the ability to limit the size of the stimulus artifact, enable higher gains 
without amplifier saturation, and record ECAPs with high fidelity. 
2.2.1 In vitro experimental setup 
We used an in vitro setup to reproduce the experimental conditions of the DBS 
electrode within the brain (Fig. 2.1A) (Rossi et al., 2007). A DBS electrode was immersed  
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Figure 2.1: Schematic of the experimental setups used to record ECAPs during 
DBS. A: For in vitro testing, the DBS electrode, tungsten microelectrodes, Ag/AgCl 
recording circuit reference electrode, and counter electrode were immersed in a saline 
bath. The microelectrodes were positioned on either side of the DBS electrode to 
deliver the mock ECAP (mECAP). B: For in vivo testing, the mini DBS electrode was 
implanted through a guide tube into the ventrolateral (VL) nucleus of the thalamus in 
an anesthetized cat. We used a stainless steel retractor placed in the ipsilateral chest 
muscle as the counter electrode, and a Ag/AgCl electrode placed on the back of the 
neck as the recording circuit reference. 
in a saline bath (137 mM NaCl) and was used to deliver monopolar or bipolar 
stimulation, with two of the non-stimulating contacts connected to the recording system. 
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Two DBS electrodes were tested: a clinical DBS electrode (Model 3387, Medtronic) and a 
custom mini DBS electrode (NuMed). The clinical DBS electrode had a lead body 
diameter of 1.27 mm, and four contacts of 1.5 mm height separated by 1.5 mm spacing. 
The mini DBS electrode, which was also used in the subsequent in vivo experiment, had 
a lead body diameter of 0.625 mm, and four contacts of 0.5 mm height separated by 0.5 
mm spacing. Each DBS pulse triggered generation of a mock ECAP (mECAP), 
synthesized by a waveform generator (Model 33120A, Agilent) as a single cycle of 
sinusoidal current and delivered by a pair of tungsten microelectrodes near the DBS 
electrode. Given that the bulk of the power in the physiological ECAP frequency 
spectrum is in the 100 Hz to 4 kHz band, we used a 4 kHz mECAP sinusoid (0.25 ms 
duration), which would be most challenging to record with high fidelity due to the short 
signal duration. A helical stainless steel wire was used as the counter electrode for 
monopolar stimulation configurations, and a Ag/AgCl electrode (Model RE-5B, BASi) 
was used as the recording circuit reference. A custom program written in LabView 
(National Instruments) controlled delivery of DBS pulses, trigger pulses for the mECAP, 
timing of digital outputs to operate components in the recording instrumentation, and 
sampling of the signal (80 kHz sampling rate). 
2.2.2 Testing artifact reduction and recording fidelity 
Using the in vitro setup, we recorded the mECAP signal in the presence of a 
stimulus artifact across various stimulation parameters, DBS contact configurations, and 
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recording system configurations. Charge-balanced, biphasic DBS was applied with 
clinically relevant stimulation parameters of 1-3 V amplitude, 50-500 s/phase pulse 
width (symmetric and asymmetric pulses), 100 Hz frequency, and cathodic-phase first 
polarity. Three different contact configurations were used for stimulation and recording, 
with contacts designated 0-1-2-3 in the ventral-to-dorsal direction: monopolar 
stimulation with either symmetrical recording contacts (monopolar symmetric: 1+ 
stimulation, 0+/2- recording) or asymmetrical recording contacts (monopolar asymmetric: 
0+ stimulation, 1+/2- recording), as well as bipolar stimulation (bipolar: 1+/2- stimulation, 
0+/3- recording). The parameters for the mECAP were 0.1-2 ms latency and 0.1-0.5 mA 
peak-to-peak (P-P) input amplitude, which generated recorded amplitudes of 0.18-0.88 
mVP-P in the monopolar symmetric configuration. We recorded these signals both with 
and without the circuit components used to suppress the artifact, as well as with a single 
commercial biopotential amplifier (SR560, Stanford Research Systems). The extent of 
artifact reduction between recording systems was quantified by the change in amplifier 
gain that could be achieved without amplifier saturation and by distortion of the 
mECAP signal. 
The signals recorded across these stimulation and recording conditions were 
analyzed to quantify mECAP distortion. For each trial, we collected a raw data set 
consisting of stimulus artifact and mECAP measurements for 10 s. Due to the small 
magnitude of the mECAPs, stimulus-triggered averaging was applied 64 times to 
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improve the signal-to-noise ratio. The distortion of the recorded mECAP sinusoid was 
measured against an ideal sinusoidal voltage with the same duration and latency 
(accounting for phase shift), and with the ideal sinusoid magnitude fit using a least-
squares approach. The sampling frequency of the ideal sinusoid was matched to that of 
the recorded sinusoid so that point-wise analysis could be performed. The magnitudes 
of both the ideal and recorded sinusoids were then normalized to the amplitude of the 
ideal sinusoid to avoid bias against larger magnitude mECAPs. Finally, distortion was 
measured as the root-mean square error between the magnitude-normalized recorded 
and ideal sinusoids. This value was divided by the number of samples in the sine wave 
to get an average distortion per sample (DPS) value. 
2.2.3 In vivo experimental setup and ECAP recording 
We investigated the feasibility of recording in vivo ECAPs during thalamic DBS 
in an adult cat (Fig. 2.1B). Animal care and experimental procedures were reviewed and 
approved by the Institutional Animal Care and Use Committee of Duke University. The 
animal was initially anesthetized with ketamine HCl (35 mg/kg i.m.) and maintained 
with alpha chloralose (65 mg/kg i.v. supplemented at 15 mg/kg as needed). Artificial 
respiration maintained end tidal CO2 at 3-4%, core temperature was maintained at 38°C 
with heating pads, arterial blood pressure was monitored with a catheter in the carotid 
artery, and fluids were continuously administered (10-15 ml/kg/hr). 
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The ventrolateral (VL) nucleus of the thalamus was targeted for implantation of 
the mini DBS electrode. The VL thalamus is the feline homologue of the Vim thalamus in 
primates (Berman and Jones, 1982). The anesthetized cat lay prone with the head fixed in 
a stereotactic frame. Following a craniotomy, the VL thalamus was located using 
stereotactic technique (Snider and Niemer, 1961, Berman and Jones) in conjunction with 
single-unit microelectrode recordings. Neurons in the dorsal region of the VL thalamus 
exhibited increased activity in response to passive movement of the contralateral hind 
limb (Berman and Jones, 1982). Once the location of the VL thalamus was identified, a 
guide tube was inserted vertically into the brain using a micromanipulator, and the mini 
DBS electrode was inserted through the guide tube into the VL thalamus. To confirm 
that the electrode was correctly placed in the VL thalamus, we recorded evoked 
responses from two contacts on the DBS electrode (0+/2-) during electrical stimulation of 
the contralateral sciatic nerve (biphasic pulses of 1 mA amplitude, 7 Hz frequency, and 
50 s/phase pulse width). 
The ECAP generated in vivo by DBS was measured across a range of clinically 
relevant stimulation parameters. Charge-balanced, biphasic DBS was applied at 1-3 V 
amplitude, 10 or 100 Hz frequency, 50 or 100 s/phase pulse width, and both cathodic- 
and anodic-phase first polarities. The two contact configurations tested were monopolar 
symmetric (1+ stimulation, 0+/2- recording) and monopolar asymmetric (3+ stimulation, 
2+/1- recording). A stainless steel retractor placed in the ipsilateral chest muscle acted as 
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the counter electrode and a Ag/AgCl electrode (Model EL504, Biopac Systems) placed on 
the back of the neck was used as the reference electrode. To evaluate the performance of 
the instrumentation in vivo, we recorded ECAPs both with and without the circuit 
components used to suppress the artifact, and with the conventional amplifier. The 
animal was killed by intravenous injection of Euthasol (Virbac), and postmortem 
recordings were made at several time points to confirm the biological origin of the 
antemortem ECAPs. During all trials, ECAPs were recorded for 10 s, with trials 
separated by 10 s, and stimulus-triggered averaging was applied 64 times.  
2.2.4 Histology 
Following completion of ECAP recording, the anatomical location of the mini 
DBS electrode was determined. The electrode was removed and the animal was 
immediately perfused transcardially with saline followed by 10% formalin. The 
hemisphere of the brain containing the electrode path was excised and post-fixed in 10% 
formalin for 24 hours at 4°C. Subsequently, the tissue sample was placed in 30% sucrose 
at 4°C until it sank, cryoprotected with optimal cutting temperature compound (Tissue-
Tek, Sakura), and frozen at -80°C (McConnell et al., 2009). The sample was cryosectioned 
into 50 m coronal sections and mounted on glass slides. The sections were defatted and 
Nissl stained with 0.1% cresyl violet. Finally, the electrode track and nuclei of interest 
were identified at 2.5x magnification, such that the location of the electrode could be 
registered to a stereotactic atlas of the cat brain (Snider and Niemer, 1961).  
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2.2.5 Computational model of the stimulus artifact 
An electrical circuit equivalent model was developed, using PSpice (Cadence 
OrCAD Capture CIS v16.3) and Comsol Script v1.2 (COMSOL) finite element modeling 
software, to study the sources of the stimulus artifact and mechanisms of artifact 
reduction by the recording instrumentation. The model included circuit representations 
of the DBS contact interface, saline or neural tissue medium, DBS voltage source, and 
components of the recording instrumentation (Fig. 2.2). The monopolar symmetric 
configuration was modeled in the electrical circuit equivalent simulations, with biphasic 
DBS delivered between contact 1 and a return electrode, and contacts 0 and 2 serving as 
inputs to the recording amplifier. The AC-coupled amplifier had a 100 M, 25 pF 
parallel input impedance in series with a 0.1 F capacitor at each input. The electrode-
tissue interface (ETI) at each DBS contact was represented as a parallel capacitance and 
resistance with values derived from literature (Wei and Grill, 2009), assuming biphasic 
DBS pulses of 1 mA amplitude. 
The DBS contacts and return electrode were electrically interconnected by 
impedance representations of the saline or neural tissue medium. To calculate the bulk 
resistance of the medium, a three-dimensional model of the DBS electrode within a 
spherical volume conductor was developed in Comsol Script. The volume of the 
spherical conductor matched the approximate volume of the saline bath or cat skull, 
3,502 or 524 cm3, respectively. The saline and neural tissue volume conductors were  
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Figure 2.2: Electrical circuit equivalent model used to calculate the stimulus 
artifact generated by DBS applied between contact 1 and a spherical return electrode, 
with differential recordings made from contacts 0 and 2 (monopolar symmetric 
configuration).The electrode-tissue interface was composed of a parallel double-layer 
capacitance (CDL) and charge transfer Faradaic resistance (RF). The volume conductor 
included both the resistance between contacts (RV01 and RV12) and the resistance 
between each contact and the return electrode (RV0, RV1, and RV2). The capacitance of 
the volume conductor (CV) was parallel to the resistance between contacts and the 
return electrode. The input impedance of the recording amplifier was represented in 
the model, and the model output was the recorded differential voltage (VREC) across 
the amplifier impedance. 
assumed to be homogenous, represented with conductivities (v) of 2 S/m (Geddes and 
Baker, 1967) and 0.3 S/m (Ranck, 1963), respectively. The clinical or mini DBS electrode 
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was represented in the model with the appropriate geometrical dimensions, with contact 
1 placed at the center of the volume conductor, and the conductivities of the DBS 
contacts and insulated shaft were 5×106 S/m and 1×10-13 S/m, respectively (Yousif et al., 
2008a). A 1 V boundary condition was specified at one contact surface and the exterior 
boundary of the volume conductor was grounded. Comsol Script created a variable 
resolution mesh and solved the Poisson equation using the conjugate gradients method. 
The resistance was calculated using Ohm's law (R = 1 V / Inorm), where Inorm was 
determined by integrating the normal current density over the contact surface. The 
resistance between two DBS contacts was calculated in a similar fashion, with the two 
contacts of interest set to ±0.5 V and the normal current density integrated across the 
contact surface.  
The permittivity of the medium was incorporated into the circuit model by 
placing capacitors between the DBS contacts and return electrode, parallel to the volume 
conductor resistance (Butson and McIntyre, 2005). Saline and neural tissue permittivity 
values were estimated from previous studies, having dielectric constants (K) of 75 (for 
137 mM NaCl at DC) (Wang and Anderko, 2001) and 1×104 - 1×106 (at frequencies below 
1 kHz) (Schwan and Kay, 1957, Foster and Schwan, 1989), respectively. The permittivity 
() was calculated as:  
0 K           (Equation 2.1) 
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where 0 is the permittivity of free space (8.85×10-12 F/m). Subsequently, the bulk 
capacitance was calculated by assuming that the geometry of the DBS contact within the 
volume conductor was one of two concentric spherical conducting shells. The 
capacitance of this spherical capacitor was then calculated as:  
ab
ba
V
rr
rr
C

 4     (Equation 2.2) 
where ra and rb are the radii of the DBS contact and volume conductor, respectively 
(Young and Freedman, 2004). The radius used for the DBS contact was set such that the 
surface area of the spherical contact and actual cylindrical contact were matched, and 
the radius of the volume conductor was identical to that used in the Comsol Script 
model.  
The circuit model was used to solve for the stimulus artifact voltage, measured 
across the amplifier inputs, resulting from DBS pulses of 3 V amplitude, 100 Hz 
frequency, 50 s/phase pulse width, and cathodic-phase first polarity. Three models 
were constructed, in accord with the experimental studies: (i) an in vitro model, with the 
clinical DBS electrode in the saline bath, (ii) an in vivo model, with the mini DBS 
electrode in neural tissue, and (iii) a postmortem in vivo model, with the mini DBS 
electrode in dead neural tissue. For the postmortem in vivo model, the dielectric constant 
K was reduced from the antemortem model by 2.7% (Schmid et al., 2003), and the 
conductivity v was reduced by 28% (Surowiec et al., 1986).  
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2.3 Results 
We developed an instrumentation system to record ECAPs during DBS, 
evaluated the performance of the system through in vitro and in vivo experiments, and 
conducted analysis of an electrical circuit equivalent model to analyze the source of the 
stimulus artifacts and their reduction by the elements of the instrumentation. 
2.3.1 Instrumentation design 
The DBS-ECAP instrumentation used three stages of series amplification and 
several circuit components to limit the stimulus artifact and enable high fidelity 
recording of short latency, small amplitude ECAP signals (Fig. 2.3(i)). Differential 
recordings were made from two non-stimulating contacts on the DBS electrode to 
reduce common-mode noise, and served as inputs to a battery-powered preamplifier 
(A1, SR560), which provided gain and high input impedance. Two additional amplifier 
stages (A2 and A3, SR560) were placed in series to increase gain further and to filter the 
signal with a 10 Hz to 10 kHz pass-band. Anti-parallel diode clamps (1N4154, Fairchild 
Semiconductor) were placed at the inputs of A2 and A3 to ground the line if the input 
voltage exceeded approximately ±0.7 V, thereby selectively clipping the stimulus artifact 
and enabling increased gain without saturation. To achieve further increases in gain, the 
signal paths in amplifiers A2 and A3 were internally grounded through an opto-isolated 
CMOS multiplexer (74HC4053), blanking the output for the duration of each stimulus 
pulse and the subsequent 60 s. The rapid turn-off time of this CMOS switch (10 s) 
 53 
ensured that short latency ECAP responses could still be recorded. In addition, a low-
resistance, rapid-response PhotoMOS relay (AQV212(A), Panasonic) was used to 
disconnect the stimulating electrodes between DBS pulses. This limited capacitive 
discharge from the ETI through the stimulator after each pulse, and thereby reduced the 
duration of the stimulus artifact (McGill et al., 1982). A 10 k parallel resistor was 
placed across the stimulating electrodes to allow accumulated charge on the stimulating 
contacts to discharge between pulses. Further, this resistor enabled near-critical 
damping of the signal recovery from artifact to baseline. The digital pulse controlling the 
closing of the stimulator relay was turned off 40 s before the end of the DBS pulse to 
account for the intrinsic delay of the relay. The digital pulses controlling the amplifier 
blanking and closing of the stimulator relay were turned on 2 ms before each DBS pulse 
to account for turn on delays, and to discharge any charge remaining on the stimulating 
electrodes. 
Several strategies were implemented to reduce the risk of inadvertent electrical 
injury to the subject. The front end of each amplifier stage was AC-coupled to prevent 
exposure to DC voltages. Further, anti-series, current-limiting diodes (1N5285, Central 
Semiconductor) were placed between the DBS leads and each input to the preamplifier 
to limit current to less than 0.3 mA in the event of an instrumentation malfunction. 
Finally, DBS generated by the LabView controller was applied through an optically-
isolated stimulator (bp isolator, FHC) (Birdno et al., 2008, Dorval et al., 2010). 
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Figure 2.3: Diagram of ECAP recording instrumentation. (i) DBS-ECAP 
instrumentation used for stimulus artifact reduction and ECAP recording during 
DBS. (a) Anti-series, current-limiting diodes (1N5285) were connected to the DBS lead 
prior to the amplification stages. (b) Differential recordings were made from two DBS 
contacts, and (c) served as inputs to the preamplifier (A1). (d) Two additional series 
amplifier stages (A2 and A3) further increased the gain and filtered the signal with a 
10 Hz to 10 kHz pass-band. (e) Anti-parallel diodes (1N4154) were placed at the inputs 
of A2 and A3. (f) During each stimulus pulse, an opto-isolated CMOS multiplexer 
(74HC4053) internally grounded the signal path in amplifiers A2 and A3. (g) A 
PhotoMOS relay (AQV212(A)) disconnected the stimulating electrodes in between 
DBS pulses. (h) The parallel resistance enabled any accumulated charge on the 
stimulating electrodes to discharge between pulses, and enabled near-critical 
damping of the signal recovery from artifact to baseline. Diagrams of the 
(ii) conventional amplifier, and (iii) series amplifiers with (anti-parallel) diodes are 
also provided. Two additional setups that were tested include the series amplifiers 
without diodes and the series amplifiers with diodes and stimulator relay (not 
shown). 
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2.3.2 In vitro evaluation of the DBS-ECAP instrumentation 
In vitro experiments were conducted to characterize the capability of the DBS-
ECAP instrumentation to reduce the stimulus artifact and record mECAPs with high 
fidelity. Compared to a conventional amplifier (Fig. 2.3(ii)), the series amplifiers with 
diodes (Fig. 2.3(iii)) reduced the magnitude of the stimulus artifact (Fig. 2.4A) and 
enabled an increase in gain by a factor of 25 (Table 2.1). Conversely, the series amplifiers 
Table 2.1: Maximum gain (G) possible without saturation for the different recording 
system configurations and contact configurations tested in vitro. DBS was applied 
with 3 V amplitude, 100 Hz frequency, 50 s pulse width, and cathodic-phase first 
polarity. The gain is also provided at each amplifier stage for recording system 
configurations with multiple stages. 
Recording 
System 
Monopolar 
Symmetric 
Monopolar 
Asymmetric 
Bipolar 
Conventional 
Amplifier 
100 20 10 
Series Amplifiers 
with Diodes 
2,500 
G1=100,G2=5,G3=5 
500   
G1=20,G2=5,G3=5 
250   
G1=10,G2=5,G3=5 
DBS-ECAP 
Instrumentation 
100,000 
G1=100,G2=200,G3=5 
40,000 
G1=20,G2=200,G3=10 
50,000 
G1=10,G2=500,G3=10 
 
without diodes saturated at the equivalent gain (Fig. 2.4B). Even with the use of the 
series amplifiers with diodes, there remained a relatively large amplitude, long duration 
stimulus artifact with a triphasic waveform shape (Fig. 2.4C). The use of the series 
amplifiers with diodes and stimulator relay reduced the magnitude and duration of the 
third phase of the artifact by limiting capacitive discharge through the stimulator after 
each pulse. Subsequent addition of amplifier blanking, completing the DBS-ECAP 
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Figure 2.4: In vitro stimulus artifact waveforms measured with the different 
recording system configurations. DBS was applied at time 0 with 3 V amplitude, 100 
Hz frequency, 50 s pulse width, and cathodic-phase first polarity using the 
monopolar symmetric configuration. The stimulus-triggered average waveform (bold 
traces) and single trials (light traces) are shown. A: Comparison of artifacts recorded 
with the conventional amplifier (black trace) and series amplifiers with diodes (red 
trace). B: Using the series amplifiers without diodes, the amplifiers saturated at the 
equivalent gain used for the series amplifiers with diodes. This resulted in clipping 
of the signal at the positive and negative voltage supply rails, and distortion of the 
stimulus artifact waveform due to the nonlinearity of the amplifier output. Some 
single trial traces are obscured by overlapping traces. C: Comparison of artifacts 
recorded with the series amplifiers with diodes (black trace) series amplifiers with 
diodes and stimulator relay (red trace), and DBS-ECAP instrumentation (blue trace). 
The inset shows a zoomed view of the stimulus artifact waveform for the DBS-ECAP 
instrumentation. D: Comparison of artifacts and mECAPs recorded with the 
conventional amplifier (black trace), series amplifiers with diodes (red trace), and 
DBS-ECAP instrumentation (blue trace). Each DBS pulse triggered a 4 kHz sinusoidal 
mECAP with 0.18 mVP-P amplitude (0.1 mAP-P input amplitude) and 0.5 ms latency. 
instrumentation, suppressed the first two phases of the artifact (corresponding to the 
two phases of the DBS pulse). Compared to the conventional amplifier, use of the DBS-
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ECAP instrumentation enabled an increase in gain by a factor of 1,000-5,000, depending 
on the contact configuration (Table 2.1). However, the maximum gain used with the 
DBS-ECAP instrumentation during mECAP recording was limited to that of the series 
amplifiers with diodes (Table 2.1) to avoid diode clipping of the mECAP and to enable 
comparison of these two recording system configurations at equal gain. 
The recording fidelity of the DBS-ECAP instrumentation was examined through 
analysis of the distortion of mECAP signals generated by applying a single cycle of a 
sinusoidal current between two microelectrodes (Fig. 2.4D). The higher gains enabled by 
the series amplifiers with diodes provided higher fidelity recording compared to the 
conventional amplifier. Further, the DBS-ECAP instrumentation limited the magnitude 
and duration of the third phase of the artifact, thereby reducing the temporal overlap of 
the artifact with short latency mECAPs and further increasing fidelity. Additional 
distortion analysis across DBS and mECAP parameters, contact configurations, and 
recording system configurations is provided in the Appendix. Use of the mini DBS 
electrode during in vitro testing generated similar stimulus artifact and mECAP 
waveforms to those recorded with the clinical DBS electrode (data not shown). 
2.3.3 In vivo ECAP recording 
The mini DBS electrode (Fig. 2.5A) was implanted in the VL nucleus of the cat 
thalamus for in vivo ECAP recording. The VL thalamus was identified by recording 
single thalamic neurons that exhibited increased activity during passive contralateral  
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Figure 2.5: The DBS electrode was implanted in the VL thalamus in an 
anesthetized cat. A: A mini DBS electrode was used for in vivo ECAP recording 
during thalamic DBS. B: The location of the VL thalamus was identified by recording 
the activity of single thalamic neurons with a microelectrode during stereotactic 
surgery. Top: Raster plot of spiking in a neuron showing increased activity during 
passive contralateral hind limb movement (dashed lines). Bottom: Waveforms of 61 
discriminated spike waveforms recorded from the neuron (gray traces) and average 
 59 
waveform across all spikes (black trace). C: Accurate implantation into the VL 
thalamus was verified by recording the evoked response from the DBS electrode 
during contralateral sciatic nerve stimulation, applied at time 0. The stimulus-
triggered average (black trace) and single trials (gray traces) are shown. D: 
Postmortem histology confirmed the location of the DBS electrode within the VL 
thalamus, with the nuclear boundary indicated by the dashed line. The arrow 
indicates the location of the ventral tip of the electrode. 
hind limb movement (Fig. 2.5B). Accurate implantation of the DBS electrode into the VL 
thalamus was confirmed subsequently by recording evoked responses from the DBS 
electrode during electrical stimulation of the contralateral sciatic nerve (Fig. 2.5C). 
Postmortem histology confirmed the position of the implanted electrode in the VL 
thalamus (Fig. 2.5D). 
The in vivo ECAP response was recorded using the different recording system 
configurations to examine the relative performance of the DBS-ECAP instrumentation 
(Fig. 2.6). Comparing responses to cathodic- and anodic-phase first stimulation enables 
one to distinguish the physiological ECAP signal, which is similar for symmetric, 
biphasic pulses (McIntyre and Grill, 2000), from the stimulus artifact, which is inverted 
for opposite polarities. The stimulus artifact recorded with the conventional amplifier 
was reduced in magnitude with the use of the series amplifiers with diodes, enabling 
higher gains (Figs. 2.6A,B), but the long duration of the artifact distorted the 
physiological ECAP. In contrast, the DBS-ECAP instrumentation suppressed the 
stimulus artifact and enabled high fidelity recording of ECAPs (Fig. 2.6C).  
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Figure 2.6: The stimulus artifact and ECAP during in vivo recording using the 
monopolar symmetric configuration with the conventional amplifier (A), series 
amplifiers with diodes (B), and DBS-ECAP instrumentation (C). The gains (G) used at 
the amplification stages of each recording system configuration are shown at the 
lower left of each graph. DBS was applied with 3 V amplitude, 100 Hz frequency, and 
50 s pulse width, with both cathodic-phase first (black traces) and anodic-phase first 
(red traces) polarities. The stimulus-triggered average waveform (bold traces) and 
single trials (light traces) are shown. 
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Figure 2.7: Effect of stimulation parameters on the in vivo ECAP response 
recorded with the DBS-ECAP instrumentation. A: ECAPs recorded using the 
monopolar symmetric configuration across DBS pulse widths (PW) and frequencies 
(F) at a 3 V amplitude. The results for cathodic-phase first (black traces) and anodic-
phase first (red traces) polarities are shown. B: ECAPs recorded using the monopolar 
symmetric configuration across DBS amplitudes at 100 Hz frequency and 50 s pulse 
width, and with cathodic-phase first polarity. C: ECAPs recorded using the monopolar 
asymmetric configuration with 3 V amplitude, 100 Hz frequency, and 50 s pulse 
width. The results for cathodic- and anodic-phase first polarities are shown. For all 
figures, the stimulus-triggered average waveform (bold traces) and single trials (light 
traces) are shown. The amplifier gains used for the monopolar symmetric and 
asymmetric configurations were 5,000 and 2,500, respectively. 
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We examined how the ECAP characteristics were dependent on stimulation 
parameters (Fig. 2.7). In the monopolar symmetric configuration, ECAPs had an early 
positive (P1) phase followed by a later negative (N1) phase (Fig. 2.7A). The magnitude 
and duration of these phases generally increased with DBS pulse width and amplitude 
(Figs. 2.7A,B), and the N1 phase was absent with low amplitude (1 V) DBS. Secondary 
positive (P2) and negative (N2) phases were observed at 10 Hz DBS (Fig. 2.7A). While 
these secondary phases were also present at the beginning of the stimulus train during 
100 Hz DBS, their amplitudes progressively decayed during the stimulus train, and were 
not present in the average waveform. ECAPs recorded using the monopolar asymmetric 
configuration exhibited an early negative (N1') phase and later positive (P1') phase (Fig. 
2.7C).  
We measured the ECAP at multiple time points following euthanasia to confirm 
that the ECAP was a biological signal. While phases P1 and N1 were both still evident at 
1 min following euthanasia (Fig. 2.8A), the latter was lost at 3 min (Fig. 2.8B). 
Postmortem recording at 5 min resulted only in a stimulus artifact, with inverted 
waveforms for opposite stimulation polarities, rather than a physiological ECAP 
response (Fig. 2.8C). 
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Figure 2.8: Postmortem in vivo ECAPs at 1 min (A), 3 min (B), and 5 min (C) 
after euthanasia recorded with the DBS-ECAP instrumentation using the monopolar 
symmetric configuration. DBS was applied with 3 V amplitude, 100 Hz frequency, 50 
s pulse width, and both cathodic-phase first (black traces) and anodic-phase first 
(red traces) polarities. The stimulus-triggered average waveform (bold traces) and 
single trials (light traces) are shown. 
2.3.4 Computational analysis of stimulus artifact sources and 
components for artifact reduction  
An electrical circuit equivalent model was used to analyze the sources of the 
stimulus artifact recorded in vitro and in vivo, and to understand better the mechanism of 
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artifact rejection by the stimulator relay of the DBS-ECAP instrumentation. The 
parameter values used in the circuit models are provided in Table 2.2. The stimulus  
artifact was calculated as the differential voltage across the recording amplifier inputs, 
with and without use of the AQV212(A) stimulator relay, which had a 0.83  on 
resistance and operational timing matching that used experimentally. 
Table 2.2: Electrical circuit equivalent model parameters used for in vitro and 
in vivo models. The in vivo model used two sets of parameters to calculate the 
stimulus artifact in antemortem and postmortem recordings. The volume capacitance 
values shown for the in vivo models were calculated for dielectric constants of 3×105 
and 2.92×105 for antemortem and postmortem, respectively. The resistance values of 
the volume conductor were calculated for conductivities of 0.3 and 0.216 S/m, 
respectively. 
Parameter In Vitro  
In Vivo  
(Ante.) 
In Vivo  
(Post.) 
Interface double-layer capacitance (CDL, F) 2.22 1.56 1.56 
Interface Faradaic resistance (RF, k) 0.96 1.50 1.50 
Volume resistance between contacts 0 & 1 (RV01, ) 200.11 3208.69 4469.48 
               contacts 1 & 2 (RV12, ) 199.80 3270.33 4546.37 
             contact 0 & return (RV0, ) 127.26 2141.15 2980.29 
             contact 1 & return (RV1, ) 126.90 2184.88 3044.96 
             contact 2 & return (RV2, ) 128.34 2183.59 3071.81 
Volume capacitance between contacts & return (CV, nF) 5.80E-3 9.38 9.13 
 
The artifact calculated with the in vitro model (Fig. 2.9A) had a waveform shape 
similar to that recorded experimentally with the clinical DBS electrode in the saline bath 
using the conventional amplifier (Fig. 2.9B). The peak-to-peak magnitude of the model 
and experimental artifacts were approximately 16 mV and 49 mV, respectively, and this 
difference likely resulted from errors associated with model assumptions. Addition of 
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Figure 2.9: Stimulus artifact waveforms calculated with the in vitro and in vivo 
electrical circuit equivalent models and comparison to experimentally recorded 
artifacts using the monopolar symmetric configuration. DBS was applied with 3 V 
amplitude, 100 Hz frequency, 50 s pulse width, and cathodic-phase first polarity. A: 
In vitro circuit model artifacts calculated without the stimulator relay (black trace), 
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and with the relay either turned off immediately after the pulse (red trace) or with a 
25 s turn off delay (blue trace). B: Stimulus-triggered average artifact waveforms 
from the in vitro experiment recorded with a conventional amplifier without signal 
filtering, with the stimulator relay absent (black trace) and present (red trace). 
C: Sensitivity analysis of in vivo circuit model artifact to dielectric constant (K) values 
between 1×104 and 1×106. A dielectric constant of 3×105 was used for subsequent circuit 
model analysis. D: Sensitivity analysis of in vivo circuit model artifact to changes in 
the bulk tissue resistance. The resistance was decreased between contacts 0 and 1, and 
increased between contacts 1 and 2, by the indicated value. A 10% bulk conductivity 
change was used for subsequent circuit model analysis. E: In vivo circuit model 
artifacts calculated with and without the stimulator relay. F: Stimulus-triggered 
average artifact waveforms from a postmortem in vivo cat experiment. Recordings 
were made with a conventional amplifier without signal filtering, both with and 
without the stimulator relay. G: Comparison of circuit model artifact waveforms 
calculated using parameter values from the original, antemortem (black trace) and 
postmortem (red trace) models. The stimulator relay was used for these data. 
the stimulator relay in the in vitro experiment reduced, but did not eliminate, the third 
phase of the artifact observed with the conventional amplifier (Fig. 2.9B). Conversely, 
results from the circuit model indicated that turning the stimulator relay off 
immediately after the DBS pulse prevented capacitive discharging from the ETI and 
eliminated the third artifact phase (Fig. 2.9A). However, when a short (25 s) turn off 
delay was added to the stimulator relay after the end of the DBS pulse, the model 
reproduced the reduced-magnitude third artifact phase seen experimentally. Although 
the digital pulse controlling the stimulator relay was turned off 40 s before the end of 
the DBS pulse to account for this turn off delay in the in vitro experiment, the typical 
measured delay for the AQV212(A) relay is longer than 40 s, and may have contributed 
to this observed post-stimulus delay time. The 25 s turn off delay was used for 
subsequent model trials with the stimulator relay. 
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We next conducted sensitivity analysis to determine how the stimulus artifact 
calculated with the in vivo circuit model depended on the dielectric constant and 
conductivity of the tissue. The stimulus artifact was calculated for dielectric constant 
values of neural tissue from 1×104 to 1×106 (Fig. 2.9C). The variations in tissue 
capacitance led to substantial changes in the waveform shape of the artifact, since higher 
capacitances resulted in longer time constants for charging and discharging of the tissue. 
Using a dielectric constant value of 3×105 resulted in an artifact (Fig. 2.9D, black trace) 
that best matched the experimental waveform shape (Fig. 2.9F). We next investigated the 
effect of inhomogeneity of tissue conductivity by decreasing the tissue resistance 
between contacts 0 and 1 by 5 to 10%, and increasing that between contacts 1 and 2 by 
the same percentage (Fig. 2.9D). A greater degree of inhomogeneity increased the 
magnitude of the stimulus artifact, due to the larger differential voltage generated at the 
two recording contacts. A change in tissue resistance values of 10% produced a model 
artifact waveform with a magnitude similar to that observed experimentally, and was 
used for subsequent artifact calculations. The presence of tissue inhomogeneities likely 
generated the larger stimulus artifact magnitudes in vivo compared to in vitro. 
Discharging of the tissue capacitance following DBS pulses led to an increased 
duration of the third phase of the artifact in vivo. This phenomenon was observed 
experimentally (Fig. 2.9F), and was qualitatively reproduced with the circuit model (Fig. 
2.9E). The stimulator relay did decrease capacitive discharging from the ETI and thereby 
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reduce the magnitude of the third phase, but it did not prevent discharging of the tissue 
capacitance. The increase in artifact duration resulting from discharging of medium 
capacitance was only observed in vivo, since the permittivity of tissue is several orders of 
magnitude greater than that of saline. 
The model was also used to investigate the increase in stimulus artifact 
amplitude in postmortem in vivo recordings (Fig. 2.8). Decreases in tissue conductivity 
and permittivity, expected after euthanasia (Surowiec et al., 1986, Schmid et al., 2003), 
increased the duration of the third artifact phase in the model (Fig. 2.9G). Further, local 
changes in brain conductivity that increased the extent of tissue inhomogeneity 
increased both the magnitude and duration of the artifact (Fig. 2.9D). These changes 
may explain the larger artifacts observed 5 minutes after euthanasia. 
2.4 Discussion 
We designed and evaluated the performance of instrumentation for high fidelity 
recording of ECAPs from the DBS electrode during stimulation. By reducing the 
magnitude and duration of the stimulus artifact, the DBS-ECAP instrumentation 
enabled recording of small amplitude, short latency mECAPs in vitro. The ability of the 
instrumentation to record physiological ECAPs was confirmed during in vivo DBS in the 
cat thalamus. The characteristics of the in vivo ECAP were dependent on stimulation 
parameters and may provide insight into the type and spatial extent of neural element 
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activation during stimulation. Thus, the ECAP signal may be a suitable feedback control 
signal for tuning DBS parameters and in closed-loop DBS systems. 
2.4.1 Design and evaluation of instrumentation 
Several hardware-based strategies were used to limit the stimulus artifact. We 
employed multiple amplifier stages with anti-parallel diode clamps at the inputs to clip 
selectively the stimulus artifact and provide overvoltage protection. The magnitude of 
the artifact was reduced further by amplifier blanking, in which the signal paths in the 
second and third amplifier stages were grounded during each DBS pulse. To reduce the 
duration of the third phase of the artifact, and minimize the extent of temporal overlap 
with the ECAP, we used a stimulator relay to reduce capacitive discharge of the ETI 
immediately after each DBS pulse (McGill et al., 1982). This relay disconnected the low 
impedance path available through the constant-voltage stimulator, thereby limiting the 
discharging current through the high impedance 10 k parallel resistance. Accumulated 
charge was able to discharge between pulses through this parallel resistance and during 
the 2 ms pre-stimulus period in which the relay was closed. The parallel resistance also 
enabled near-critical damping of the signal recovery from artifact to baseline. Replacing 
the resistor with a potentiometer could enable rapid selection of a parallel resistance that 
achieved full critical damping of the system.   
Other techniques used to suppress the stimulus artifact in neural recordings 
were not optimal for this application. Signal processing techniques such as curve fitting, 
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template subtraction, polarity averaging, and masker-probe paradigms are applied after 
the signal has been amplified and require lower gains to avoid saturation. Further, the 
performance of the template subtraction and polarity averaging techniques suffers from 
the assumptions that the artifact shape is constant between stimulus pulses (Wagenaar 
and Potter, 2002) and that the artifact perfectly follows the stimulus pulse in polarity 
(Bahmer et al., 2010), respectively. Signal filtering was not feasible due to overlapping 
frequency spectra of the ECAP signal and stimulus artifact. Alternatively, sample-and-
hold amplifiers have not demonstrated the capacity to make artifact-free recordings of 
sub-ms latency neural activity, as required to capture physiological ECAPs, and have 
yielded inconsistent results. 
Our novel DBS-ECAP instrumentation reduced the artifact magnitude and 
enabled a total in vitro gain of 40,000-100,000 without saturation during 3 V DBS, 
depending on the contact configuration. These gains far surpassed the conventional 
amplifier by a factor of 1,000-5,000. Further, the reductions in artifact duration and use 
of high gains facilitated low distortion recording of physiologically-realistic mECAPs at 
latencies as short as 0.5 ms and amplitudes as small as 0.11-0.30 mVP-P (Appendix). This 
was the case for all contact configurations when using clinically-relevant DBS 
parameters of 3 V amplitude, 100 Hz frequency, and 50 s pulse width. Conversely, the 
conventional amplifier recorded mECAPs with relatively high distortion. Long, 
asymmetric DBS pulses precluded low distortion recording of ECAPs with the DBS-
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ECAP instrumentation except at latencies of at least 1 ms. Since physiological ECAPs 
have latencies in the sub-ms range, it may not be feasible to use long, asymmetric pulses, 
such as those generated by the present clinical device (Miocinovic et al., 2009), during 
ECAP recording. 
The 4 kHz mECAP frequency used for in vitro validation was selected to examine 
the limits of instrumentation performance in recording physiological ECAPs. The bulk 
of the power of the in vivo ECAPs was in the 100 Hz to 4 kHz band. The DPS values 
were consistently lower for 1 kHz mECAPs compared to 4 kHz mECAPs when recorded 
with the DBS-ECAP instrumentation because any distortion influenced a shorter 
proportion of the longer 1 kHz signal, and the reported distortion values can be 
considered an upper bound. 
We expect that the high recording fidelity of the DBS-ECAP instrumentation 
observed at 100 Hz DBS will translate across the entire range of clinical DBS frequencies. 
Increasing the DBS frequency from 100 to 180 Hz decreases the interpulse interval from 
10 to 5.56 ms, but after accounting for the 2 ms pre-stimulus amplifier blanking period, 
this would still provide a recording window of 3.56 ms from the start of the stimulus 
pulse at 180 Hz DBS. Since the physiological ECAP signal returned to baseline by 
approximately 3 ms post-stimulus (Fig. 2.7), we do not anticipate increases in distortion, 
generated by temporal overlap of the ECAP signal with the subsequent amplifier 
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blanking period, as the DBS frequency is increased to the high end of the clinical range. 
This was validated through in vitro testing of mECAPs at 180 Hz (data not shown). 
The contact configurations used for stimulation and ECAP recording influenced 
the fidelity of the recording (Appendix). The stimulus artifact magnitude was larger 
when the voltages generated during stimulation were not symmetrical at the recording 
contacts (i.e., the monopolar asymmetric and bipolar configurations). This required 
reductions in amplifier gain (Table 2.1) and made it more challenging to record short 
latency mECAPs. Moreover, the recorded mECAP magnitude increased with the 
distance between recording contacts (maximal in the bipolar configuration), since the 
contacts measured a larger differential-mode signal. Collectively, this suggests that high 
fidelity recording is most challenging in the monopolar asymmetric configuration, due 
to the short distance between recording contacts and their non-symmetrical positioning 
about the stimulating contact. This was confirmed through the distortion analysis of 
mECAP recordings made in vitro across contact configurations. 
The artifact waveforms calculated with the electrical circuit equivalent model 
were similar in magnitude and shape to the in vitro and in vivo artifacts, and provided 
insight into the origin of the artifact (Fig. 2.9). In the in vitro experiment, the only source 
of the third artifact phase was capacitive discharging from the ETI, which was limited 
with the use of the stimulator relay. However, the turn off delay of the relay, which was 
approximately 25 s after the end of the DBS pulse, allowed some discharging. 
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Consequently, the size of the third phase was reduced but not eliminated. This suggests 
that using a stimulator relay with a shorter turn off delay may improve the performance 
of this system. The model indicated that there were two sources of the third artifact 
phase observed in vivo: capacitive discharging after each DBS pulse of (1) the tissue 
capacitance, and (2) the ETI. Previous computational (Butson and McIntyre, 2005, Tracey 
and Williams, 2011) and experimental (Lempka et al., 2010) studies have also 
demonstrated that the tissue capacitance is charged during the DBS pulse (influencing 
the DBS waveform shape). The stimulator relay cannot suppress the artifact resulting 
from discharging of the tissue capacitance, and thus the third phase is larger in vivo than 
in vitro. We investigated a means to rapidly discharge the tissue capacitance by shorting 
the amplifier inputs with a PhotoMOS relay for 100 s immediately after each pulse. 
However, this technique did not reduce the third phase of the in vivo artifact, and 
electrical equivalent circuit modeling indicated that the lack of effect was caused by 
negligible current flow through the relay due to its internal impedance (data not shown). 
Finally, the peak-to-peak magnitude of the artifact recorded with the conventional 
amplifier was greater in vivo than in vitro, and results from the circuit model suggest that 
this may have been caused by inhomogeneities in the neural tissue, which were not 
present in the saline bath. 
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2.4.2 Insight provided by the physiological ECAP 
The results from our in vivo experiment confirmed that physiological ECAPs 
could be recorded during thalamic DBS. The DBS-ECAP instrumentation enabled high 
gain recordings of ECAPs, uncontaminated by the stimulus artifact, during DBS of the 
VL thalamus. This could be performed using both the monopolar symmetric and 
asymmetric configurations (Fig. 2.7), of which the latter was revealed by in vitro analysis 
to be the most challenging configuration for high fidelity recording. The similarity of 
ECAP waveform shapes recorded during cathodic- and anodic-phase first polarity 
stimulation corroborated the neural origin of the signal, and the elimination of the ECAP 
response at 5 min after euthanasia (Fig. 2.8) further verified the biological origin of the 
recorded signal. The increase in stimulus artifact magnitude observed after euthanasia 
could have been caused by decreases in bulk tissue conductivity and permittivity 
(Surowiec et al., 1986, Schmid et al., 2003) and/or local changes in brain conductivity that 
increased the extent of tissue inhomogeneity. Electrical circuit equivalent modeling 
indicated that these changes increased the magnitude and duration of the third phase of 
the artifact. 
Measuring the ECAP across DBS parameters provided insight into the activation 
patterns during DBS. The magnitude and duration of the ECAP phases increased with 
DBS amplitude and pulse width, as a result of activation of additional neural elements 
having higher stimulation thresholds (Ranck, 1975). ECAPs generated with the 
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monopolar symmetric configuration had an early positive (P1) phase and later (N1) 
negative phase. To interpret this finding, we used results from the modeled cochlear 
ECAP response, in which a large negative phase, flanked on each side by small positive 
phases, corresponded to action potential propagation near the recording contact (Briaire 
and Frijns, 2005). We propose that P1 was generated by early dorsal activity (near the 
negative recording contact) whereas N1 corresponded to later ventral activity (near the 
positive contact). Furthermore, we observed secondary positive (P2) and negative (N2) 
phases during low frequency DBS, and at the beginning of the pulse train during high 
frequency DBS. This suggests that the P2 and N2 phases corresponded to post-synaptic 
activity, and the loss of these phases at high stimulation frequencies corresponded to a 
reduction in post-synaptic activity (Anderson et al., 2006). Recording the ECAP with the 
monopolar asymmetric configuration revealed an early negative (N1') phase and later 
positive (P1') phase. These two phases likely corresponded to dorsal-to-ventral 
propagation of action potentials, initiated in cells near the stimulating contact, and 
propagating first past the positive recording contact (N1') and subsequently past the 
negative contact (P1').  
These findings suggest that the ECAP may provide signatures of clinical 
effectiveness and be a suitable feedback signal in closed-loop DBS systems. For example, 
the ECAP magnitude could indicate when there is sufficient neural activation for clinical 
efficacy. As DBS amplitude is increased from 1 to 3 V, the in vivo ECAP increased in 
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magnitude (Fig. 2.7B), and tremor decreases over this same range (Kuncel et al., 2007). 
We therefore expect a correlation between ECAP magnitude and tremor that could be 
used to set the DBS amplitude in a closed-loop system. An analogous correlation has 
been established for cochlear implants between the cochlear nerve ECAP magnitude and 
perceptional hearing levels (Jeon et al., 2010). 
2.4.3 Study limitations 
The electrical circuit equivalent model provided insight into the sources of the 
stimulus artifact; however, there are several limitations that should be noted. First, 
calculations of medium resistance and capacitance assumed a spherical volume 
conductor surrounding the DBS electrode, with the return electrode at the volume 
conductor boundary. Further, the medium capacitance calculations assumed that the 
DBS contacts were spherical. In the in vitro and in vivo experiments, the return electrode 
did not bound the DBS electrode, but rather was located at a single, distant position (Fig. 
2.1). This model assumption may have resulted in underestimation of the medium 
resistance and overestimation of the medium capacitance between DBS contacts and the 
return electrode. Further, neither the saline tank nor the DBS contacts were actually 
spherical, but these assumptions likely had a negligible effect on model results due to 
the large difference in size between DBS contacts and the volume conductor, which 
would be expected to mitigate the effects of these geometric approximations.  
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The second limitation was an assumption in the circuit model that the mini DBS 
electrode had the same ETI properties as the clinical DBS electrode, for which the 
impedance values were measured (Wei and Grill, 2009). However, when the interface 
resistance and capacitance values were modified to account for the smaller surface area 
of the mini DBS electrode, the effect on the artifact waveform was negligible (data not 
shown). Third, this model did not include capacitive coupling between stimulating and 
recording leads (McGill et al., 1982, Grumet, 1999), which was reasonable considering 
this would generate a common-mode stimulus artifact and be rejected at the differential 
preamplifier stage. The fourth limitation was that we did not account for the frequency-
dependence of tissue permittivity (Bossetti et al., 2008) in calculating bulk volume 
capacitance, and it remains unclear which permittivity value best represents brain tissue 
(Butson and McIntyre, 2005). However, under conditions of voltage-controlled 
stimulation in a homogenous medium, using a frequency-independent permittivity can 
closely approximate the solution of a fully dispersive model (Grant and Lowery, 2010). 
Fifth, the medium capacitance between two DBS contacts was not included in the circuit 
model. 
The final major limitation of the circuit model was that changes in neural tissue 
properties measured after euthanasia in literature were made in porcine (Schmid et al., 
2003) and bovine (Surowiec et al., 1986) brains, rather than the cat. Further, the change in 
permittivity was measured at high frequencies (900 MHz), outside of the bandwidth of 
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the DBS pulse (Schmid et al., 2003). Similarly, the change in conductivity was measured 
at a relatively high frequency (100 kHz) (Surowiec et al., 1986). Therefore the tissue 
properties used in the postmortem in vivo circuit model were only approximations for 
impedance changes in the cat brain during DBS. 
A limitation of the experimental methods used in this study was that a clinical 
DBS electrode was used for most of the in vitro testing, whereas a mini DBS electrode 
was used in the in vivo experiments. We chose to evaluate the in vitro performance of the 
DBS-ECAP instrumentation with the clinical DBS electrode since the ECAP recording 
technique is intended for clinical translation. Conversely, the mini DBS electrode was 
more appropriate for the size of the cat brain. Nevertheless, the stimulus artifact and 
mECAP waveforms recorded with the clinical DBS electrode were very similar to those 
recorded with the mini DBS electrode during in vitro testing. 
2.5 Appendix 
Distortion values were calculated as the error between the recorded and ideal 
mECAPs, and decreased as DBS pulse width was reduced or mECAP latency increased 
(Fig. 2.10A). With 3 V DBS in the monopolar symmetric configuration, the DBS-ECAP 
instrumentation recorded small magnitude (0.18 mVP-P) mECAPs with relatively low 
DPS values in the range of 0.17 to 0.26 at latencies of only 0.5 ms after DBS pulses of 50 
or 100 s duration, or latencies of 1 ms after long, asymmetric DBS pulses with 50 s first 
phase and 500 s second phase (Fig. 2.10A, filled bars). In cases where a very short 
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Figure 2.10: Distortion per sample of the mECAP across DBS and mECAP 
stimulation parameters, measured in vitro with the monopolar symmetric 
configuration. A: Effect of DBS pulse width and mECAP latency on distortion. DBS 
parameters were 3 V amplitude, 100 Hz frequency, and cathodic-phase first polarity, 
and sinusoidal mECAP parameters were 0.18 mVP-P amplitude (0.1 mAP-P input 
amplitude) and 4 kHz frequency. The narrow, filled bars show distortion values for 
the DBS-ECAP instrumentation, whereas the wider, open bars show the distortion for 
the series amplifiers with diodes. For some trials, the mECAP was masked and these 
are marked by a white X when masked with series amplifiers with diodes, and a filled 
X when masked with both instrumentation systems. The inset shows mECAPs 
recorded with the DBS-ECAP instrumentation (solid trace) and ideal mECAP sinusoid 
(dashed trace) for a DBS pulse width of 50 s and the denoted mECAP latency. B: 
Effect of DBS and mECAP amplitudes on distortion. DBS parameters were 100 Hz 
frequency, 50 s pulse width, and cathodic-phase first polarity, and the sinusoidal 
mECAP parameters were 0.2 ms latency and 4 kHz frequency. Data presentation is 
otherwise identical to that in (A). 
latency mECAP was coupled with a relatively long DBS pulse width, the mECAP was 
masked by amplifier blanking. Using the series amplifiers with diodes, the mECAP was 
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more distorted (Fig. 2.10A, open bars) and masked by the artifact in some trials, while 
using the conventional amplifier resulted in a minimum DPS value of 1.26 across all 
combinations of DBS pulse widths and mECAP latencies tested.  
Distortion decreased as DBS amplitude was reduced or mECAP amplitude was 
increased (Fig. 2.10B). Short latency mECAPs overlapped with the stimulus artifact, and 
larger mECAP amplitudes or smaller DBS amplitudes increased the relative magnitude 
of the mECAP signal over the artifact. Applying 50 s DBS pulses with the monopolar 
symmetric configuration, the DBS-ECAP instrumentation recorded short latency (0.2 
ms) mECAPs with relatively low DPS values under 0.35 at mECAPs amplitudes of only 
0.18 mVP-P for 0 or 1 V DBS, and amplitudes of 0.53 mVP-P for 2 or 3 V DBS (Fig. 2.10B, 
filled bars). Using the series amplifiers with diodes, distortion was larger (Fig. 2.10B, 
open bars). The conventional amplifier could record mECAPs with DPS values under 0.5 
at a DBS amplitude of 1 V, only with a large mECAP amplitude of 0.88 mVP-P.  
Compared to the monopolar symmetric configuration, the minimum mECAP 
latencies and amplitudes necessary for low distortion recording were generally 
equivalent for the bipolar configuration and greater for the monopolar asymmetric 
configuration with the DBS-ECAP instrumentation. This disparity across contact 
configurations was generated by differences in the magnitude of the stimulus artifacts 
and of the recorded mECAPs for a given input amplitude. For example, a mECAP with 
0.1 mAP-P input amplitude corresponded to a recorded amplitude of 0.18, 0.11, and 0.30  
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Figure 2.11: In vitro stimulus artifact waveforms measured with the monopolar 
asymmetric and bipolar contact configurations, using the series amplifiers with 
diodes (black traces), series amplifiers with diodes and stimulator relay (red traces), 
and DBS-ECAP instrumentation (blue traces). DBS was applied with 3 V amplitude, 
100 Hz frequency, 50 s pulse width, and cathodic-phase first polarity. The stimulus-
triggered average waveform (bold traces) and single trials (light traces) are shown. 
The insets show a zoomed view of the stimulus artifact waveforms for the DBS-ECAP 
instrumentation. 
mVP-P for the monopolar symmetric, monopolar asymmetric, and bipolar configurations, 
respectively. Further, the artifact magnitude increased from monopolar symmetric to 
asymmetric configurations, and from monopolar asymmetric to bipolar configurations 
(Figs. 2.4C, 2.11), which decreased the amplifier gain possible without saturation (Table 
2.1). Moreover, the relative magnitude of the stimulus artifact and mECAP has a critical 
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influence on the recording fidelity (Fig. 2.10B), and likely also contributed to the 
differences in distortion observed between contact configurations. 
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3. Neural origin of evoked potentials during thalamic 
deep brain stimulation 
This chapter has been previously published and is used with permission (Kent 
and Grill, 2013). 
3.1 Introduction 
Deep brain stimulation (DBS) is a clinically effective treatment for movement 
disorders, including Parkinson’s disease (PD) (Benabid et al., 1994) and essential tremor 
(ET) (Benabid et al., 1991, Pahwa et al., 2006), and is being investigated for other 
neurological disorders such as epilepsy (Hodaie et al., 2002). Present DBS systems 
operate in an open-loop fashion, in which patients receive invariant stimulation 24 
hr/day indefinitely, and a physician closes the loop through periodic re-tuning of 
stimulation parameters (Kuncel and Grill, 2004). The selection of stimulation parameters 
can be time-consuming and costly (Ondo and Bronte-Stewart, 2005), may not result in 
optimal settings for the patient (Okun et al., 2005, Moro et al., 2006), and presents a 
significant clinical burden. The efficacy of therapy can be improved by more frequent 
parameter adjustment (Moro et al., 2006, Frankemolle et al., 2010, Lee et al., 2010), 
potentially compensating for progression of the disease state (Krack et al., 2003, Deuschl 
et al., 2006, Weaver et al., 2012). We are exploring evoked potentials as a feedback signal 
for closed-loop control of DBS parameters, and the objective of this work was to 
characterize evoked potentials during stimulation. 
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Closed-loop DBS systems would automatically and periodically adjust 
stimulation parameters to optimize symptom relief and reduce the time required for 
programming. One potential closed-loop feedback signal is the local field potential (LFP) 
recorded from the DBS electrode and reflecting synchronized network activity 
(Marceglia et al., 2007, Santaniello et al., 2011) that is correlated to motor symptoms in 
PD (Smirnov et al., 2008, Tass et al., 2010) and ET (Kane et al., 2009). Beta band (13-35 
Hz) activity in PD (Brown and Williams, 2005) and theta band (4-7 Hz) activity in ET 
(Kane et al., 2009) are disrupted by DBS (Ray et al., 2008, Bronte-Stewart et al., 2009, 
Rosa et al., 2011, Santaniello et al., 2011, Eusebio et al., 2012), suggesting that LFP 
recordings might be used to identify clinically effective stimulation parameters (Yoshida 
et al., 2010). Additionally, a closed-loop DBS system used single-unit activity from 
primary motor cortex (M1) as a trigger for each stimulus pulse in the globus pallidus 
interna (GPi), and demonstrated greater symptom reduction than continuous, open-loop 
stimulation (Rosin et al., 2011). 
We are investigating evoked compound action potentials (ECAPs) as a potential 
feedback control signal for closed-loop DBS. The ECAP is generated by the 
transmembrane currents of activated neurons near the electrode following each 
stimulation pulse, and therefore provides insight into the activity of neural elements that 
are affected by stimulation. We previously demonstrated that ECAPs can be recorded 
from the DBS electrode during thalamic stimulation (Chapter 2). Similarly, clinical 
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recordings of ECAPs made from the cochlea served as a feedback signal in the selection 
of stimulation parameters in cochlear implants (Miller et al., 2008, Jeon et al., 2010), and 
closed-loop cochlear systems have been designed (Mc Laughlin et al., 2012).  
In this work we quantified the effects of changes in stimulation parameters on 
the characteristics of the ECAPs recorded during thalamic DBS in cats. Characteristic 
changes in the ECAP across stimulation parameters could potentially provide insight 
into the type and extent of neural activation during DBS. We combined administration 
of pharmacological agents to block specific neural elements and a computational model 
of thalamic DBS (Birdno et al., 2012) to determine the contribution of different neural 
elements to the ECAP. 
3.2 Methods 
We combined experimental measurements and computational modeling to 
quantify changes in the ECAP across DBS parameters and to identify the neural origin of 
the ECAP. 
3.2.1 In vivo ECAP recording  
We recorded the ECAPs generated during thalamic DBS in 17 male, domestic 
short-haired cats (Table 3.1), initially anesthetized with ketamine HCl (35 mg/kg i.m.) 
and maintained with alpha chloralose (65 mg/kg i.v. supplemented at 15 mg/kg as 
needed). A ventilator maintained end tidal CO2 at 3-4%, body temperature was 
maintained at 38°C with heating pads, arterial blood pressure was monitored with a 
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catheter, and fluids were administered continuously (10-15 ml/kg/h). The Institutional 
Animal Care and Use Committee of Duke University reviewed and approved all animal 
care and experimental procedures. The methods were reported previously in detail 
(Chapter 2), and are reviewed briefly here.  
Table 3.1: Summary of in vivo experiments, including DBS electrode location 
as identified from histology, stimulation and recording contacts for the three contact 
configurations, and the pharmacological agents tested in order of administration. The 
asterisk (*) indicates that the DBS electrode location was not confirmed with 
histology, but was consistent with evoked responses recorded during sciatic nerve 
stimulation. VPL: ventral posterolateral nucleus, VL: ventral lateral nucleus, VA: 
ventral anterior nucleus, LGN: lateral geniculate nucleus.  
  Stimulation (Recording)  
Cat 
Electrode 
Location 
Mono. 
Symm. 
Mono. 
Asymm. Bipolar 
Pharmacological Agent(s) 
(Volume Injected in µL) 
A VPL-VL 1 (0+/2-) 0 (1+/2-) -- -- 
B VA 1 (0+/2-) 2 (1+/0-) -- -- 
C VPL-VL 1 (0+/2-) 3 (2+/1-) -- -- 
D VPL-VL 1 (0+/2-) 0 (1+/2-) -- -- 
E VPL-VL 1 (0+/2-) 0 (1+/2-) -- -- 
F VPL-VL 2 (1+/3-) 0 (1+/2-) 0+/2- (1+/3-) -- 
G LGN 1 (0+/2-) 0 (1+/2-) 0+/2- (1+/3-) TTX (10) 
H VPL-VL 2 (1+/3-) 1 (2+/3-) 0+/2- (1+/3-) Saline (5), CNQX/APV (5) 
I VPL-VL 1 (0+/2-) 0 (1+/2-) 0+/2- (1+/3-) Saline (5), CNQX/APV (5) 
J VPL-VL* 2 (1+/3-) 0 (1+/2-) 0+/2- (1+/3-) 
Isoflurane, Saline (5), 
CNQX/APV (10) 
K VPL-VL 2 (1+/3-) 3 (2+/1-) 1+/3- (0+/2-) Isoflurane, 2% Lidocaine (20) 
L VPL-VL 2 (1+/3-) 1 (2+/3-) 0+/2- (1+/3-) Isoflurane, 2% Lidocaine (20) 
M VPL-VL* 2 (1+/3-) 3 (2+/1-) 0+/2- (1+/3-) Muscimol (20) 
N 
Dorsal 
thalamus 
1 (0+/2-) 0 (1+/2-) 0+/2- (1+/3-) Muscimol (10) 
O VPL-VL 1 (0+/2-) 1 (2+/3-) 0+/2- (1+/3-) 5% Lidocaine (20), CNQX/APV (20) 
P VPL-VL 1 (0+/2-) 3 (2+/1-) 1+/3- (0+/2-) 10% Lidocaine (20), CNQX/APV (10) 
Q VPL-VL 1 (0+/2-) 2 (1+/0-) 1+/3- (0+/2-) 10% Lidocaine (20), CNQX/APV (20) 
 
 87 
With the cat prone and the head fixed in a stereotactic frame, a craniotomy was 
performed and thalamic nuclei were located using stereotactic technique and single-unit 
microelectrode recordings. The target implantation site was the ventrolateral (VL) 
nucleus of the thalamus, which is a cerebellar receiving area (Jimenez Castellanos, 1949, 
Berkley, 1983, Steriade et al., 1997) and appears to represent the feline homologue of the 
human ventral intermediate (Vim) nucleus of the thalamus (Steriade et al., 1997). The 
medial and lateral ventral posterior (VPM and VPL) nuclei form the ventrobasal 
complex (referred to as the ventrolateral complex by some authors (Butler and Hodos, 
2005)) and function as the principal somatosensory relay nuclei (Jimenez Castellanos, 
1949, Steriade et al., 1997). The VL thalamus also receives somatosensory input, 
including Group I muscle afferents (Boivie, 1971, Jones and Burton, 1974, Craig and 
Burton, 1985, Hirai and Jones, 1988), and the border region between the VPL and VL in 
the cat receives converging somatosensory and cerebellar afferents (Berkley, 1983). We 
attempted to identify the location of the VPL-VL thalamic complex through single-unit 
recording of neurons responding to passive movement of the contralateral hind limb 
(Mallart, 1968, Berkley, 1983). A guide tube was then inserted into the brain using a 
micromanipulator, and a mini DBS electrode (Numed) implanted through the guide 
tube into the VPL-VL thalamus (Fig. 3.1A). The mini DBS electrode had a lead body 
diameter of 0.625 mm, and four contacts of 0.5 mm height separated by 0.5 mm. 
Accurate implantation was confirmed by recording with the DBS electrode responses 
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evoked by electrical stimulation of the contralateral sciatic nerve. At the conclusion of 
each experiment, the anatomical location of the electrode with reference to a stereotactic 
atlas of the cat brain (Snider and Niemer, 1961) was determined from Nissl stained 
sections of formalin-fixed brain samples (McConnell et al., 2009). For all experiments, we 
verified that the ECAP was indeed a biological response by recording the neural activity 
at several time points following euthanasia and confirming that the ECAP was 
eventually abolished. 
 
Figure 3.1: Experimental setup used to record ECAPs in vivo during DBS. A: 
The mini DBS electrode was inserted through a guide tube and implanted in the VPL-
VL thalamic complex, and was used to deliver stimulation and record the resulting 
ECAP. Pharmacological agents were administered through a needle cannula, with 
injection speed and volume controlled using a microsyringe. Modified from (Kent 
and Grill, 2012). B: Example DBS contact connections used for stimulation and 
recording across the three contact configurations tested. The contacts that were not 
used are colored grey. 
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DBS was symmetric biphasic pulses with zero inter-phase delay. Voltage-
controlled stimulation was used for clinical relevance, and parameters ranged from 1-3 
V amplitude, 10 or 100 Hz frequency, 50 or 100 μs/phase pulse width, and both cathodic- 
and anodic-phase first polarities. Impedances measured between each contact and the 
counter electrode were approximately 1 k, resulting in a maximum charge of 0.3 
µC/phase and maximum charge density of 30 µC/cm2. Differential ECAP recordings 
were made from two non-stimulating contacts and a Ag/AgCl reference electrode 
(Model EL504, Biopac Systems) placed on the neck using our previously developed 
DBS-ECAP instrumentation (Chapter 2). This DBS-ECAP hardware was used to 
suppress the stimulus artifact, which could otherwise mask or distort experimental 
ECAP signals. It uses three stages of amplification, an amplifier blanking technique, and 
other circuit components to reduce selectively the amplitude and duration of the artifact. 
Three different contact configurations were used for stimulation and differential 
recording: monopolar stimulation between a contact on the DBS electrode and a 
stainless steel retractor in the ipsilateral chest with either symmetrical recording contacts 
(monopolar symmetric) or asymmetrical recording contacts (monopolar asymmetric), as well 
as bipolar stimulation in which stimulation and recording contacts were interleaved (Fig. 
3.1B). ECAP recording trials were 10 s in duration and were separated by 10 s. A 
LabView program controlled the DBS output, digital pulses to operate the DBS-ECAP 
instrumentation, and sampling (80 kHz) of the ECAP. 
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We conducted pharmacological interventions to block specific neural elements 
and determine the corresponding effect on the ECAP (Table 3.1). Most pharmacological 
agents were administered using local microinjection through a 22G needle cannula, 
which was connected to a 250 μL microsyringe (Model 1725, Hamilton) via saline-filled 
tubing (Fig. 3.1A). The agent was loaded at the cannula end of the injection system, and 
the cannula was implanted using a second micromanipulator at a distance of less than 1 
mm anterior or posterior to the stimulation contact. Within one minute of cannula 
implantation, we injected 5-20 μL of the agent at approximately 5 μL/min. Following 
administration and again after washout, ECAPs were recorded across a range of 
stimulation parameters using the monopolar symmetric contact configuration. Some 
animals received multiple pharmacological treatments, with successive administration 
after recovery from the prior treatment. 
Agents were chosen to inhibit synaptic transmission or neural excitation. First, 
we blocked post-synaptic excitation by administering CNQX (2.54 mM, Sigma-Aldrich) 
and APV (2.15 mM, Sigma-Aldrich), which are glutamate AMPA and NMDA receptor 
antagonists, respectively. Second, the GABAA receptor agonist muscimol (8.8 mM, 
Sigma-Aldrich) was injected to inhibit post-synaptic cells. Third, we administered 
sodium channel antagonists tetrodotoxin (TTX, 100 μM, EMD Chemicals) or 2-10% 
lidocaine HCl (0.07-0.35 M, Sigma-Aldrich) for non-selective inhibition of neural 
excitation. To limit dilution of lidocaine HCl by the saline present in the tubing of the 
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microinjection system, 5 μL mineral oil was loaded into the system to serve as a border 
between the saline and lidocaine (Noudoost and Moore, 2011). Fourth, 2% isoflurane 
anesthesia was administered through the ventilator, which selectively inhibited pre-
synaptic inputs in the rodent thalamus (Joksovic et al., 2009, Ying et al., 2009) and 
brainstem (Wu et al., 2004). As well, a saline control was injected to test whether the 
fluid flow generated by microinjection changed ECAP characteristics (Rathnasingham et 
al., 2004, Rohatgi et al., 2009). Due to the relatively long half-life of TTX (Boehnke and 
Rasmusson, 2001) and CNQX/APV (Long et al., 1990), we did not wait for signal 
recovery from washout of these agents, and these were the final agents tested in an 
experiment.  
3.2.2 Computational model of the ECAP 
We used a three-stage computational model of thalamic DBS to calculate the 
ECAP and determine the neural elements that contributed to the compound response 
(Fig. 3.2). The first stage was a finite element method (FEM) model used to calculate the 
voltages generated in the modeled tissue during DBS. The results of the FEM were 
coupled to the second stage, multi-compartment cable models of a population of 
thalamocortical (TC) neurons and their pre-synaptic inputs, to calculate the 
transmembrane potentials and currents in the neural elements during DBS. In the third 
stage of the model, we used the reciprocity theorem to calculate the ECAP generated by 
the transmembrane currents of the neural elements.  
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A FEM model was constructed in COMSOL Script 1.2 (COMSOL) to calculate the 
voltages generated by a three-dimensional representation of the mini DBS electrode 
within a prism representation of the cat VL thalamus (Fig. 3.2A) (Birdno et al., 2012). The 
dimensions of the thalamic nucleus were similar to the original model, except that the  
perpendicular distance between prism bases along the superior-inferior axis was 
reduced from 10 mm to 2.8 mm, which more closely matched the anatomy of the cat 
(Jimenez Castellanos, 1949). DBS contacts 0 to 2 were located within the VL thalamus, 
where contacts were labeled 0-1-2-3 in a ventral-to-dorsal direction. The electrode and 
VL thalamus laid within a cylindrical representation of surrounding brain tissue, 
oriented parallel to the electrode with a diameter 64 times that of the electrode and 
centered at the electrode tip. This modeled tissue volume was sufficiently large because 
doubling the diameter changed the potentials by only 4.2±2.4% (mean ± SD). The tissue 
was homogenous and isotropic with a resistivity of 300 Ω-cm (Moffitt and McIntyre, 
2005), and the resistivities of the DBS electrode contacts and insulating material were 
20×10-6 Ω-cm and 1×1015 Ω-cm, respectively (Yousif et al., 2008a). The boundary of the 
active DBS stimulation contact(s) was set to ±1 V and the outer boundary of the 
cylindrical representation of the tissue was grounded. All other internal boundaries 
were set to a condition of continuity of normal current density. COMSOL Script created 
a variable resolution mesh with approximately 350,000 tetrahedral elements, which was 
a sufficient mesh density as doubling the number of elements changed the potentials by  
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Figure 3.2: Computational model of a population of thalamic neurons used to 
calculate ECAPs during thalamic DBS. A: The FEM model geometry included a mini 
DBS electrode implanted in a prism representation of the cat VL thalamus, all 
encompassed in a cylindrical representation of surrounding brain tissue (not shown). 
The VL thalamus contained 500 thalamocortical (TC) neurons, with cell locations 
indicated by the dots, and pre-synaptic inputs from the cortex (CTx), cerebellum 
(CER), reticular nucleus (RN), and thalamic interneurons (TIN). The anatomical 
positions of the elements are shown for one neural unit, including the cell body, 
dendritic tree, and axon of the TC cell (black shapes) and the axons of the pre-synaptic 
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inputs (grey lines). B: The synaptic connections made between neural elements in the 
model included glutamatergic and GABAergic synapses from pre-synaptic elements 
to the TC neuron. Additionally, there were excitatory 1:1 synapses between the neural 
elements, implemented using virtual axons. Modified from (Birdno et al., 2012). 
only 0.2±0.1%. Voltages were calculated by solving the Poisson equation at the mesh 
nodes using the conjugate gradient method. Since the bulk conductivity was linear, 
potentials generated at different stimulation amplitudes were scaled versions of the 
original solution. 
In the second stage, the FEM solution was coupled to validated multi-
compartment cable models (McIntyre et al., 2004a, Birdno et al., 2012) implemented in 
NEURON 7.1 (Hines and Carnevale, 2001) (Fig. 3.2). The model of a population of 
thalamic neurons included 500 TC neurons, with cell body locations randomly 
distributed within the VL thalamus, and their pre-synaptic inputs, including excitatory 
glutamatergic inputs from the cortex (CTx) and cerebellum (CER), and inhibitory 
GABAergic inputs from the reticular nucleus (RN) and local thalamic interneurons (TIN) 
(Birdno et al., 2012). The TC neurons had a multi-compartment soma, initial segment, 
and branching dendritic tree (McIntyre et al., 2004a), and the myelinated axons of the TC 
neurons and pre-synaptic inputs were represented with a double-cable model (McIntyre 
et al., 2002). Additionally, there were reliable 1:1 synapses (one input spike 
corresponded to one time-delayed output spike) from TC and CTx to RN, and from CTx 
and CER to TIN, implemented with virtual terminating axons. The synaptic time delays 
representing conduction of the action potentials down the virtual axons were reduced to 
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0.225 ms for connections to TIN and 0.3 ms for connections to RN, from the values in the 
original model, to match better the latency of experimentally-recorded post-synaptic 
potentials (Ando et al., 1995). Neural elements that intersected with the electrode were 
removed from analysis. Further, we removed the intrinsic activity applied to CTx and 
CER inputs and the TC somatic noise present in the original model. 
The voltages calculated with the FEM were interpolated at the locations of the 
neural elements, scaled according to the DBS amplitude, and applied to elements using 
the extracellular mechanism in NEURON. The time-dependent DBS waveform was 
symmetric and biphasic with specified pulse width and frequency, and both cathodic- 
and anodic-phase first polarities were applied. The transmembrane potential and 
current at model compartments were calculated by backward Euler implicit integration. 
Neural activation was detected using a -20 mV threshold at the initial segment of the TC 
neuron or the proximal end of pre-synaptic inputs. The simulation time was 1.5 s, with a 
pre-stimulation period of 0.5 s, and a 25 μs time step. 
The final stage of the model was the calculation of ECAPs using the reciprocity 
theorem. The theorem of reciprocity states that the voltage at a particular point in space 
resulting from a unit current source at the electrode contact translates to the voltage that 
would be imposed on the contact by a unit current at the particular point (Helmholtz, 
1853). Applying this theorem, the FEM model was solved with a unit current source 
placed at the boundary of one of the recording contacts, and subsequently repeated for 
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the other recording contact. The potentials generated by the current source were 
interpolated at the compartment locations of the neural elements. By the reciprocity 
theorem, the scale factors were used to calculate the voltage impressed on the contact by 
transmembrane currents calculated from the NEURON simulation at each time step 
(Moffitt and McIntyre, 2005). The voltages generated by these currents at each recording 
contact were summed across every compartment of all neural elements, and the time-
dependent ECAP calculated as the differential voltage between the two recording 
contacts. We accounted for the true cell density (65 cells/mm2 in 50 μm sections (Hirai et 
al., 1989)) by scaling the ECAP magnitude by a factor of 102. As well, we filtered the 
model-generated signals with two cascaded first-order 10 Hz - 10 kHz bandpass filters 
to replicate the filtering performed experimentally. 
We used template subtraction to remove the stimulus artifact, generated by 
passive charging and discharging of the membrane capacitance of neural elements 
(Briaire and Frijns, 2005), from the model-generated ECAP. The artifact template was 
calculated using a sub-threshold stimulation train (0.01 V), with pulse width, frequency, 
and polarity identical to those used in the trial of interest. This template was scaled 
according to the amplitude of DBS in the trial of interest and subtracted from the signal 
(Fig. 3.3). 
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Figure 3.3: Template subtraction method used to remove the stimulus artifact 
from the model ECAP. Responses were calculated using a monopolar symmetric 
contact configuration with 100 Hz frequency and 50 µs/phase pulse width. The 
stimulus-triggered average ECAP (bold lines) are shown for cathodic- and anodic-
phase first DBS polarities. The single trials (light traces) are also shown for the two 
polarities in dark and light grey, respectively. A: The signal calculated at 3 V included 
a stimulus artifact followed by the ECAP. B: A template of the stimulus artifact was 
calculated at a sub-threshold amplitude of 0.01 V, and scaled (300x) to create the 
artifact at 3 V. C: Subtracting the artifact template from the original signal produced 
an artifact-free ECAP. 
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Model ECAPs were calculated using stimulation parameters, contact 
configurations, and pharmacological conditions matching those tested experimentally. 
We modeled the effects of TTX and lidocaine by blocking sodium channels. The effects 
of CNQX/APV were represented by blocking excitatory glutamatergic receptors on TC 
cells and 1:1 synaptic receptors on TINs. Muscimol was modeled by increasing the 
concentration of GABA to which GABAA receptors were exposed by 20% of the 
maximum concentration present in the untreated case for the entire simulation. This was 
based on the 15-20% of GABAA receptors bound by muscimol in cat motor thalamic 
nuclei (Kultas-Ilinsky et al., 1988). We also calculated the ECAP after selective inhibition 
of pre-synaptic inputs, which was the presumed effect of isoflurane. For the bipolar 
contact configuration, we investigated the effect on the ECAP of a ventral or dorsal shift 
of the electrode along its axis, such that contact 0 or 2 was outside the VL thalamus, 
respectively. We also modeled the ECAP generated in the internal capsule (IC), which is 
adjacent and lateral to the VPL-VL thalamus, by replacing the neural elements with a 
population of 500 passing axons with 2 m diameter lying parallel to the DBS electrode. 
3.2.3 Data analysis 
Stimulus-triggered averaging (64 responses for experimental signals and 8 
responses for computational signals) was applied to the ECAPs to improve the signal-to-
noise ratio. We quantified ECAP characteristics by calculating the signal energy of the 
experimental and computational ECAPs. First, any offset present in the stimulus-
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triggered averaged ECAP signal was calculated as the mean of the final 1 ms of signal 
and subtracted. Second, the integral of the square of the signal was calculated for 
different ECAP phases. 
Experimental and computational ECAPs were compared both qualitatively, 
through analysis of waveform shape, and quantitatively through calculation of 
correlation coefficients for ECAP signal energy values across stimulation parameters. 
Subsequently, neural element activation in the model was analyzed as the percentage of 
neural elements (TC neurons and pre-synaptic inputs from CTx, CER, TIN, and RN) that 
fired an action potential following a stimulus pulse within a given 0.1 ms bin, and 
analyzed over the same time interval used for calculation of the stimulus-triggered 
average ECAP. 
Differences in experimental ECAP characteristics across stimulation parameters 
were identified with the non-parametric Wilcoxon signed-rank test following a 
Bonferroni correction (α=0.002), using Statview 5 (SAS Institute).   
3.3 Results 
The characteristics of ECAPs during thalamic DBS were consistent across 
experiments but varied systematically with stimulation parameters. Pharmacological 
interventions resulted in clear changes in ECAP waveforms and provided insight into 
the neural origin of the different ECAP phases. The model-generated ECAPs were 
similar to the experimental waveforms across stimulation conditions and following 
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pharmacological interventions, and provided additional insight into the type and extent 
of neural element activation constituting the ECAP signal. 
3.3.1 Experimental and computational ECAPs 
The mini DBS electrode was implanted in the VPL-VL thalamic complex 
accurately in 14 of 17 experiments (Table 3.1), and quantitative analysis of ECAP 
characteristics was performed using results from experiments with accurate electrode 
implantation.  
The characteristics of ECAPs recorded with the monopolar symmetric 
configuration were dependent on the electrode position and DBS parameters (Figs. 3.4A-
E, top row). Characterization of ECAPs with the monopolar asymmetric and bipolar 
contact configurations is presented in the Appendix. ECAPs exhibited primary positive 
(P1) and negative (N1) phases with latencies of approximately 0.25 and 0.75 ms, 
respectively, and secondary phases of either short latency (P2 at 1 ms and N2 at 1.5 ms) 
and short duration (less than 1 ms), or long latency (P2 at 3 ms) and long duration (on 
the order of 10 ms), as shown in cat Q (Figs. 3.4A-D) or cat I (Fig. 3.4E), respectively. The 
secondary phase latency was always greater than 0.7 ms. ECAPs had short latency 
secondary phases in 8 experiments, long latency secondary phases in 3 experiments, and 
both types were present in 3 experiments (in which case the additional phases were 
labeled in succession as P3, N3, etc.). When the short latency secondary response was  
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Figure 3.4: ECAPs recorded with the monopolar symmetric contact 
configuration. A-E: Comparison of ECAPs recorded experimentally (top row) with 
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those calculated using the computational model (middle row), and percentage of 
model elements activated in 0.1 bins following DBS pulses (bottom row). The latter 
was calculated for each element type individually and is shown in a stacked bar 
format, in which activation of a specific type of neural element (0-100%) is given by 
the height of the corresponding segment within the bar. The "standard" DBS 
parameter set was 3 V amplitude, 100 Hz frequency (F), 50 μs/phase pulse width (PW), 
and cathodic-phase first polarity, and one parameter (polarity, amplitude, PW, or F) 
was varied between subplots. The stimulus-triggered average ECAP (bold lines) and 
single trials (light traces) are shown, and ECAP phases are labeled. The experimental 
recordings were from cat Q (A-D) or cat I (E). The ECAP signal appears cutoff at 100 
Hz DBS in (E) because the interpulse interval (corresponding to the ECAP recording 
window) was 10 ms. F: Model ECAP contributions individually from TC neurons or 
pre-synaptic inputs with 3 V, 10 Hz, 50 μs/phase, and both cathodic- and anodic-phase 
first polarities. 
present, the electrode was generally implanted centrally within the VPL-VL thalamus or 
at the lateral border, while when the long latency secondary response was present the 
electrode was typically located at the dorsolateral border. ECAPs were similar for 
cathodic- and anodic-phase first polarities (Fig. 3.4A). Moreover, the magnitude and 
duration of the phases generally increased with DBS amplitude (Fig. 3.4B) and pulse 
width (Fig. 3.4C). The latency of primary phases also increased with longer pulse 
widths, and N1 masked the secondary phases at 100 µs pulse width for cat Q (Fig. 3.4C). 
The P1 phase had a lower DBS amplitude threshold than the other phases in 5 of 14 cats, 
N1 had the lowest threshold in 1 cat, and P1 and N1 had the same threshold in the 
remaining cats. Further, we never observed the presence of secondary phases without 
N1 also being present. Reducing DBS frequency from 100 Hz to 10 Hz led to increases in 
the magnitude of secondary phases, and in some experiments, also generated additional 
P3 and N3 phases (Figs. 3.4D,E). 
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The signal energy of ECAPs was quantified across experiments for the entire 
ECAP signal and separately for the primary and secondary phases (Fig. 3.5A). The 
ECAP energy (Fig. 3.5B) increased with higher DBS amplitudes (P<0.0001) and pulse 
widths (P<0.002). There was also a small effect of frequency, and ECAP energy was 
greater at 10 Hz than 100 Hz for amplitudes of 2 or 3 V and a pulse width of 100 s 
(P<0.002). Similar trends were observed between the signal energy of primary phases 
and DBS amplitude (P<0.001) and pulse width (P<0.002), except that no frequency effect 
was observed (Fig. 3.5C). Lastly, the signal energy of secondary phases (Fig. 3.5D) 
increased with DBS amplitude (P<0.002) and pulse width (P<0.002) only at 10 Hz, and 
was generally greater at 10 Hz than 100 Hz across tested amplitudes and pulse widths 
(P<0.002). This difference between DBS frequencies was not simply a reflection of 
cropping of the secondary phases by the shorter interpulse interval (IPI) at 100 Hz 
compared to 10 Hz DBS. The ECAP returned to baseline prior to the end of the IPI at 100 
Hz in 10 out of 14 experiments. In the other 4 experiments (cats J, L, P, and Q), the final 
ECAP value at the end of the IPI was only 4.9%±0.7% (mean ± SE, range: 0.3-23.7%) of 
the peak ECAP magnitude across stimulation parameters, and removing these 
experiments from the statistical analysis did not change the statistical significance 
between 10 and 100 Hz DBS as identified in Fig. 3.5D. The variance observed in signal 
energy measurements across experiments was generated both by variance between  
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Figure 3.5: Quantification of ECAP characteristics across experiments with the 
monopolar symmetric contact configuration. A: The ECAP signal was squared, and 
signal energy was calculated by integrating across the entire ECAP signal and 
separately for the primary phases (dark fill) and secondary phases (grey fill). The 
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signal energy values across experiments for the (B) entire ECAP signal, (C) primary 
phases, and (D) secondary phases. The boxes have lines at the lower quartile, median, 
and upper quartile values. Statistical differences between parameters were identified 
using the Wilcoxon signed-rank test with Bonferroni correction: # significantly 
greater than 1 V DBS, ∧ significant greater than 2 V DBS, * significant difference 
between indicated bars (P<0.002). Polarity was treated as a replicate. 
different response classes (i.e., short latency, long latency, or both short and long latency 
secondary phases) and by variance within each class. 
We used a computational model of thalamic DBS to calculate the ECAP and the 
corresponding neural element activation. The model-generated ECAP calculated for 
three cell populations with different random distributions of TC locations within the VL 
thalamus had qualitatively similar waveform characteristics, and we used one 
population for all subsequent analysis. 
The model ECAP waveform characteristics closely matched those of the 
experimentally recorded waveforms in phase polarity, magnitude, and latency across 
DBS parameters. For the monopolar symmetric configuration with 100 Hz DBS, model 
responses had the expected primary phases P1 and N1 followed by secondary phases, 
which included both shorter latency P2 and N2 phases and a longer latency positive 
phase (PLONG) akin to the secondary phase in cat I (Figs. 3.4A-E, middle row). Greater 
DBS amplitudes and pulse widths typically led to increases in the magnitude and/or 
duration of ECAP phases. The latency of the P1 phase also increased with a longer pulse 
width. Moreover, model ECAPs were similar for opposite stimulation polarities. Finally, 
when DBS frequency was reduced from 100 to 10 Hz, the model response exhibited 
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additional secondary phases, P3 and N3, and increases in the magnitude of existing 
secondary phases, as observed experimentally. There were strong correlations between 
the signal energies of the model-generated and experimental ECAPs (Fig. 3.6). Both the 
computational and experimental ECAP signal energies had low values for secondary 
phases at 100 Hz DBS, and data were log-transformed to allow for a linear regression 
(Fig. 3.6C).   
We used the model to deconstruct the ECAP signal and determine the neural 
elements contributing to the ECAP components. Monopolar stimulation generated 
direct activation of all model elements, but predominately pre-synaptic elements, within 
approximately 0.6 ms of pulse onset, which corresponded in time with the primary P1 
and N1 phases (Figs. 3.4A-E, bottom row). Subsequently, TC neurons and inputs from 
RN and TIN were post-synaptically activated in the 0.9-3.1 ms window, aligning with 
both the short and long latency secondary phases. The RN inputs were then reactivated 
via the TC-to-RN excitatory synapse in the 4.4-6.3 ms window, and contributed to the 
long latency secondary phase (PLONG) (Fig. 3.4E). Transmembrane potential recordings 
from individual neural elements measured during DBS are provided in the Appendix. 
We selectively recorded the potentials generated by either individual activation of the 
TC neurons or the pre-synaptic inputs to determine their corresponding ECAP 
contributions, and found that the former was primarily responsible for the P1, P3-N3, 
and PLONG phases, whereas the latter generated the N1 and P2-N2 phases and  
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Figure 3.6: Correlation between values of ECAP signal energy from the 
computational model and in vivo experiments, measured with the monopolar 
symmetric configuration, for the entire ECAP signal (A), primary phases (B), and 
secondary phases (C). Each data point corresponds to computational and median 
experimental signal energy values for a single set of stimulation parameters. The size 
of the data point is proportional to the DBS amplitude (1 to 3 V), and color indicates 
the corresponding DBS pulse width and frequency. Polarity was treated as a replicate. 
The correlation coefficients for the linear trend lines (black lines) are provided 
(P<0.002). 
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Figure 3.7: Model ECAPs calculated from a population of parallel axons using 
the monopolar symmetric (A) or bipolar (B) contact configurations. The DBS 
parameters were 3 V, 10 Hz, 50 µs/phase, and both cathodic- and anodic-phase first 
polarities. The stimulus-triggered average ECAP is shown and overlapping the single 
trials (top row), and the percentage activation of the parallel axons in 0.1 ms bins 
following DBS pulses for cathodic-phase first polarity is also provided (bottom row). 
There was a small residual artifact for the bipolar configuration after template 
subtraction, observed as inverted peaks for opposite stimulation polarities. 
contributed to the PLONG phase (Fig. 3.4F). Increasing DBS amplitude or pulse width 
generated a greater extent of direct neural excitation, which paralleled an increase in 
magnitude and/or duration of primary ECAP phases. In some cases, this also led to a 
corresponding increase in post-synaptic activation and larger secondary ECAP phases. 
Decreasing DBS frequency from 100 Hz to 10 Hz reduced the extent of RN and TIN post-
synaptic activity, and increased the synchronization of TC post-synaptic activity (i.e., 
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less temporal dispersion of activation times). The latter may have been responsible for 
generation of P3-N3 and increase in magnitude and duration of PLONG. Lastly, 
stimulation of a population of parallel axons, representing a lateral shift toward the IC 
that was characteristic of electrode placement in some experiments, generated neural 
activation in the range of 0.9-1.8 ms and a corresponding negative ECAP phase with this 
same latency (Fig. 3.7A).  
3.3.2 Pharmacological interventions 
We quantified the effect on ECAP characteristics of pharmacological agents to 
determine the neural origin of the ECAP. Saline microinjection generated negligible 
changes in 2 of 3 cats tested (Fig. 3.8A), and a moderate increase in N1 in cat J, which 
may have still been recovering from isoflurane administration. Microinjection of 
CNQX/APV led to a large reduction in the magnitude and duration of both short and 
long latency secondary phases in 4 of 6 cats (Fig. 3.8A). CNQX/APV also caused a 
decrease (3 cats) or increase (1 cat) in the magnitude of N1, and P1 was reduced in 2 of 
these cats. Administration of muscimol shifted secondary phases towards longer 
latencies and generated a shorter latency negative signal feature (NMUSC) following N1 in 
both cats tested (Fig. 3.8B). A similar but less pronounced negative signal feature was 
also observed after administration of CNQX/APV in cat I (Fig. 3.8A) and lidocaine in cat 
K, but was not reproduced in any other experiment. ECAP signal recovery from the 
effects of muscimol was observed after a 1 hr washout in 1 of 2 cats tested (Fig. 3.8B).  
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Figure 3.8: Effect of pharmacological interventions on the ECAPs measured 
with the monopolar symmetric contact configuration from different experiments (see 
Table 3.1). DBS was applied with 3 V, 10 Hz, 50 or 100 μs/phase, and with cathodic- 
phase first polarity unless otherwise denoted. The stimulus-triggered average ECAP 
(bold lines) and single trials (light traces) are shown. The dashed line indicates 0 mV. 
The ECAP phases are labeled on the untreated traces. A: Signal recorded before 
treatment and 5 min after administration of 5 μL of saline or 5 μL CNQX/APV. B: 
Signal recorded before treatment, 5 min after administration of 20 μL of muscimol, 
and following recovery after a 1 hr washout period. A negative phase (NMUSC) was 
generated after muscimol administration that was not observed in the untreated 
condition. C: Signal recorded before treatment, 5 min after administration of 20 μL of 
10% lidocaine, and following recovery after a 2 hr washout period. D: Signal recorded 
before treatment and 20 min after administration of 10 μL TTX. E: Signal recorded 
before treatment, 10 min after administration of isoflurane anesthesia, and following 
recovery after a 1 hr washout period. The ECAP signal was abolished with 
administration of TTX and isoflurane, and reduced with lidocaine, and the resulting 
signals contained residual stimulus artifact observed as inverted peaks for opposite 
stimulation polarities. 
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 Administration of 5-10% lidocaine reduced the ECAP magnitude, with recovery 
of the signal observed after at least 30 min in 2 of 3 cats (Fig. 3.8C). Conversely, 2% 
lidocaine led to relatively small and inconsistent changes in ECAP characteristics in 2 of 
2 cats. Microinjection of TTX completely eliminated the ECAP in the one cat tested (Fig. 
3.8D). Administering isoflurane anesthesia also completely abolished the signal (Fig. 
3.8E) in 2 of 3 cats, whereas only P1 was eliminated in the other cat. The ECAP 
recovered in 2 of 3 cats following cessation of isoflurane administration and a washout 
period of at least 30 min.  
 The model was also used to simulate the effects of the pharmacological 
interventions performed experimentally. Administration of CNQX/APV was modeled 
by blocking excitatory receptors on TC and TIN, which eliminated post-synaptic 
activation of these elements relative to the untreated case (Figs. 3.9A,B). Further, 
CNQX/APV resulted in reduced direct activation of TC neurons, due to the decrease in 
excitatory input, hyperpolarization of TC somata, and an increased stimulation 
threshold (Fig. 3.9B). These changes were manifested as a reduction in secondary ECAP 
phases, while primary phases were relatively unaffected. The residual secondary phase 
activity was generated by post-synaptic activation of RN inputs, and was eliminated by 
inhibiting all model synapses (Fig. 3.9C). Administration of muscimol was modeled as 
an increase in the concentration of GABA at GABAergic receptors on TC neurons, and 
led to hyperpolarization of TC somata (Fig. 3.9D). As a result, direct activation of TC  
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Figure 3.9: Simulation of effects of pharmacological agents on the model-
generated ECAP. The ECAP (top row), and percentage of neural elements activated in 
0.1 bins following the DBS pulse (bottom row) are shown for the untreated case (A), 
and after inhibition of excitatory receptors on TC and TIN (B), inhibition of all 
synapses (C), addition of a GABAA agonist (D), inhibition of sodium channels (E), and 
inhibition of pre-synaptic inputs (F). The monopolar symmetric contact configuration 
was used, with DBS applied using 3 V, 10 Hz, 50 μs/phase, and both cathodic- and 
anodic-phase first polarities. Percentage activation is shown for cathodic-phase first 
polarity. The insets in (B) and (D) show the transmembrane potential recordings from 
TC somata following a DBS pulse applied at t=2 ms for the untreated case and after 
pharmacological intervention. The cell hyperpolarization generated by inhibition of 
excitatory synapses blocked direct activation of the TC cell. Similarly, cell 
hyperpolarization generated by the presence of the GABAA agonist led to inhibition 
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of post-synaptic activity in Soma A, and delayed generation of an action potential in 
Soma B. 
neurons was reduced, and post-synaptic activation was either inhibited in some cells or 
delayed in others. The effect on the ECAP was evident in secondary phases P3, N3, and 
PLONG as a shift towards longer latencies, which matched the changes observed 
experimentally. Blocking sodium channels abolished all neural activation and the 
corresponding ECAP (Fig. 3.9E), as observed with experimental administration of TTX 
and to a lesser extent with lidocaine. Selectively inhibiting pre-synaptic inputs, 
presumed to be the mechanism of action of isoflurane (Wu et al., 2004, Joksovic et al., 
2009, Ying et al., 2009), abolished all ECAP phases except P1 (Fig. 3.9F), which differed 
from the experimental effect, where the ECAP was completely eliminated in a majority 
of experiments. 
3.4 Discussion 
This study characterized the evoked potentials generated by DBS, quantified 
their dependence on stimulation parameters, and determined the neural elements 
contributing to the different phases of the ECAP. For the monopolar symmetric 
configuration, the primary phases corresponded to direct neural activation and 
secondary phases to post-synaptic activation. The ECAP phases increased in magnitude 
and/or duration with DBS amplitude and pulse width, suggesting a greater extent of 
neural activation, and were modulated by DBS frequency due to changes in post-
synaptic activity. If these systematic changes in ECAP characteristics observed across 
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stimulation parameters are correlated with changes in symptoms, the ECAP may be 
suitable as a feedback control signal for closed-loop DBS systems. Further, these ECAP 
signatures of clinical efficacy could inform design of electrodes and stimulation methods 
for selective stimulation of the neural elements mediating the symptom relieving effects 
of DBS. Finally, the electrode position dependent character of the ECAP may provide a 
signal useful for electrode targeting during implantation or contact selection during 
programming of stimulation parameters. 
3.4.1 Neural origin of ECAP phases 
We combined experimental pharmacology with model-based deconstruction to 
identify the neural elements that generated the different components of the ECAP. The 
primary P1 and N1 phases recorded with the monopolar symmetric configuration 
occurred at latencies of <1 ms and were generated by direct neural excitation. This was 
evident from the direct activation of model elements within 0.6 ms, and by the lack of 
any consistent effect on these phases of pharmacological agents targeting synaptic 
transmission. More specifically, the model indicated that P1 was generated by TC 
neuron activation and N1 by pre-synaptic axon activation. Local circuit currents 
generated by action potential propagation in the TC neuron would be expected to 
generate a triphasic waveform with a dominant negative phase at an external recording 
contact (Gold et al., 2006). Since the TC axon projects past the dorsal, negative recording 
contact, this would be recorded predominately as a positive voltage, and therefore result 
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in the P1 phase. Likewise, pre-synaptic inputs, including CER and CTx inputs, project 
past both the positive and negative recording contacts, respectively, and would result in 
contributions to ECAP phases of both polarities, including the N1 phase. 
The secondary phases of the ECAP recorded with the monopolar symmetric 
configuration occurred at latencies >0.7 ms and were generated by post-synaptic 
activation. This conclusion was supported by several results, including the post-synaptic 
activation of model elements in the 0.9 – 6.3 ms window, the effects of DBS frequency on 
secondary phases, the reduction in magnitude with application of glutamate receptor 
antagonists CNQX/APV, and the invariable association between the presence of N1 
generated by pre-synaptic inputs and the secondary phases in experimental recordings. 
The model indicated that the short latency secondary phases were generated by post-
synaptic activation of TC, RN, and TIN elements, whereas long latency phases 
apparently resulted from late post-synaptic activation of TC neurons and from the re-
excitation of RN by these TC neurons in the 4.4-6.3 ms window. These long latency 
phases were observed in 6 of 14 experiments, and in these experiments the electrode was 
implanted near the dorsal and/or lateral VPL-VL thalamic border, potentially near local 
RN cells receiving input from TC neurons or near passing axons within the IC. 
Therefore, post-synaptic activation of RN local cells, which were not explicitly 
represented in the model, may have also contributed to the longer latency secondary 
phase. On the other hand, IC axons were directly activated at a latency of 0.9-1.8 ms, and 
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were therefore unlikely to be the source of these phases with latencies >3 ms. An 
additional source of the long latency secondary phases could have been activation 
derived from reciprocal thalamocortical-corticothalamic connections (Hersch and White, 
1981, Briggs and Usrey, 2007), which also were not represented in the model. The 
average time required for action potential propagation in the reciprocal pathway from 
the lateral geniculate (LGN) nucleus of the thalamus to the primary visual cortex and 
back to the LGN in non-human primates was 9.3 ms (Briggs and Usrey, 2007), which 
was within the latency range observed for long latency secondary ECAP phases 
measured in this study. 
3.4.2 Identification of neural elements through pharmacological 
interventions. 
Specific pharmacological interventions enabled identification of the neural 
elements contributing to the different phases of the ECAP. First, the predominate effect 
of CNQX/APV was a reduction in post-synaptic activity and corresponding secondary 
ECAP phases, but there were also changes to the primary ECAP phases recorded 
experimentally and associated with direct neural excitation. The latter may have 
resulted from a reduced direct excitability of TC neurons due to a decrease in the 
relative strength of excitatory inputs, although the model suggested this would have a 
negligible effect on primary phases. Alternatively, the effect of CNQX/APV on 
experimentally recorded primary phases could have been generated by antagonism of 
the thalamic triad in the VL thalamus. In this thalamic triad, a CER afferent makes 
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synaptic connections to both a post-synaptic TC dendrite and a pre-synaptic input from 
a local interneuron, and the latter establishes synaptic contact with the same TC dendrite 
(Sato et al., 1996). There is evidence for AMPA and NMDA receptors on the pre-synaptic 
terminal of local interneurons in a similar triad arrangement within the LGN of cats 
(Sherman, 2004). Therefore, antagonism of the triad arrangement in the VL thalamus by 
CNQX/APV could have decreased the direct excitability of TIN inputs and reduced the 
amplitude of primary phases, particularly the N1 phase. Because the thalamic triad was 
not explicitly represented in the model, an effect of CNQX/APV on primary ECAP 
phases would not have been observed. 
Second, hyperpolarization of TC neurons by muscimol reduced their propensity 
for direct activation and inhibited or delayed post-synaptic activation, with the latter 
shifting the secondary ECAP phases towards longer latencies. A novel negative phase 
feature was also revealed following injection of muscimol, and in some experiments 
after delivery of CNQX/APV and lidocaine. This could have been otherwise masked by 
other secondary ECAP phases, and may have corresponded to the early latency P2-N2 
phases generated by post-synaptic activation of TIN (Fig. 3.9D). 
Third, inhibiting neural activation with lidocaine or TTX generally led to a 
reduction or abolition of all ECAP phases, respectively. Whereas Levy and colleagues 
found that 2% lidocaine was sufficient to reduce neural activity at least 0.78 mm from 
the injection site (Levy et al., 2001), we observed ECAP reduction only with higher 
 118 
concentrations of 5-10%, more closely matching results from (Boehnke and Rasmusson, 
2001). The smaller effect of lidocaine relative to TTX may be explained by the use-
dependent effects in neurons of the former (Strichartz, 1973, Courtney, 1975, Khodorov 
et al., 1976, Balser et al., 1996) but not the latter (Ulbricht and Wagner, 1975, Cohen et al., 
1981), or from the larger effective spread of TTX compared to lidocaine (Boehnke and 
Rasmusson, 2001). 
Fourth, we found that isoflurane abolished the ECAP, suggesting non-selective 
inhibition of both pre- and post-synaptic elements. Whereas some studies identified 
selective inhibition of pre-synaptic afferents by isoflurane (Wu et al., 2004, Joksovic et al., 
2009, Ying et al., 2009), another study found an increase in GABAergic inhibition and 
depression of glutamate release (Detsch et al., 2002), which would be expected to 
decrease the excitatory drive of post-synaptic TC neurons. In fact, the selective 
elimination of P1 in one experiment following administration of isoflurane is indicative 
of selective TC inhibition, although this was not a consistent result across experiments. 
There was a residual stimulus artifact in the recordings after neuronal inhibition 
following administration of TTX, isoflurane, or lidocaine. Similar results were observed 
in Chapter 3 at 5 minutes following euthanasia, and it was hypothesized that the artifact 
size increased in the post-mortem condition due to the generation of tissue 
inhomogeneities and/or decreases in tissue conductivity and permittivity. Similarly, it is 
possible that microinjection generated local changes in conductivity near the electrode 
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and thereby increased the size of the artifact. Alternatively, a latent artifact may have 
been present in the untreated condition and distorted the short latency ECAP phases. 
3.4.3 Effect of DBS parameters on the ECAP 
Changes in ECAP characteristics across DBS parameters measured 
experimentally and calculated with the computational model were in strong agreement, 
and provided insight into the effect of stimulation parameters on neural activation.  
Delivery of stimulus pulses with opposite polarities generated similar neural 
responses. This suggested that a polarity averaging technique (Brown and Abbas, 1990) 
could reduce the stimulus artifact with minimal error. The small effect of polarity on the 
neural response was expected for symmetric, biphasic pulses delivered with monopolar 
and bipolar contact configurations (McIntyre and Grill, 2000). In contrast, applying 
opposite stimulation polarities with the asymmetric waveforms used in clinical DBS 
systems can generate differential effects on neural activation (McIntyre and Grill, 2000, 
Wang et al., 2012) and clinical outcomes (Yousif et al., 2012).  
Increasing DBS amplitude and pulse width led to an increase in ECAP amplitude 
and signal energy, reflecting a greater extent of direct neural activation, which could in 
turn generate additional post-synaptic activation. Compared to the model, the 
experimental waveforms exhibited smaller changes in ECAP magnitude across DBS 
amplitudes (Fig. 3.4B). This may have resulted from a neural stun or microlesion effect 
of nearby elements following experimental electrode implantation, which could reduce 
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differences in the volume of tissue activated across stimulation amplitudes. This was 
confirmed in the computational model by removing neural elements that passed within 
200 µm of the DBS electrode, after which we observed smaller relative increases in 
ECAP magnitude with greater DBS amplitudes (data not shown). Using a longer pulse 
width increased the latency of primary ECAP phases, which could have been caused by 
activation of higher threshold neural elements (Kuncel and Grill, 2004) near the end of 
the longer pulse. These elements would make longer latency contributions to the 
recorded ECAP and shift the time at which the phases were observed.  
Decreasing the frequency from 100 Hz to 10 Hz resulted in an increase in the 
number and magnitude of secondary phases. This could arise from neurotransmitter 
depletion and less reliable synaptic transmission at high frequencies (Wang and 
Kaczmarek, 1998, Urbano et al., 2002, Wesseling and Lo, 2002, Zucker and Regehr, 2002, 
Anderson et al., 2006). However, neurotransmitter depletion was not represented in the 
model, and on the contrary, the model exhibited greater post-synaptic activation of RN 
and TIN at 100 Hz. Alternatively, the model indicated that there was increased 
synchronization of post-synaptic TC activity at 10 Hz, and this may have contributed to 
the additional phases and increase in magnitude and/or duration of existing ECAP 
phases. Clinical symptoms are suppressed only at high DBS frequencies and low 
frequencies are ineffective or may lead to exacerbation (Birdno and Grill, 2008), and the 
extent of post-synaptic synchronization may contribute to this frequency dependence. 
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We found that TC neurons corresponding to P1 had the lowest activation 
threshold in five experiments, pre-synaptic inputs corresponding to N1 had a lower 
threshold in just one experiment, and thresholds were similar in the remaining 
experiments. Although activation occurs at the axon for both elements (McIntyre and 
Grill, 1999), the TC neuron initial segment may be hyper-excitable and thereby have 
lower thresholds than pre-synaptic inputs. Conversely, Baldissera and colleagues 
applied stimulation to the feline red nucleus and found that the threshold of the 
preterminal segment of pre-synaptic interpositorubral efferents was only 10% of that for 
the post-synaptic rubrospinal fibers (Baldissera et al., 1972). Moreover, our model results 
indicated that pre-synaptic inputs had a lower threshold than TC neurons, with greater 
activation of the former at 1 V (Fig. 3.4B). Therefore, based on this contradictory 
evidence, the relative thresholds of pre- and post-synaptic elements in the VPL-VL 
thalamus remain unclear. The responses in these experiments were recorded at only 
three stimulation amplitudes, resulting in relatively crude estimates of relative 
thresholds, which may have contributed to these inconclusive findings. 
The consistent effects of stimulation parameters on ECAP characteristics suggest 
that the ECAP could be used to identify stimulation parameters that generate a sufficient 
extent of activation of the appropriate types of neural elements. The ECAP signal energy 
may indicate the extent of neural activation, and if correlated with changes in 
symptoms, could be used to set the DBS amplitude and pulse width. The signal energy 
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takes into account changes in either the magnitude or duration of ECAP phases, and 
may be a more robust measure of neural activation than the ECAP magnitude alone. 
Similarly, the energy of secondary ECAP phases may enable identification of the critical 
DBS frequency above which pathological firing patterns are masked and symptoms are 
suppressed (Kuncel et al., 2007, Birdno and Grill, 2008). The ECAP could also be used to 
distinguish between activation of pre-synaptic inputs or post-synaptic cells that are 
associated with clinical benefit or side effects. For example, it is hypothesized that Vim-
DBS provides tremor suppression in ET by activating cerebellar axonal inputs (Birdno et 
al., 2012), whereas paresthesias are caused by stimulation of local neurons within the 
adjacent ventral caudal (Vc) nucleus of the thalamus (Lenz et al., 1993). Similarly, it is 
thought that treatment of PD with DBS in the subthalamic nucleus (STN) is effective 
through activation of pre-synaptic cortico-STN afferents (Gradinaru et al., 2009), 
whereas stimulation of passing axons in the IC causes side effects (Krack et al., 2002, 
Tamma et al., 2002). The ECAP could be used to test these hypotheses, and enable 
selective targeting of elements required for therapy. 
3.4.4 Experimental and computational limitations 
There were several limitations in this work that should be addressed. First, we 
did not investigate the relationship between ECAP characteristics and the pathological 
symptom response to DBS, as required to demonstrate that the ECAP is a viable 
feedback control signal for closed-loop DBS. Second, use of general anesthetics may 
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have affected neural activity and the corresponding experimental ECAP response. 
Ketamine is a NMDA receptor antagonist (Kemp and McKernan, 2002), and may have 
decreased post-synaptic activation and the corresponding secondary ECAP phases. The 
mechanisms of action of alpha chloralose remain unclear (Posner and Burns, 2009), and 
so the resulting effect on the ECAP is uncertain.    
We determined the neural origin of ECAPs with pharmacological interventions, 
but there were several potential limitations in our approach. First, although we found 
that administration of 5 µL saline control typically had a negligible effect on the ECAP, 
we delivered up to 20 µL of some pharmacological agents, and therefore we cannot be 
certain that these larger volumes would not have affected the ECAP due to the 
mechanical forces of fluid flow. However, this was likely mitigated by the use of a 
constant injection rate. Second, the volume of a specific pharmacological agent necessary 
for ECAP modulation varied between experiments, which likely resulted from slight 
differences in the relative distance between the injection cannula and the DBS electrode. 
Third, the administration of multiple agents in some experiments may have caused 
interaction effects on the ECAP characteristics if recovery from one agent was not 
complete when another agent was delivered.  
The computational model corroborated identification of neural elements 
contributing to the ECAP, but also had several limitations. First, the geometrical 
representation of the VL thalamus was an approximation (Jimenez Castellanos, 1949) 
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based on the human Vim thalamus (Birdno et al., 2012) with a reduced dimension along 
the superior-inferior axis. Using a more accurate morphology of the cat VL thalamus, 
including the true anatomical shape from a cat brain atlas, accurate fiber trajectories, and 
correct relative positioning of the DBS electrode, may have changed neural activation 
and the calculated ECAP response. The use of a simplified prism representation of the 
nucleus may have contributed to the differences between the experimental and 
computational ECAPs. Second, while using a population of 500 local neurons generated 
ECAPs that were consistent across different cell distributions, the responses were not 
identical. However, there existed a tradeoff between further increasing cell density to 
reduce this variability and maintaining a shorter computational time by minimizing the 
number of cells used. Third, we did not account for the ETI, tissue capacitance, or tissue 
inhomogeneities in our model, which would lead to filtering of both the potentials 
generated by DBS (Butson and McIntyre, 2005, Yousif et al., 2008a, Grant and Lowery, 
2010, Lempka et al., 2010, Tracey and Williams, 2011) and the ECAP signal (Bedard et al., 
2004, 2006). Low-pass filtering of the latter would reduce the high frequency fluctuations 
observed in the computational ECAP and likely produce a closer match between 
computational and experimental waveforms. 
3.5 Appendix 
In addition to measuring ECAPs with the monopolar symmetric contact 
configuration, we also conducted experimental and computational ECAP recordings 
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with the monopolar asymmetric and bipolar contact configurations. Transmembrane 
potential recordings of model elements during DBS were also investigated. 
3.5.1 Monopolar asymmetric configuration 
The experimental ECAPs recorded with the monopolar asymmetric 
configuration included primary negative (N1') and positive (P1') phases at latencies of 
0.23 and 0.5 ms, respectively, followed by a secondary negative phase (N2') at 
approximately 2 ms (Figs. 3.10A-D, top row). Similarly, the model ECAP had primary 
N1' and P1' phases, although the smaller magnitude secondary N2' phase observed 
experimentally was not prominent in the model at 100 Hz (Figs. 3.10A-D, bottom row). 
Experimental ECAPs exhibited similar waveform shapes for opposite stimulation 
polarities (Fig. 3.10A), although the positive and negative phases were consistently 
greater in magnitude with cathodic- and anodic-phase first polarities, respectively. In 
contrast, the magnitude of primary phases was larger with cathodic-phase first polarity 
for the computational ECAPs. In addition, the magnitude of the experimental and 
computational ECAPs increased with DBS amplitude (Fig. 3.10B) and pulse width (Fig. 
3.10C). Finally, using a lower DBS frequency in the model led to the generation of a 
small N2' phase, which was present experimentally but unaffected by frequency (Fig. 
3.10D). 
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Figure 3.10: ECAPs recorded with the monopolar asymmetric contact 
configuration. A-D: Comparison of ECAPs recorded experimentally (cat H, top row) 
and calculated with the computational model (bottom row). Since the same 
stimulation contact was used as in Fig. 3.4, the percentage neural activation was 
identical and is therefore omitted here. Data presentation is otherwise similar to Fig. 
3.4. The N1' phase is masked in (C) for a pulse width of 100 μs/phase due to amplifier 
blanking with the DBS-ECAP instrumentation. E: Analysis of the neural origin of the 
computational ECAP. Left: Diagram of the prism representation of the VL thalamus, 
implanted DBS electrode (stimulation and recording contacts identified), and axon 
node locations of the elements from one neural unit (TC and CTx nodes are 
overlapping). This is viewed from an anterior position perpendicular to the electrode 
axis. Right: ECAPs recorded from all elements in the neural unit, and selectively from 
the TC neuron and CTx input (other elements had negligible contribution). The 
corresponding transmembrane potential is shown at selected nodes in the TC axon 
during action potential propagation, with nearly identical recordings made in the CTx 
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axon. The N1' phase was generated by action potential propagation near the positive 
recording contact, and P1' by subsequent propagation near the negative recording 
contact. 
Using the model, we found that the ECAP recorded with the monopolar 
asymmetric configuration was generated by action potential propagation in TC neurons 
and CTx inputs. The contribution of the other neural elements to the ECAP was 
negligible. The action potential was initiated at a site near the stimulation contact, and 
local circuit currents generated the negative N1' phase with propagation near the 
positive recording contact, followed by a positive P1' phase with propagation near the 
negative recording contact (Fig. 3.10E). The propagation speed and corresponding 
latency difference between model ECAP primary phases were in agreement with the 
typical latency difference of 0.2-0.3 ms observed experimentally. The small magnitude 
N2' phase observed experimentally corresponded in time with post-synaptic activation 
of model elements (Figs. 3.4, 3.10). However, the lack of DBS frequency effects on N2' 
suggested another source, and this may have instead been generated by potassium ion 
efflux during membrane repolarization at the trailing edge of the action potential (Gold 
et al., 2006).  
3.5.2 Bipolar configuration 
For the bipolar contact configurations, there were two experimental ECAP 
waveform variants; the first had primary negative (N1") and positive (P1") phases at 
approximately 0.2 and 0.5 ms (always less than 0.8 ms across experiments), and a 
 128 
secondary negative (N2") phase at 1.1 ms (Figs. 3.11A-D, top row). In the second variant, 
these ECAP phases were inverted (data not shown). Of the 12 experiments in which the 
bipolar configuration was tested, 4 generated responses of the initial negative phase 
variant, 7 generated responses with the initial positive phase variant, and 1 generated a 
large artifact that masked the ECAP. The electrode was generally implanted near the 
ventral or dorsal border of the VPL-VL thalamus when the initial negative variant was 
observed, and centrally or near the lateral border of the target nuclei when the initial 
positive variant was recorded. The model ECAP had primary N1" and P1" phases 
followed by a secondary N2" phase, which were observed in the initial negative phase 
variant of the responses seen experimentally (Figs. 3.11A-D, middle row). The effect of 
DBS parameter adjustment on ECAP characteristics was similar to that observed for the 
monopolar asymmetric configuration, except that the secondary phase (N2") was 
modulated by frequency in both the experimental and model conditions, typically being 
slightly larger at 10 Hz than at 100 Hz. 
We attempted to reproduce the apparent dependence of experimental waveform 
characteristics recorded with the bipolar configuration on the electrode location by 
implementing in the model a dorsal or ventral shift of the electrode (Fig. 3.11E) or 
placing the electrode within a population of parallel IC axons (Fig. 3.7B). These alternate 
electrode positions approximated the experimental electrode locations at the dorsal, 
ventral, or lateral border of the VL thalamus. Whereas the model indicated that the 
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original, central location or a dorsal shift generated ECAPs similar to the initial negative 
phase variant observed experimentally, a ventral shift or lateral position near the 
population of parallel axons generated responses of the initial positive phase variant. 
Both the experimental and computational results suggested that the response recorded 
with the bipolar configuration was particularly sensitive to electrode position. 
The temporal pattern of neural activation observed for the monopolar symmetric 
configuration was very similar for bipolar stimulation (Figs. 3.11A-D, bottom row). The 
primary phases corresponded to direct neural excitation and secondary phases to post-
synaptic activation. Selectively recording the ECAP contribution from pre-synaptic 
inputs and TC neurons indicated that the former were primarily responsible for all of 
the phases, N1", P1", and N2" (Fig. 3.11F). 
Bipolar stimulation led to a greater extent of activation compared to monopolar 
stimulation. This was reflected in the larger magnitude ECAPs with bipolar stimulation 
observed in experiments that used the same recording contacts for both configurations 
(data not shown), and in the extent of neural activation of model elements between these 
configurations (Figs. 3.4, 3.11). This result can be explained by the generation of neural 
activation near both contacts with bipolar stimulation when using symmetric, biphasic 
pulses. 
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Figure 3.11: ECAPs recorded with the bipolar contact configuration. A-D: 
Comparison of experimental ECAPs (cat I, top row), computational ECAPs (middle 
row), and percentage activation of model elements (bottom row). Data presentation is 
 131 
similar to Fig. 3.4, except that experimental ECAPs for (B) were collected at 10 Hz DBS 
frequency due to high noise in one response at 100 Hz. The N1" phase is masked in 
(C) for a pulse width of 100 μs/phase due to amplifier blanking with the DBS-ECAP 
instrumentation. E: Effect on the model ECAP of a dorsal or ventral shift of the DBS 
electrode with respect to the VL thalamus. Stimulation parameters were 3 V, 10 Hz, 50 
μs/phase, and both cathodic- and anodic-phase first polarities. F: Selective recording 
of the contribution of TC neurons or pre-synaptic inputs to the model ECAP. The 
same parameters were used as in (E). 
3.5.3 Model transmembrane potential recordings 
 
Figure 3.12: Transmembrane potential recordings from model neural elements 
(TC, CTx, CER, RN, and TIN) with DBS applied at time 0 with 3 V, 100 Hz, 50 
µs/phase, and cathodic-phase first polarity. 
The effect of synaptic transmission on network activity was investigated through 
measurement of transmembrane potentials from individual neural elements in the 
computational model (Fig. 3.12). For the neural unit shown, CTx and CER were 
activated directly by DBS, based on the short latency of excitation following each pulse 
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(~0.2 ms). This generated post-synaptic activation of TC at 2-3 ms, RN at ~2.5 ms, and 
TIN at ~1.5 ms. Finally, the excitatory connection from TC to RN resulted in subsequent 
post-synaptic excitation of the latter at 4-6 ms. We found that post-synaptic activation of 
TC was occasionally suppressed due to GABAergic inhibition from RN and TIN, and 
this depended on the latency of firing of the latter two elements. In another neural unit 
for which the RN input was removed, we did not observe this suppression of TC post-
synaptic excitation (data not shown). 
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4. Measurement of evoked potentials during thalamic 
deep brain stimulation 
4.1 Introduction 
Deep brain stimulation (DBS) is an effective therapy for movement disorders, 
including essential tremor (ET) and Parkinson's disease (PD) (Benabid et al., 1991, 
Limousin et al., 1995, Gross and Lozano, 2000). To treat ET and tremor-dominant PD, the 
DBS electrode is typically implanted in the ventral intermediate (Vim) nucleus of the 
thalamus, and is connected to an implanted pulse generator (IPG) via a subcutaneous 
wire. There remains a lack of understanding of the mechanisms of action of DBS, and 
consequently, tuning of stimulation parameters is an ad hoc, empirical process. 
Parameter adjustment sessions are inconvenient, time-consuming, and costly (Ondo and 
Bronte-Stewart, 2005), and can result in sub-optimal clinical outcomes (Okun et al., 2005, 
Moro et al., 2006). Moreover, inappropriate parameter settings can lead to side effects 
(Limousin et al., 1995, Limousin et al., 1996, Hamani et al., 2005, Pahwa et al., 2006) and 
deplete the battery more quickly than optimized settings (Moro et al., 2002, Kuncel and 
Grill, 2004, Volkmann et al., 2006). An automated, rational approach to the selection of 
DBS parameters could reduce follow-up visits and improve patient outcomes. 
Closed-loop DBS systems are one approach to automated selection and 
optimization of stimulation parameters. Neural activity measured during DBS may 
provide information related to symptoms, and both single-unit recordings and local 
field potentials (LFPs) have been proposed as feedback signals. Closed-loop DBS of the 
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globus pallidus interna (GPi), triggered from single-unit activity measured from the 
primary motor cortex (M1), generated greater motor symptom reduction in MPTP-
treated monkeys than continuous, open loop stimulation (Rosin et al., 2011). However, 
this approach required implantation of additional hardware, and the long-term stability 
of microelectrode recordings may not be sufficient for clinical use (Williams et al., 1999). 
Alternatively, LFPs can be recorded from the DBS electrode, and reflect synchronized 
oscillatory neural activity (Brown and Williams, 2005). For example, theta oscillations 
recorded from the basal ganglia or thalamus may be related to tremor in PD and ET 
(Brown et al., 2001, Brown, 2003, Kane et al., 2009, Pedrosa et al., 2012), and anti-kinetic 
beta oscillations are elevated in the basal ganglia in PD (Priori et al., 2004, Marceglia et 
al., 2007, Bronte-Stewart et al., 2009) and are reduced by DBS (Brown et al., 2004, 
Wingeier et al., 2006, Bronte-Stewart et al., 2009). Proposed LFP-based closed-loop 
systems would titrate stimulation in response to changes in LFP activity (Burgess et al., 
2010, Afshar et al., 2012), or select the most effective stimulation contacts and inform 
DBS voltage settings (Chen et al., 2006, Miyagi et al., 2009, Yoshida et al., 2010). 
However, further work is required to demonstrate that LFPs are derived from local 
sources, rather than volume conducted from other brain regions (Brown and Williams, 
2005), and that there is causality between LFP activity and clinical symptoms (Priori et 
al., 2006, Smirnov et al., 2008, Tass et al., 2010).  
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In the present work we investigated the evoked compound action potential 
(ECAP) as a potential feedback control signal. The ECAP is generated by synchronous 
activation of an ensemble of neural elements near the electrode, and is recorded from 
two non-stimulating contacts on the DBS electrode implanted for therapy. ECAPs 
recorded from the DBS electrode during peripheral nerve stimulation were used to 
determine the electrode position during implantation (Hanajima et al., 2004, Valls-Sole 
et al., 2008). Further, ECAPs recorded from the cochlear nerve were dependent on 
stimulation parameters (Miller et al., 1998, Matsuoka et al., 2001, Briaire and Frijns, 2005, 
Macherey et al., 2008, Miller et al., 2008, van Wieringen et al., 2008, Westen et al., 2011), 
guided programming of stimulation levels (Miller et al., 2008, Jeon et al., 2010), and were 
proposed for use in closed-loop cochlear implants (Mc Laughlin et al., 2012). An ECAP-
based closed loop DBS system could adjust stimulation settings automatically to 
generate activation of the appropriate neural elements.  
We demonstrated previously the feasibility of recording ECAPs by reducing the 
stimulus artifact, which can otherwise mask or distort the physiological signal (Chapter 
2), and ECAPs recorded in acute, preclinical experiments provided insight into the 
extent and types of neural elements activated during thalamic DBS (Chapter 3). 
However, it was not known whether high-fidelity ECAP signals could be recorded from 
humans in an acute or chronic state. The objectives of the present work were to 
determine whether ECAPs could be recorded during clinical DBS; to determine the 
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source of the ECAP and any artifact; to investigate changes in ECAP characteristics 
across DBS parameters; and to correlate ECAP characteristics with changes in tremor 
across DBS parameters.  
4.2 Methods 
We conducted intraoperative recordings of ECAPs in acute and chronic 
conditions and investigated correlations between ECAP characteristics and tremor 
across stimulation parameters. Computational modeling was used to determine the 
origin of the ECAP signal and stimulus artifact. 
4.2.1 Human subjects 
The protocol was reviewed and approved by the Institutional Review Boards at 
Duke University and Emory University, and subjects participated on a volunteer basis 
following written informed consent. The study was performed on 15 participants, 11 
with ET, 3 with tremor-dominant PD, and 1 with Fragile X-associated tremor/ataxia 
syndrome (FXTAS) (Ferrara et al., 2009). We recruited patients who were either 
undergoing surgical implantation of the Medtronic 3387 DBS electrode in Vim (acute 
setting, n=7) or replacement of their battery-depleted IPG for Vim-DBS (chronic setting, 
n=8). Subjects undergoing IPG replacement surgery were asked to decline general 
anesthesia, so that they were responsive during the study, and sedation, which can 
otherwise reduce motor symptoms. Subjects undergoing DBS implantation are not 
normally given general anesthesia, and sedation was provided only as necessary so as to 
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minimize the effect on motor symptoms. Further, all subjects were asked to withhold 
anti-tremor and/or dopaminergic medications overnight prior to the experiment, and 
subjects that were unable to tolerate withholding medications were excluded from the 
study. Demographic information for the subjects is shown in Table 4.1. Subject EP13D 
was enrolled in the study but subsequently declined participation. Some patients 
reported transient paresthesias during stimulation delivered within the study. One 
adverse event unrelated to the study occurred: a postoperative reaction to antibiotics 
administered at the IPG site, which resolved uneventfully. 
4.2.2 Intraoperative experimental setup 
After implantation of the DBS electrode or removal of the battery-depleted IPG, 
external hardware for stimulation and recording was connected via a temporary, 
percutaneous extension cable to the DBS electrode. In subjects undergoing IPG 
replacement, the connection from the extension cable to the DBS brain lead was made 
through a Multi-Lead Trialing Cable (355531, Medtronic), and if necessary, a 1x4 Pocket 
Adapter (64001, Medtronic). For subjects undergoing electrode implantation, the 
connection to the DBS electrode was made through a Twistlock Screening Cable (3550-
03, Medtronic). 
ECAPs were recorded differentially from two non-stimulating contacts using 
three series amplifier stages (A1, A2, and A3) and additional circuit components to reduce 
the stimulus artifact (Fig. 4.1A), as discussed in detail in Chapter 2. The amplifier gains  
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Table 4.1: Demographic characteristics for each subject. Asterisk (*) indicates 
that the subject underwent DBS electrode implantation surgery. 
Subject Age/Gender Diagnosis 
Mo. After 
Implant 
Medications Taken Morning 
of Experiment 
EP12A 65/M ET 34 None 
EP12B 73/M ET 44 None 
EP12C 68/M PD 58 None 
EP12D 73/F ET 77 Fentanyl before surgery 
EP12E 76/M PD 40 None 
EP13A 72/M ET 74 
Gabapentin, divalproex before surgery; 
fentanyl before/during surgery 
EP13B* 74/F ET 0 
Primidone before surgery; fentanyl, 
dexmedetomidine, midazolam during 
surgery 
EP13C* 73/F 
ET with mild 
Parkinsonism 
0 Primidone before surgery 
EP13E* 64/M FXTAS 0 Fentanyl during surgery 
EP13F 74/M PD 90 
Isoflurane, dexmedetomidine during 
surgery 
EP13G* 62/M ET 0 Propofol during surgery 
EP13H* 66/M ET 0 Propofol during surgery 
EP13I* 70/F ET 0  Propofol, fentanyl during surgery 
EP13J* 61/F ET 0 
Fentanyl before surgery; midazolam, 
propofol during surgery  
EP13K 71/M ET 176 Gabapentin before surgery 
 
at each stage were set to ensure that amplifier saturation did not occur, and the signal 
was band-pass filtered at A2 and A3 using a low-pass cutoff of 10 kHz and a high-pass 
cutoff of 0.1 Hz (or 10 Hz, EP12A-D only). DBS was delivered through an isolated 
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stimulator (bp isolator, FHC) connected in series with two 100 μF capacitors, with 
stimulation pulses controlled via a high-speed digital-to-analog converter using a 
custom LabView program (National Instruments), which also controlled digital pulses 
to operate circuit components and sampled the ECAP at 80 kHz. 
 
Figure 4.1: Intraoperative recording of ECAPs during DBS. A: Diagram of the 
recording instrumentation. Stimulation was delivered using a monopolar, AC-
coupled configuration between a DBS contact and distant counter electrode. The 
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PhotoMOS relay (AQV212(A)) opened after each DBS pulse to limit discharge of 
capacitive charge from the electrode-tissue interface through the parallel 10 kΩ 
resistor, rather than through the low-impedance stimulator. ECAPs were recorded 
from the two contacts adjacent to the stimulating contact, and were amplified by a 
differential SR560 preamplifier stage (A1) and two subsequent SR560 amplifier stages 
(A2 and A3), which also filtered the signal. To reduce the size of the stimulus artifact, 
anti-parallel diodes (IN4154) were placed at the inputs to A2 and A3, grounding the 
line if the voltage exceeded ±0.7 V, and the latter two stages were internally blanked 
during each pulse and the subsequent 60 µs. All amplifiers were AC-coupled at the 
front-end, either externally (A1) or internally (A2 and A3), and anti-series current 
limiting diodes (CCL0035) were placed at the inputs to the first amplifier stage. 
Modified from (Kent and Grill, 2012). B: Diagram of subject positioning and electrode 
placement for the intraoperative study. For subjects undergoing IPG implantation 
surgery, the connection to the DBS lead was made through an incision in the chest, 
and the counter electrode (CE) was typically placed on the chest opposite the surgical 
site. Alternatively, for subjects undergoing DBS electrode implantation, the 
connection to the DBS lead was made through the cranial burr hole, and the CE was a 
retractor at the cranial burr hole or implant cannula. The recording reference electrode 
(RE) was typically placed on the thigh ipsilateral to stimulation. The accelerometer 
used for tremor measurement was taped to the hand contralateral to stimulation. 
Modified from (Swan et al., 2013). 
DBS was applied unilaterally with symmetric, biphasic, voltage-regulated pulses. 
Charge densities were below the manufacturer's recommended limit of 30 µC/cm2, using 
a conservative impedance estimate of 500 . We used a monopolar stimulation 
configuration with symmetrical recording contacts to minimize the size of the artifact 
(Chapter 2). In choosing the hemisphere for stimulation in subjects that had or were 
receiving bilateral electrode implants, we considered the following: dominant hand, side 
with greater tremor symptoms with DBS off, and side with lower clinical amplitude and 
pulse width (IPG replacement subjects only). Further, we preferred the side that used a 
clinical stimulation configuration with contacts 1 or 2 (where contacts are labeled 0-1-2-3  
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Table 4.2: Clinical stimulation settings and experimental settings for each 
subject. For stimulation contacts, "C" corresponds to case return for the clinical 
settings, and a distant counter electrode for experimental settings. Degree symbol (°) 
indicates that the subject performed a counting task during tremor measurement.  
 
Clinical Settings Experimental Settings 
Subject 
Voltage 
(V) 
Frequency 
(Hz) 
Pulse Width 
(μs) 
Stim. 
Contacts 
Stim. 
Contacts 
Rec. 
Contacts 
Arm Position During Tremor 
Measurement 
EP12A° 6.1 185 60 0-/1-/C+ 1-/C+ 0+/2- 
Elbow flexed and unsupported, 
hand held near face, holding 
tape roll 
EP12B° 4.1 145 90 1-/C+ 1-/C+ 0+/2- 
Elbow extended and 
unsupported, arm ~30 deg above 
horizontal 
EP12C 4.6 150 60 0-/1+ 1-/C+ 0+/2- Elbow flexed 90 deg and 
unsupported 
EP12D° 1.8 180 90 0-/C+ 1-/C+ 0+/2- Elbow flexed and unsupported, 
hand held near face 
EP12E 4.6 185 90 1-/2-/C+ 2-/C+ 1+/3- Elbow extended and supported, 
arm parallel to horizontal 
EP13A° 2.3 180 60 1-/2-/3+ 1-/C+ 0+/2- 
Elbow extended and 
unsupported, arm parallel to 
horizontal 
EP13B° 1 180 90 1-/0+ 1-/C+ 0+/2- 
Elbow extended and 
unsupported, arm ~30 deg above 
horizontal 
EP13C 1 180 90 1-/0+ 1-/C+ 0+/2- Elbow flexed and supported, 
arm ~30 deg above horizontal 
EP13E 1 180 90 0-/1+ 1-/C+ 0+/2- 
Elbow extended and 
unsupported, arm ~45 deg above 
horizontal 
 EP13F° 4.6 90 60 0-/1-/3+ 1-/C+ 0+/2- 
Elbow flexed and unsupported, 
arm perpendicular to horizontal 
EP13G 2 180 90 1-/0+ 1-/C+ 0+/2- Elbow flexed and unsupported, 
hand held near face 
EP13H 1 180 60 2-/3+ 1-/C+ 0+/2- 
Elbow flexed and unsupported, 
hand held near face, holding 
water bottle 
EP13I° 1 180 90 1-/2+ 1-/C+ 0+/2- Elbow flexed and unsupported, 
hand held near face, holding cup 
EP13J 2 185 90 1-/2+ 1-/C+ 0+/2- 
Elbow extended and 
unsupported, arm parallel to 
horizontal 
EP13K 4.4 185 90 1+/2-/3- 2-/C+ 1+/3- 
Elbow extended and 
unsupported, arm parallel to 
ground 
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in the ventral-to-dorsal direction), as it was necessary to use one of these contacts in the 
monopolar stimulation – symmetrical recording configuration, and we sought to match 
the clinical configuration as closely as possible (Table 4.2). For subjects undergoing 
electrode implantation, clinical settings were determined by a neurologist during 
surgery as the parameters and contacts that maximized tremor reduction without side 
effects. The recording reference electrode (RedDot M2255, 3M) was placed on the skin, 
either on the chest opposite the surgical site (EP12A only) or the thigh ipsilateral to 
stimulation (Fig. 4.1B). For subjects undergoing IPG replacement, the stimulation 
counter electrode (StimCare Carbon Foam Electrode, Empi) was placed on the thigh 
(EP12A only) or the chest opposite the surgical site, and in subjects undergoing electrode 
implantation, the retractor at the cranial burr hole or implant cannula (EP13I and EP13J 
only) was used as the counter electrode.  
We measured tremor with an accelerometer (5 V / 4 g sensitivity, CXL04LP3, 
Crossbow Technology) taped to the dorsum of the hand contralateral to stimulation.  
Accelerometer-based tremor measurements correlate well with clinical rating scales of 
tremor (Elble et al., 2006). Tremor was measured by having the supine subject hold their 
arm in a position that was pre-determined to maximize tremor, and with the wrist 
extended such that it was parallel with the forearm. The accelerometer measurement 
was sampled at 1 kHz. 
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4.2.3 Stimulation and measurement protocol 
We measured ECAPs and tremor in single experimental sessions lasting 
approximately 45 min, or until the patient was fatigued. In the first phase of the 
experiment, we determined the maximum tolerable voltage with the experimental 
contact configuration by slowly increasing the amplitude up to 140% of the clinical 
voltage (VCLIN). DBS was delivered for 5 s at 130 Hz with the clinical pulse width and 
cathodic-phase first polarity. In the second phase, we measured ECAPs and tremor 
across a range of stimulation parameters delivered in a randomized manner with both 
the subject and the experimenter who was interacting with the subject blinded. 
Frequencies were 10 Hz and 130 Hz, in which we typically tested only VCLIN for the 
former and a range of amplitudes for the latter. However, if the subject had low tremor 
in DBS off conditions, a range of amplitudes was instead tested at 10 Hz. Amplitudes 
were 20%, 60%, 100%, and 140% of VCLIN, but if a higher voltage was not tolerated in the 
first experimental phase, then we used 40% and/or 80% of VCLIN. Additionally, we tested 
both cathodic- and anodic-phase first polarities, and pulse width was fixed at the clinical 
setting. Each trial within the block was 2 min in duration, with DBS off for the first 
minute (baseline period) and DBS on for the second minute (stim period) (Fig. 4.2A). At 
approximately 30 s into the baseline and stim periods, we measured the subjects' tremor 
for 20 s. Further, we recorded ECAPs in the stim period, either just when tremor was 
measured (EP12A-C only) or through the entire period. Depending on patient fatigue,  
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Figure 4.2: Intraoperative measurements of ECAPs and tremor. A: The timeline 
of each trial, in which ECAPs were measured during DBS (stim) and tremor was 
recorded during baseline and stim periods. Modified from (Birdno et al., 2012). B: Raw 
accelerometer measurements made for 20 s along the X-, Y-, and Z- axes for EP12E 
during 130 Hz DBS at VCLIN with cathodic-phase first polarity, and in the preceding 
baseline period with DBS off. C: Power spectral density (PSD) of the tremor data from 
(B) on both a log scale, for comparison between DBS off and DBS on conditions, and a 
linear scale, for comparison of the relative magnitude of different peaks in the 
signals. D: Raw ECAP recording made from EP12D for 130 Hz DBS at VCLIN with 
cathodic-phase first polarity. 
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we conducted a second block with different randomized presentation of stimulation 
parameters in some experiments. We were unable to complete the first block of the 
second phase in subjects EP13B, EP13C, and EP13J due to subject fatigue. A poor 
connection between the hardware and DBS electrode or between the reference electrode 
and skin in EP13C, EP13E, and EP13H led to low ECAP signal fidelity, and so no further 
analysis was conducted for these experiments. 
4.2.4 Postoperative measurement of impedance 
Following completion of the experiment, an IPG (Activa, Medtronic) was 
implanted (except in some patients undergoing DBS electrode implantation surgery), 
and post-operative electrode impedance measurements were taken with the Activa 
device. The Activa impedance measurement used trains of 0.7 or 1.5 V, 210 µs/phase, 
and 30 Hz, applied between pairs of contacts or between one contact and the IPG case. 
Impedance was measured at the beginning of the pulse, and since the double-layer 
capacitance of the electrode-tissue interface (ETI) is shorted at high frequencies (Wei and 
Grill, 2005), the impedance measurement was dominated by the tissue resistance. 
4.2.5 Clinical data analysis 
Tremor was analyzed by calculating the power spectral density (PSD) of the 
acceleration measured along each axis (AX, AY, and AZ). The acceleration signals were 
detrended using local linear regression (2 s window size, 1 s step size) (Fig. 4.2B), the 
PSD was calculated in MATLAB using the psd function (Welch's averaged periodogram, 
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Hanning window, fast Fourier transform (FFT) length of 5,000 samples) with corrected 
amplitude scaling (Fig. 4.2C), and tremor power was calculated in the X-, Y-, and Z-
dimensions by integrating each spectrum over the 2-7 Hz band, to get PX, PY, and PZ 
(Kuncel et al., 2007). This band was chosen to exclude steady-state acceleration 
generated by gravity, and to include the fundamental frequency and first harmonic (Fig. 
4.2C). Finally, we summed PX, PY, and PZ, and change in tremor was quantified for each 
of n trials as:  
Change in tremor = )
P
P
(log
baselinen,
stimn,
10    (Equation 4.1) 
where Pn,stim was tremor power measured during the stim period of trial n and Pn,baseline 
was that measured during the baseline period of trial n. 
The ECAP was analyzed by calculating signal power in different ECAP phases, 
as described in Chapter 3. First, the raw ECAP signal (Fig. 4.2D) was stimulus-triggered 
averaged across the first 64 responses. Second, in experiments with a large stimulus 
artifact tail, we used a polarity averaging technique common in cochlear ECAP 
recording (Brown and Abbas, 1990), in which responses recorded with opposite 
polarities (but other stimulation parameters identical) were averaged together. The 
artifact was expected to be inverted for opposite stimulation polarities and was removed 
with this technique, whereas the ECAP response was expected to be similar for opposite 
polarities with symmetric, biphasic DBS pulses and so was relatively unaffected by 
polarity averaging (Chapter 3). Third, any signal offset was calculated as the average of 
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the final 1 ms of signal and subtracted. Finally, we squared the signal and integrated 
across distinct ECAP phases. The resulting signal energy measure accounted for both the 
magnitude and duration of the phases. 
Pearson correlation coefficients were calculated for linear regressions between 
tremor and ECAP signal energy values. One-tailed t-tests were performed to determine 
whether the slope of the regression was significantly different from zero (α=0.05), and 
the slope was expected to be negative for 130 Hz DBS and positive for 10 Hz DBS. 
4.2.6 Computational model of ECAP recording during thalamic DBS 
A computational model of thalamic DBS was used to calculate the ECAP and 
corresponding neural element activation, and thereby determine the origin of the 
recorded signal. This three stage model was discussed in detail in Chapter 3, and is 
reviewed briefly here. 
The first stage of the model used the finite element method (FEM) to calculate the 
potentials generated by a three-dimensional representation of the DBS electrode within 
brain tissue (Fig. 4.3A). A clinical DBS electrode was placed within a prism 
representation of the Vim thalamus (Birdno et al., 2012), all encompassed within a 
cylindrical representation of surrounding brain tissue with height and diameter of 190.5 
mm. The conductivity of brain tissue was 30. S/m (Moffitt and McIntyre, 2005), and that 
of the DBS contact and insulation were 5×106 S/m and 1×10-13 S/m, respectively (Yousif et 
al., 2008a).  
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Figure 4.3: Computational model of ECAP recording during thalamic DBS. A: 
The FEM model included a three-dimensional representation of the DBS electrode 
within a prism representation of the Vim thalamus, all encompassed within a large 
volume representing surrounding brain tissue (not shown). The model contained 500 
thalamocortical (TC) neurons, with soma locations indicated by the dots, and pre-
synaptic inputs from the cortex (CTx), cerebellum (CER), reticular nucleus (RN) and 
thalamic interneurons (TIN). The anatomical locations of the elements are shown for 
one neural unit, with the TC neuron and pre-synaptic inputs represented by the black 
shapes and gray lines, respectively. Modified from (Kent and Grill, 2013). B: FEM 
geometry of different electrode positions within Vim, including the (i) original 
position from (Birdno et al., 2012), (ii) a more dorsal position, and (iii) a more ventral 
position. The geometries are shown from a lateral view. 
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In the second stage, multi-compartment cable models with appropriate 
geometrical and ion channel representations of the dendrites, soma, and axon of 500 
thalamocortical (TC) neurons were randomly distributed in the thalamic nucleus, along  
with axonal inputs from the cortex (CTx), cerebellum (CER), reticular nucleus (RN), and 
thalamic interneurons (TIN) (Birdno et al., 2012). The model included excitatory 
glutamatergic synaptic connections to TC neurons from CTx and CER, inhibitory 
GABAergic synapses from RN and TIN, and 1:1 excitatory synapses (one input spike 
corresponded to one time delayed output spike) from CTx and CER to TIN, and from 
CTx and TC to RN (Fig. 3.2B). The voltages calculated in the FEM model were 
interpolated at the neural element compartment locations, scaled to match the desired 
DBS amplitude, and applied to elements as a stimulation train with a specified 
frequency, pulse width, and polarity. Transmembrane potentials were measured over 
time to detect neural activation, and transmembrane currents were measured in all 
neural compartments within the population to calculate the ECAP signal in the third 
stage of the model. The simulation time was 1.5 s, with a pre-stimulation period of 0.5 s 
and a 25 µs time step. 
The third stage employed the reciprocity theorem to calculate the differential 
voltage across the two DBS recording contacts generated by neuronal transmembrane 
currents over the course of the simulation (Helmholtz, 1853, Moffitt and McIntyre, 2005). 
The FEM model described in the first stage was solved with a unit current placed at the 
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boundary of one recording contact, and the resulting potentials were measured at the 
neural compartment locations. This was repeated for the second recording contact. The 
resulting scale factors were used to calculate potentials at the recording contacts for a 
given transmembrane current amplitude. The magnitude of the model-generated ECAP 
signal was scaled by 364 to account for the cell density of 1,300 cells/mm3 derived from 
(Hirai et al., 1989). This signal was then filtered with two cascaded first-order 10 Hz - 10 
kHz bandpass filters to replicate experimental filtering, the stimulus artifact was 
removed using a template subtraction method in which the artifact was calculated using 
a sub-threshold stimulus (Briaire and Frijns, 2005), and stimulus-triggered averaging 
was applied 8 times. 
Model outcomes included ECAP signals and measurements of neural activation, 
and were compared across different electrode positions (Fig. 4.3B). The monopolar 
symmetric configuration was used, with DBS applied at contact 1 using a range of 
amplitudes, 10 and 130 Hz frequency, 50 µs/phase pulse width, and both cathodic- and 
anodic-phase first polarities, and differential ECAP recordings were made from contacts 
0 and 2. In addition to recording the composite ECAP generated by all neural elements, 
we selectively measured the ECAP contribution derived from activation of distinct types 
of elements within the population (i.e., TC, CTx, CER, RN, or TIN). Finally, we analyzed 
the percentage activation of each type of neural element that fired an action potential in 
0.1 ms bins following the stimulus pulse. 
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4.2.7 Modeling the stimulus artifact 
Computational modeling was also conducted to investigate how changes in the 
properties of the tissue or ETI affected the size of the stimulus artifact. Two models were 
constructed, one using an electrical circuit equivalent of the recording setup and the 
second using a FEM model to determine the effect of heterogeneity in tissue 
conductivity. 
The electrical circuit equivalent model was implemented using PSpice (Cadence 
OrCAD Capture CIS v16.3). This model represented the tissue medium, ETI, DBS 
voltage source, and components of the recording instrumentation used for ECAP 
measurement (Fig. 2.2). The development of this model, and validation against artifact 
waveforms recorded experimentally in vitro and in vivo, was discussed in detail in 
Chapter 2, and is reviewed briefly here. DBS was delivered using the monopolar 
symmetric configuration between contact 1 and a distant return electrode, and contacts 0 
and 2 served as inputs to an AC-coupled recording amplifier, with input impedance 
matching that of the amplifier used experimentally. Stimulation parameters were 1 V, 10 
and 130 Hz, 50 µs/phase, and cathodic-phase first polarity. A relay was placed between 
the voltage source and stimulating contact, with operational timing matching that used 
experimentally, and with an on resistance of 0.83 . The ETI was modeled as a parallel 
double-layer capacitance (CDL) and Faradic resistance (RF) with values derived from 
literature (Wei and Grill, 2009). The circuit values used in the initial iteration of the 
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model are provided in Table 4.3. The PSpice model solved for the differential voltage 
across the amplifier impedance over time to calculate the stimulus artifact.  
Table 4.3: Electrical circuit equivalent model parameters. 
Parameter Value  
Interface double-layer capacitance (CDL) 1.56 µF 
Interface Faradaic resistance (RF) 1.50 kΩ 
Volume resistance between contacts 0 & 1 (RV01) 1200.80 Ω 
             contacts 1 & 2 (RV12) 1218.69 Ω 
             contact 0 & return (RV0) 764.70 Ω 
             contact 1 & return (RV1) 773.52 Ω 
             contact 2 & return (RV2) 770.83 Ω 
Volume capacitance between contacts & return (CV) 23.21 nF  
 
The DBS contacts and return were electrically interconnected by impedance 
representations of neural tissue, including properties of bulk resistivity and permittivity. 
The PSpice bulk volume resistivity (RV) values between each contact and the distant 
return, as well as between contact pairs, were calculated using COMSOL Script v1.2 
(COMSOL). A three-dimensional geometrical representation of the clinical DBS 
electrode was placed within a spherical volume conductor with a radius of 8.75 cm, 
representing the boundary of the head, and with contact 1 centered in the volume. The 
conductivity of the brain tissue and DBS electrode matched those used in the thalamic 
DBS model discussed previously. The resistance values were calculated by applying 
voltage boundary conditions at the contact(s), measuring the normal current across the 
contact surface, and using Ohm's law. The mesh density was sufficiently high, as 
doubling the number of elements changed the calculated resistance values by <2.8%.  
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The permittivity of the brain tissue was represented by capacitors in parallel with 
the resistors between each contact and the distant return (Butson and McIntyre, 2005). 
The capacitance of the volume (CV) was calculated by considering the geometry of the 
DBS contact within the volume conductor as two concentric spherical conducting shells, 
given by Equations 2.1 and 2.2 (Young and Freedman, 2004). The dielectric constant (K) 
was initially set to 3×105. 
 
Figure 4.4: Two-dimensional FEM model of the DBS electrode within 
heterogeneous brain tissue. A: The peri-electrode space was represented using a 
checkerboard arrangement, with each square having a random conductivity value 
(refer to color bar legend), and the remaining brain tissue conductivity was fixed. The 
average conductivity of the peri-electrode space was 0.1±0.02 S/m (mean ± SD) in the 
figure. The DBS electrode is shown with contacts filled in black. The boundary of the 
surrounding tissue is not shown. B: FEM voltage solution resulting from a 1 V 
boundary condition at contact 1 using the conductivity values shown in (A).  
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A FEM volume conductor model was implemented in COMSOL Script to 
determine the effect of heterogeneity in tissue conductivity on the artifact (Fig. 4.4). A 
two-dimensional representation of the clinical DBS electrode was placed within a square 
volume conductor with 63.5 cm length and with contact 1 centered in the volume. The 
model included a representation of the peri-electrode space (Yousif et al., 2008b) with 
thickness of 100-1000 µm (Butson et al., 2006) divided into a checkerboard arrangement 
(Fishler, 1998), with each square division having 25-100 µm length. The conductivity of 
each square could be set independently, and random spatial variability was introduced 
by drawing conductivity values from a normal distribution with mean of 30.0.05 S/m 
(Butson et al., 2006) and standard deviation (SD) of 0-0.05 S/m (Fig. 4.4A). For each mean 
conductivity value, a limit was set on the maximum SD to avoid generating negative 
conductivity values. Outside of the peri-electrode space, the tissue conductivity was 
fixed at 30. S/m, and the conductive properties of the DBS electrode matched those used 
in the models described previously. The model was solved by setting a 1 V boundary 
condition at contact 1 and grounding the outer boundary of the volume conductor (Fig. 
4.4B). The differential voltage generated at the boundaries of recording contacts 0 and 2 
was calculated as a measure of the artifact magnitude. For each parameter variation, the 
artifact magnitude was measured across ten replicate trials, each time drawing a new 
distribution of conductivity values in the peri-electrode space. Sensitivity analysis 
indicated that the volume conductor was sufficiently large, as doubling the size changed 
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the calculated artifact magnitude by <7.5%, and the mesh density was sufficient high, as 
doubling the number of elements changed the magnitude by <0.04%. 
4.3 Results 
ECAPs were recorded during thalamic DBS and correlated with tremor. 130 Hz 
DBS was effective in reducing tremor (Figs. 4.2B,C) and 10 Hz DBS exacerbated tremor 
except in EP12D, EP13A, EP13F, and EP13J. Administration of sedatives or anesthetics in 
these studies may have limited the expected exacerbation of tremor (Table 4.1). 
Similarly, no tremor was observed in the DBS off condition in several subjects, 
presumably resulting from a transient microlesion effect in patients undergoing 
electrode implantation surgery or from administration of sedatives or anesthetics. If 
tremor was determined to be minimal in the DBS off condition at the start of the 
experiment, the subject was asked to perform a counting task during each tremor 
measurement (Table 4.2) and/or DBS was delivered predominately with a 10 Hz 
frequency (EP12B and EP13E) to exacerbate tremor (Table 4.4). Subsequently, 
computational models were used to investigate the neural origin of the ECAP signal and 
the source of the stimulus artifact recorded in some experiments. 
4.3.1 ECAP measurement and characterization 
We studied the effect of stimulation polarity, amplitude, and frequency on the 
ECAP during intraoperative DBS (Fig. 4.5). The waveform included a primary negative 
phase (N1), followed by a primary positive phase (P1), secondary negative phase (N2), 
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and in some cases, a secondary positive phase (P2). The ECAP was similar for opposite 
polarities with symmetric, biphasic stimulation waveforms, as expected from prior work 
in Chapters 2 & 3. The magnitude of the ECAP phases generally increased with higher 
DBS amplitudes, particularly the N1 and P1 phases (Fig. 4.5A). Nevertheless, this trend 
was not always sustained, as exceeding the clinical voltage led to a decrease in N1 for 
EP12D with anodic-phase first polarity, and a decrease in P1 with both polarities. 
Reducing DBS frequency from 130 Hz to 10 Hz increased the magnitude of P2 for 
anodic-phase first polarity, decreased N1, and had an ambiguous effect on P1 (Fig. 4.5B). 
 
Figure 4.5: Stimulus-triggered average ECAPs recorded during thalamic DBS 
across stimulation parameters in EP12D. The ECAP phases are labeled. A: Effect on 
ECAPs of stimulation amplitude, provided as a percentage of VCLIN, and shown for 
both cathodic- and anodic-phase first polarities. B: Effect on ECAPs of stimulation 
frequency, shown for both polarities at VCLIN. 
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Recording ECAPs was technically challenging due to the presence of a stimulus 
artifact, which had variable amplitude between experiments (Fig. 4.6). The ECAP was 
recorded without any artifact in EP12D (chronic) as well as EP13B and EP13I (acute), 
and there was a small residual artifact in EP13G and EP13J (acute). A relatively large 
artifact tail was observed in all remaining experiments except EP12E, for which 
amplifier blanking was not used (because of an offset present during the blanking 
period), and the two artifact phases corresponded to the two phases of the DBS 
waveform. Therefore, low artifact recordings were obtained in all 4 acute experiments 
(excluding experiments with poor signal fidelity), but in just 1 of 7 chronic experiments 
(Table 4.4). Averaging the responses for opposite stimulation polarities cancelled out the 
stimulus artifact, and revealed an underlying ECAP signal in EP12A and EP12B that 
otherwise overlapped with the artifact tail. There were negligible ECAP responses even 
after polarity averaging in EP12C, EP12E, EP13A, EP13K, and EP13F, except at an 
amplitude 20% of VCLIN for the latter.  
When present, the ECAP had a consistent waveform shape, with N1-P1-(N2-P2) 
phases, where N2 and/or P2 were not always present (Fig. 4.6). Across subjects and DBS 
parameters, the peak-to-peak ECAP magnitude ranged from 0.17-1.48 mV, and for a 
fixed DBS voltage (~1 V), was larger in the acute condition (range of 0.40-1.33 mV) than 
in the chronic condition (range of 0.17-0.35 mV). The latency range for the different 
ECAP phases were: N1 at 0.21-0.43 ms, P1 at 0.35-0.8 ms, N2 and P2 (when present) at  
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Table 4.4: ECAP and tremor recording conditions and outcomes across 
subjects. 
Subject 
Recording 
Condition 
ECAP Recording 
Fidelity 
Tremor Presence with DBS Off,  
Response to DBS 
EP12A Chronic 
ECAP present with 
large artifact 
High, reduced at 130 Hz 
EP12B Chronic 
ECAP present with 
large artifact 
Low, exacerbated at 10 Hz 
EP12C Chronic Large artifact High, reduced at 130 Hz 
EP12D Chronic ECAP present Low, reduced further at 130 Hz 
EP12E Chronic 
No amplifier 
blanking 
High, reduced at 130 Hz 
EP13A Chronic Large artifact Low, DBS largely ineffective 
EP13B Acute ECAP present Low, reduced further at 130 Hz 
EP13C Acute 
Poor fidelity due to 
bad connection 
High, reduced at 130 Hz 
EP13E Acute 
Poor fidelity due to 
bad connection 
Low, exacerbated at 10 Hz 
EP13F Chronic Large artifact High, reduced at 130 Hz 
EP13G Acute 
ECAP present with 
minimal artifact 
High, reduced at 130 Hz 
EP13H Acute 
Poor fidelity due to 
bad connection 
Low, reduced further at 130 Hz 
EP13I Acute ECAP present Low, DBS largely ineffective 
EP13J Acute 
ECAP present with 
minimal artifact 
High, reduced at 130 Hz 
EP13K Chronic Large artifact High, reduced at 130 Hz 
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Figure 4.6: ECAP waveforms recorded during thalamic DBS across subjects 
who were undergoing either IPG replacement surgery or DBS implantation surgery. 
Stimulus-triggered average ECAPs are shown in the bold traces, and single responses 
are shown as the dark and light gray traces for cathodic- and anodic-phase first 
polarities, respectively. Other DBS parameters were 130 Hz frequency and an 
amplitude equal to VCLIN, except for EP12C, EP13J, and EP13K for which ECAPs are 
shown with an amplitude that was 60%, 40%, and 80% of VCLIN, respectively, and was 
the maximum tested in that experiment. For experiments in which a relatively large 
artifact was present, the responses for cathodic- and anodic-phase first polarities were 
averaged. When present, the ECAP phases are labeled. The insets for EP13B, EP13G, 
and EP13I show ECAP responses for voltages below VCLIN, with cathodic- and anodic-
phase first polarities, as well as the polarity average (EP13G only), to demonstrate a 
more apparent N1 phase. Similarly, the inset for EP13F shows responses for voltages 
at 20% of VCLIN for cathodic- and anodic-phase first polarities, and the polarity 
average, to demonstrate the presence of a P1 phase. 
0.68-1.98 ms. The N1 phase was not as marked in EP13B, EP13G, EP13I, or EP13J (acute 
recordings) at the clinical voltage, but was more evident at lower amplitudes (see insets). 
There were non-monotonic relationships between the signal energy of different ECAP 
phases and DBS amplitude (Fig. 4.7, rows 1-4). We also found increases in the 
magnitude of secondary phases as DBS frequency was reduced from 130 Hz to 10 Hz 
(Fig. 4.7, row 5). 
4.3.2 Correlation between tremor and ECAP characteristics 
We quantified the relationship between tremor and ECAP characteristics across 
subjects (Fig. 4.7). With near statistical significance, tremor was negatively correlated 
with N1 phase energy at 130 Hz for EP12D (R=0.6, P<0.078) and positively correlated at 
10 Hz for EP12B (R=0.86, P<0.068). Similarly, tremor was negatively correlated with P1 
phase energy at 130 Hz for EP12D (R=0.65, P<0.058), and with secondary phase energy at 
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130 Hz for EP13G (R=0.87, P<0.067). Finally, the energy of secondary phases was greater 
at 10 Hz compared to 130 Hz at the clinical voltage for EP12B and EP12D, and this was 
correlated to increases in tremor with near statistical significance (R=0.69, P<0.061). 
 
Figure 4.7: Relationship between changes in tremor and ECAP characteristics 
across stimulation parameters. ECAP characteristics were analyzed by calculating the 
signal energies of the N1 phase (left column), P1 phase (middle column), and 
secondary phases (right column). Measurements were made across DBS amplitudes, 
indicated both by the size of the marker and the adjacent text showing amplitude as a 
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percentage of VCLIN, and DBS frequencies, including either 130 Hz or 10 Hz shown 
with circle and diamond markers, respectively. Further, these data are shown for 
cathodic- and anodic-phase first polarities with black and white fill color, 
respectively. For experiments requiring polarity averaging of the ECAP signal due to 
the presence of a stimulus artifact, one value of the ECAP characteristic is given for 
both stimulation polarities, and the average of the corresponding tremor 
measurements across polarities is shown with the gray fill color. Change in tremor 
was defined in Equation 4.1, such that negative values corresponded to reductions in 
tremor from baseline, and positive values corresponded to tremor exacerbation. 
Tremor data was not recorded for EP12D at 130 Hz DBS frequency, 60% of VCLIN, and 
anodic-phase first polarity, and so the data point is not shown. Despite successful 
ECAP recording, data is not provided for EP13B and EP13J because a full trial block 
was not completed, and for EP13I because no tremor was evident in the DBS off 
condition. The bottom row shows data collected for both EP12B and EP12D at VCLIN 
with 10 and 130 Hz DBS frequency and both stimulation polarities. EP12A was not 
included in this plot since both polarities were not tested at 10 Hz in this subject, and 
EP13G was not included because of the large relative values for change in tremor. 
Linear regressions were calculated between tremor and ECAP measures, using the 
polarity average (gray fills) when applicable. 
4.3.3 Neural origin of the ECAP response 
A computational model of thalamic DBS was used to determine the neural origin 
of the clinical ECAP response. Modeling the DBS electrode in its original position within 
Vim (Birdno et al., 2012) resulted in an initial positive ECAP (P1-N1-P2-N2), rather than 
the initial negative ECAP (N1-P1-(N2-P2)) observed in clinical recordings (Fig. 4.8A). 
Shifting the position of the clinical electrode along its axis by 2 mm in a dorsal direction 
or 6 mm in a ventral position, such that contacts 1 or 0 were at the dorsal or ventral 
border of the nucleus, respectively, resulted in an ECAP waveform that was more 
similar to the experimental signal (Figs. 4.3B, 4.8A). The former had a N1-P2-N2 
waveform shape (P1 not present), whereas the latter had the P1-N1-P2-N2 waveform, 
but with a relatively small P1 phase. There was a negligible effect when DBS frequency  
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Figure 4.8: ECAP responses calculated with the model of thalamic DBS. A: 
Model responses for different relative electrode positions within the thalamus (refer 
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to Fig. 4.3B), including the original position (left column), dorsal position (center 
column), and ventral position (right column). ECAPs are shown for both cathodic- and 
anodic-phase first polarities, and the corresponding percentage activation of each 
neural element type in 0.1 ms bins following DBS pulses is shown for cathodic-phase 
first polarity. DBS amplitudes for each subplot were varied to generated similar 
percentage activation, DBS frequencies were 130 or 10 Hz, and pulse width was fixed 
at 50 µs/phase. The stimulus-triggered ECAP and single responses are shown in the 
bold and light traces, respectively, and ECAP phases are labeled. A small stimulus 
artifact remained with the dorsal electrode position following artifact template 
subtraction, observed as the initial inverted phases for opposite stimulation 
polarities. B: The contribution of different neural element types to the composite 
ECAPs recorded with the ventral electrode position at 3 V. The DBS frequency was 
130 Hz, unless otherwise designated. 
was reduced from 130 Hz to 10 Hz except with the DBS electrode positioned ventrally, 
for which there was a polarity-dependent effect on secondary phases, as seen 
experimentally (Fig. 4.5B). 
The neural origin of the ECAP signal was determined by analysis of the temporal 
pattern of neural excitation (Fig. 4.8A) and by measuring the ECAP contribution from 
activation of distinct types of elements within the population (Fig. 4.8B). For 130 Hz 
DBS, direct activation of neural elements occurred within ~0.9 ms from the start of the 
DBS pulse, whereas post-synaptic activation of TC, RN, and TIN occurred within ~0.9-
3.3 ms from the start of the pulse. Additionally, with the electrode in the ventral 
position, CER activation occurred as late as 1.6 ms. This extended CER activation 
resulted from direct stimulation, since CER received no synaptic input, and occurred in 
elements located dorsally within the thalamic nucleus. This long latency CER activation, 
and corresponding ECAP contribution, resulted from the delay for action potential 
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propagation from the initiation site (near the stimulating contact in ventral Vim) to the 
proximal node of Ranvier where activation was detected. Reducing DBS frequency from 
130 Hz to 10 Hz shifted timing for direct activation to earlier latencies, reduced post-
synaptic activation of RN and TIN, and decreased the latency and increased the 
synchronization of post-synaptic TC cell activation (i.e., less temporal dispersion of 
activation times). Recording from different neural elements revealed their respective 
contributions to the ECAP for a ventral electrode position, with direct activation of CER 
inputs generating the dominant contribution to the P1-N1-P2-N2 waveform (Fig. 4.8B). 
Contributions from direct excitation of CTx reduced the magnitude of P1, N1, and N2, 
and shifted P2 to more positive voltages. The contributions to the ECAP of TC and TIN 
elements were relatively small, and those of RN were negligible. Lastly, the frequency 
effect observed in the composite ECAP was generated by changes in the contribution 
from CER inputs at 130 Hz versus 10 Hz DBS. The DBS frequency effect was relatively 
small for contributions from other types of elements (data not shown). 
4.3.4 Origin of the stimulus artifact 
The stimulus artifact observed in all experiments except EP12D, EP13B, and 
EP13I may have resulted from tissue inhomogeneity and corresponding impedance 
imbalances between the stimulation electrode and each recording contact. Across 
chronic and acute experiments in which impedance was measured, there was a 
difference in impedances between the experimental stimulation contact and each 
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recording contact of 28±10% (mean ± SE, n=7) and 6.1±3.4% (n=3), respectively, 
calculated by normalizing to the average of the two impedance values. This larger 
imbalance in chronic experiments would be expected to increase the differential voltage 
measured between the two recording contacts during each stimulus pulse, resulting in 
larger artifacts. However, we did not detect any trend across chronic experiments 
between the percentage impedance imbalance and the artifact magnitude.  
Two computational models were implemented to understand better the sources 
of the stimulus artifact. An electrical circuit equivalent was used to compare the 
stimulus artifacts with the initial parameter set (Table 4.3) to those after alteration of the 
ETI or bulk tissue properties (Fig. 4.9). Adding a highly resistive glial encapsulation 
layer of 0.1 S/m conductivity and 500 μm thickness (Haberler et al., 2000, Moss et al., 
2004, Butson et al., 2006) around the electrode (in the FEM model stage) increased RV01 
and RV12 by ~36% and RV0, RV1, and RV2 by ~5%, and consequently increased the artifact 
magnitude and duration (Fig. 4.9A). Introducing impedance imbalances between the 
stimulation contact and each recording contact by decreasing RV01 and increasing RV12 by 
5 or 10% increased the artifact magnitude by ~9 and 17 times, respectively (Fig. 4.9B). 
After altering the dielectric constant within the physiological range between 1×104 and 
1×106 (Schwan and Kay, 1957, Foster and Schwan, 1989), for CV values of 0.77 to 77.36 nF, 
we found that greater tissue permittivity increased the artifact duration (Fig. 4.9C). 
Other alterations made to the model, including doubling and halving CDL or RF, or  
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Figure 4.9: Stimulation artifacts calculated with the electrical circuit equivalent 
model for 130 Hz DBS. An amplifier blanking scheme was not implemented, and so a 
triphasic artifact waveform was observed. Results were independent of DBS 
frequency. A: Stimulus artifact waveforms recorded with and without a highly 
resistive encapsulation layer. B: Artifact waveforms recorded prior to and following 
unbalancing of volume conductor resistances, by decreasing RV01 and increasing RV12 
by the percentage indicated. C: Artifact waveforms recorded with two different 
dielectric constants (K). 
introducing an imbalance in these values between contacts 0 and 2 by up to 50%, had a 
negligible effect on the artifact. These results suggest that tissue impedance is the 
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dominant determinant of stimulus artifact size, particularly the extent of impedance 
imbalance between recording contacts. 
The second FEM model was used to study the effect on the artifact magnitude of 
changes in the properties of the peri-electrode space, including heterogeneity in the 
tissue conductivity. In the homogeneous condition, there was a non-monotonic trend 
between conductivity of the peri-electrode space and the artifact magnitude. The artifact 
increased as conductivity of the peri-electrode space was reduced from 30. to 0.1 S/m, 
before declining at 0.05 S/m (Fig. 4.10A). An artifact with 0.68 mV magnitude was 
observed when the conductivity of the peri-electrode space was equal to that of the brain 
tissue ( 30. S/m), and was generated by the axial discontinuity arising at the electrode tip 
and by the presence of the highly conductive but unused contact 3. This was 
demonstrated both by extending the representation of the insulation downwards, such 
that the distances between the center of the stimulation contact and the top and bottom 
of the insulation were equal, and by removing contact 3 from the model, which reduced 
the artifact magnitude to 0.007 mV. 
Heterogeneity of the peri-electrode conductivity generated a range of artifact 
magnitudes across ten replicate simulations. The maximum artifact was always larger 
than in the homogenous case with the same mean conductivity, the minimum was 
always less than the homogenous case, and the median value was close to the 
homogenous case (Fig. 4.10A). Furthermore, the range of artifact magnitudes generally  
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Figure 4.10: Evaluation of stimulation artifacts using the FEM-based model of 
tissue heterogeneity. A: The artifact magnitude was calculated for different mean and 
SD conductivity values within the peri-electrode space. The thickness of the peri-
electrode space was 500 µm and the square size was 50 µm. The range (black bar) and 
median values (white line) from 10 repeated trials are provided, except for 
homogenous conditions (SD=0), in which case a single value is given. B: Artifact 
magnitude calculated for various peri-electrode space thickness values. The SD of 
conductivity was also varied for each thickness value, whereas the mean conductivity 
was fixed at 0.1 S/m and the square size at 50 µm. C: Artifact magnitude calculated for 
different peri-electrode space square sizes. The thickness of the peri-electrode space 
was fixed at 500 µm and the conductivity was 0.1±0.02 S/m. For reference, the artifact 
magnitude for the homogenous condition is also provided (square size had no effect). 
increased with greater variability in tissue conductivity. Increasing the thickness of the 
peri-electrode tissue from 100 to 1000 µm increased the artifact magnitude when the 
peri-electrode tissue was homogenous, and shifted the range of artifact magnitudes 
towards higher values when the tissue was heterogeneous (Fig. 4.10B). Finally, 
increasing the size of the square division from 25 to 100 µm, thereby changing from a 
fine to a coarse spatial scale, increased the range of artifact magnitude values across 
trials (Fig. 4.10C). These results show that a glial encapsulation layer can increase the 
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artifact magnitude, particularly as the thickness of this layer increases, and that 
heterogeneity in the conductivity can further increase the artifact magnitude.  
4.4 Discussion 
ECAPs were recorded from implanted electrodes during thalamic DBS in 
subjects with tremor. There was large subject-to-subject variation in stimulus artifact 
amplitude, and model-based analysis revealed that the larger artifacts may have been 
caused by glial encapsulation of the electrode, resulting in imbalances in the tissue 
impedance between the contacts. High fidelity ECAP recordings obtained from both 
acute and chronically implanted electrodes revealed that specific phase characteristics of 
the signal varied systematically with stimulation parameters and were correlated with 
changes in tremor. Further, results from this study suggest that excitation of cerebellar 
afferents during DBS is important for reduction of motor symptoms, consistent with 
prior findings (Coenen et al., 2011, Sandvik et al., 2011, Birdno et al., 2012, Keane et al., 
2012). The demonstration of high-fidelity recordings of ECAPs from both acutely and 
chronically implanted DBS electrodes, as well as the identification of ECAP 
characteristics correlated with motor symptoms, support the feasibility of an ECAP-
based closed-loop DBS system, which could optimize therapy and reduce the clinical 
burden of parameter selection. 
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4.4.1 ECAP waveform and the effect of stimulation parameters 
The ECAP waveform generally exhibited N1-P1-(N2-P2) phases, although in 
acute recordings the N1 phase was typically not as evident at the higher stimulation 
amplitudes. In comparison, ECAP signals recorded in preclinical experiments (Chapter 
3) were inverted, with primary P1-N1 phases followed by secondary P2-N2 phases. We 
reproduced the clinical ECAP polarity in the model only with ventral or dorsal 
positioning of the clinical DBS electrode within the thalamic nucleus (Fig. 4.8A). Clinical 
electrode implantation for thalamic DBS typically involves placement of contact 0 at the 
ventral border of Vim, and the model indicated that this location was an important 
factor in generating the specific ECAP shape observed experimentally.  
The ECAP magnitude was larger in the acute stage (EP13B, EP13G, EP13I, and 
EP13J) than in the chronic stage (EP12A, EP12B, EP12D), with DBS amplitude 
approximately constant. One possible reason was that the chronic recordings used an 
external counter electrode, which may have resulted in a voltage drop across the skin 
that reduced voltages in the brain tissue, ultimately decreasing the number of activated 
neurons. Second, glial scar formation in the 6 to 8 weeks after chronic electrode 
implantation leads to neuronal cell loss near the electrode (Henderson et al., 2002, 
McConnell et al., 2009), which could have reduced the ECAP magnitude, as suggested 
by prior modeling performed in Chapter 3. Third, the glial encapsulation layer could 
electrically isolate recording contacts from the surrounding neurons and further 
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diminish the ECAP. On the other hand, LFPs recorded from a DBS electrode at 7 years 
after DBS implantation were similar to those recorded in the acute condition (Giannicola 
et al., 2012b), suggesting a smaller effect of glial encapsulation on LFPs. 
The ECAP varied systematically with stimulation parameters. Responses were 
similar for opposite stimulation polarities, as observed in our previous work (Chapter 
3), and which enabled polarity averaging to remove the stimulus artifact, when 
necessary. There was a non-monotonic relationship between ECAP magnitude and DBS 
amplitude (Figs. 4.5, 4.7), as also observed in cochlear nerve recordings (Miller et al., 
1998, Matsuoka et al., 2001, Westen et al., 2011). The ECAP magnitude is thought to 
reflect the spatial extent of neural activation (Chapter 3), and the model indicated that 
the decline in ECAP N1 and N2 magnitude at the highest DBS amplitudes resulted from 
greater activation of cortical inputs, which increased their corresponding positive ECAP 
phase contributions and thereby reduced the negative phases through destructive 
interference. Alternatively, the non-monotonic relationship may have resulted from a 
hyperpolarizing "anodal surround" region of action potential block close to the electrode 
at high amplitudes (Ranck, 1975). In contrast, a monotonic relationship between ECAP 
magnitude and DBS amplitude was observed in preclinical experiments (Chapter 3), 
although the maximum amplitude was limited to 3 V. Decreasing DBS frequency from 
130 Hz to 10 Hz increased the magnitude of N2 and/or P2 in EP12B and EP12D, and our 
previous study suggested that the increased post-synaptic synchronization of TC cells at 
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low frequencies increased the magnitude of secondary phases (Chapter 3). While this 
increased TC synchronization was still evident with lower DBS frequencies (Fig. 4.8A), 
the corresponding effect on the ECAP was masked by the much larger contribution from 
directly excited cerebellar afferents, which were also affected by frequency (Fig. 4.8B).   
4.4.2 Relationship between ECAP signatures and clinical 
effectiveness 
Tremor was generally reduced from baseline with 130 Hz DBS and exacerbated 
at 10 Hz (Birdno and Grill, 2008). For high-frequency DBS, we typically observed a non-
monotonic relationship between tremor and stimulation voltage, in which increasing the 
amplitude initially led to greater reductions in tremor before reversing beyond some 
optimal voltage (Fig. 4.7). This could have been caused by the activation of more distant, 
tremor aggravating brain areas at higher voltages (Cooper et al., 2008) or activation of 
the internal capsule, which might aggravate tremor due to increased stress from the side 
effects of stimulation (Kuncel et al., 2006).  
The relationship between the ECAP signal and tremor provides insights into 
mechanisms of DBS and reveals a potential feedback signal for automated parameter 
tuning. Increasing ECAP phase energy was related to reductions in tremor at 130 Hz 
and exacerbation of tremor at 10 Hz. Since the ECAP signal energy provides a measure 
of the extent of neural activation (Chapter 3), these results suggest that DBS must 
activate a sufficient volume of tissue for clinical benefit at 130 Hz, or for symptom 
exacerbation at 10 Hz. The thalamic DBS model revealed that cerebellar afferents were 
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the dominant contributors to the ECAP response, and since the energy of ECAP phases 
was correlated with tremor, this suggests that activation of cerebellar inputs is critical to 
tremor suppression by DBS. This is consistent with the findings that activation of 
cerebellothalamic afferents suppressed tremor in ET patients by overriding pathological 
bursting activity, and that electrode contacts in the subthalamic area ventral to Vim may 
be more effective than contacts within Vim (Coenen et al., 2011, Sandvik et al., 2011, 
Birdno et al., 2012, Keane et al., 2012). As well, in EP12B and EP12D, increasing 
secondary phase energy was correlated with reductions in DBS effectiveness across 
stimulation frequencies, and these changes may have been related to synaptic 
mechanisms (Chapter 3). 
The ECAP could provide a feedback control signal for automated adjustment of 
stimulation parameters in closed-loop DBS systems. For example, DBS amplitude and/or 
pulse width could be adjusted to attain pre-determined ECAP phase energy threshold 
values. However, the absolute phase energy values varied by an order of magnitude 
between subjects, and the relationship between ECAP phase energy and tremor varied 
across subjects (Fig. 4.7). Therefore, the threshold values used to set DBS parameters 
may be subject specific, and may need to be specified as a normalized value of some 
maximum signal energy within subjects. Although not tested in this study, ECAPs could 
also be used to target a brain region for implantation, given the dependence of ECAP 
waveform shape on electrode location, and to select the optimal contact(s) for 
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stimulation, potentially identified as that which attained the target ECAP phase energies 
using settings that minimized power consumption (Kuncel and Grill, 2004). 
4.4.3 Source of the stimulus artifact 
The stimulus artifact was highly variable between experiments, and in some 
cases interfered with the ECAP signal. This variability in stimulus artifact magnitude 
and ECAP recording fidelity across subjects was consistent with cochlear ECAP 
measurements (Miller et al., 2008). We initially theorized that larger artifacts resulted 
from stimulation current traveling past the reference electrode on the chest to the 
stimulation counter electrode on the leg as used in EP12A, but moving these electrodes 
in subsequent experiments did not reduce the artifact. Alternatively, the observation 
that the artifact was minimal in the acute condition, in both clinical and preclinical 
experiments (Chapters 2 & 3), suggested that changes in the cellular milieu around the 
DBS electrode influenced the stimulus artifact. 
The peri-electrode space is filled with cerebrospinal fluid after acute 
implantation (Yousif et al., 2008b) and is subsequently replaced by a glial scar (Haberler 
et al., 2000, Henderson et al., 2002) that increases the tissue impedance (Lempka et al., 
2009, Newbold et al., 2010). Further, protein and cell adsorption onto the contact 
surfaces can influence the double-layer capacitance, and thereby the impedance of the 
ETI (Lempka et al., 2009, Newbold et al., 2010). The electrical circuit equivalent model 
suggested that the formation of a highly resistive encapsulation layer increased the 
 176 
magnitude and duration of the artifact, and imbalances of only 5-10% in the resistance 
between the stimulation contact and each recording contact led to substantial increases 
in the artifact magnitude. The FEM-based model corroborated these findings, also 
indicating that increases in the thickness of the encapsulation layer led to larger artifacts. 
Further, greater heterogeneity within the encapsulation layer increased the range of 
artifact magnitudes, perhaps reflecting the range of artifact magnitudes observed across 
subjects. The imbalance in tissue impedance between contacts could result from 
applying chronic stimulation at just one of the two contacts used for ECAP recording, 
since this would reduce the impedance in the chronic condition by polarizing the contact 
surface and causing attached proteins and cells to desorb (Lempka et al., 2010, Newbold 
et al., 2011, Cheung et al., 2013). Differences in the brain composition and tissue 
conductivity near each contact could also contribute to the impedance imbalances. 
Regardless, these results indicate that the cellular milieu near the DBS electrode plays a 
critical role in determining the size of the stimulus artifact observed in chronic 
experiments, and thus the fidelity of ECAPs recorded during DBS. 
We attempted to document the contribution of impedance imbalances to the 
stimulus artifact by measuring post-operative impedances of implanted electrodes. In 
the majority of chronic experiments, one of two ECAP recording contacts had been used 
for clinical stimulation (Table 4.2), and this generally led to larger impedance imbalances 
between the experimental stimulation contact and each of the two recording contacts, 
 177 
compared to acute experiments. However, holding DBS amplitude approximately 
constant, the artifact size was not related to the impedance imbalance across chronic 
experiments. This differs from the conclusion made with the two models, and may relate 
to the temporal evolution of the encapsulation layer, since impedance measurements 
were taken post-operatively. Specifically, the composition of this layer may have been 
modulated by discontinuation of chronic, clinical DBS before surgery, and by 
application of DBS at experimental stimulation contacts during ECAP recording. 
4.4.4 Study limitations 
There were several limitations in both the experimental and computational 
aspects of this work. First, the experimental contact configuration often differed from 
that used clinically and identified by a neurologist as the most effective for therapy. We 
used the monopolar symmetric contact configuration to minimize the stimulus artifact 
(Chapter 2), and thus only contacts 1 or 2 were available as the stimulation contact. 
Second, the symmetrical, biphasic DBS waveform, used to minimize the duration of the 
stimulation artifact, did not match the asymmetrical waveform used clinically in IPGs 
(Miocinovic et al., 2009). Third, a voltage drop across the skin was likely generated with 
the use of a skin surface counter electrode in the chronic condition (McGill et al., 1982), 
which would result in a reduction in the voltage across the brain tissue. Nevertheless, 
sufficient voltage was still delivered to the thalamus to generate ECAPs, changes in 
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tremor, and paresthesias. All three of these limitations could reduce the effectiveness of 
DBS in treating tremor, compared to clinical DBS delivered with an IPG.  
Other limitations included the short duration of DBS prior to the assessment of 
motor symptoms, the short interval between trials, and conducting only a single trial at 
each DBS setting in most experiments. While tremor reduction following the onset of 
DBS typically occurs within a few seconds (Beuter and Titcombe, 2003), our trial design 
may have underestimated the magnitude of changes in tremor after 30 s of stimulation. 
Nevertheless, similarly short trial lengths have been used previously in testing the 
effects of parameter settings (Kuncel et al., 2006), and are used routinely for 
intraoperative testing and post-operative tuning (Moro et al., 2002, O'Suilleabhain et al., 
2003). The washout of DBS effects on tremor occurs over seconds to minutes, with 85% 
of the return in tremor after cessation of DBS occurring within 5 minutes (Beuter and 
Titcombe, 2003). However, using longer trial lengths, longer intervals between trials, or 
replicate trials would have resulted in the experiment becoming too long to conduct 
during an intraoperative procedure, and there are presently no other settings in which to 
conduct this study.  
The correlations between tremor and ECAP signal characteristics were variable 
and not statistically significant. Testing a larger number of DBS parameter combinations 
in a given experiment would have increased the number of data points used in the 
correlation, and thus, the statistical significance. However, we were limited in the 
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number of trials that could be tested within the intraoperative setting. Similarly, 
correlations between cochlear ECAP thresholds and perceptional hearing measures were 
statistically significant but not strong (Miller et al., 2008, Jeon et al., 2010).   
There were also limitations in the computational models, which have been 
discussed previously (Chapters 2 & 3). Briefly, in the thalamic DBS model, the position 
of the DBS electrode and neural fiber trajectories were approximations, and using more 
accurate representations may have changed neural activation and the model ECAP 
response. This could potentially explain the smaller positive phase observed in the 
model compared to the experimental ECAP recordings. Further, this model did not 
account for the ETI, tissue capacitance, or tissue inhomogeneities, which could filter DBS 
potentials (Butson and McIntyre, 2005, Yousif et al., 2008a, Grant and Lowery, 2010, 
Lempka et al., 2010, Tracey and Williams, 2011) and the ECAP signal (Bedard et al., 2004, 
2006, Buzsaki et al., 2012). The electrical circuit equivalent model used geometrical 
approximations to calculate the resistance and capacitance of the medium, and did not 
account for the capacitive coupling between stimulating and recording leads (McGill et 
al., 1982, Grumet, 1999), the capacitance of the medium directly between two DBS 
contacts, or the frequency dependence of tissue permittivity (Bossetti et al., 2008). 
 180 
5. Analysis of electrode characteristics for neural 
recording during deep brain stimulation 
5.1 Introduction 
Deep brain stimulation (DBS) is an effective surgical therapy for the treatment of 
movement disorders (Benabid et al., 1991, Limousin et al., 1995, Gross and Lozano, 2000, 
Krauss et al., 2004), and is being investigated for other neurological diseases. However, 
the mechanisms of action of DBS are still unclear, which limits the optimization of this 
therapy (Grill and McIntyre, 2001, McIntyre et al., 2004b).  
Measuring neural activity using the DBS electrode could contribute to 
understanding of the therapy and improve outcomes through closed-loop control. Local 
field potentials (LFPs), representing synchronized neural oscillations, have been 
recorded from the DBS electrode array (Brown et al., 2004, Wingeier et al., 2006, Bronte-
Stewart et al., 2009), and may serve as a feedback control signal for automatic 
adjustment of stimulation to optimize therapy (Priori et al., 2012, Stanslaski et al., 2012). 
The evoked compound action potential (ECAP) can also be recorded from the DBS 
electrode. The ECAP is generated by activation of an ensemble of neurons adjacent to 
the electrode and provides insight into the type and spatial extent of neural element 
excitation during DBS (Chapters 3 & 4). The aim of the current work was to conduct a 
systematic assessment of the influence of the electrode on ECAP and LFP recording, 
including the physical presence of the recording contacts, the dimensions of the 
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electrode, and the presence of edema or glial encapsulation in acute and chronic 
recording conditions, respectively. 
We first determined the effect of the large, highly conductive electrode contacts 
on the recorded signals, as well as changes in the electrode diameter, contact length, and 
contact spacing. Prior analyses of electromyogram (EMG) recording (van Dijk et al. 2009) 
and cortical pyramdical cell recording (Moffitt and McIntyre 2005) suggested modest 
effects of the presence of the electrode on the recorded signal. Reductions in the 
recording contact surface area generally increased signal amplitude, as demonstrated by 
LFP recordings with a microelectrode versus a DBS electrode (Lempka and McIntyre, 
2013), single-unit recordings made with microelectrodes (Moffitt and McIntyre, 2005, 
Lempka et al., 2011), electroneurogram (ENG) recordings with needle electrodes 
(Schoonhoven and De Weerd, 1984), and motor unit EMG recordings with surface 
electrodes (Dimitrova et al., 1999). Further, smaller contacts should be more spatially 
sensitive, with neuronal contributions extending several millimeters with measurement 
from a DBS electrode (Lempka and McIntyre, 2013) and only ~100 μm from a 
microelectrode (Henze et al., 2000, Moffitt and McIntyre, 2005). Smaller contact spacings 
reduce the distance from recording contacts to the activated neural population, but can 
also reduce contributions from more distant neurons, and therefore may decrease the 
maximum signal amplitude (Lempka and McIntyre, 2013). Previous studies have 
investigated modified DBS electrode design for targeted stimulation or improved energy 
 182 
efficiency, including segmentation of electrodes (Wei and Grill, 2005, Buhlmann et al., 
2011, Keane et al., 2012), adjustment of the contact diameter-to-length ratio (Butson and 
McIntyre, 2006), and high perimeter contact shapes (Grill and Wei, 2009), but we are 
unaware of analogous DBS electrode design analysis for improving neural recording 
fidelity.  
Subsequently, we quantified the effects of changes in the peri-electrode space 
between acute and chronic recording conditions on the recorded signals. Several studies 
have documented the reduction in voltages within the brain during stimulation 
following acute edema or chronic glial encapsulation (Yousif et al., 2008a, Lempka et al., 
2010). Further, acute edema reduced the amplitude of simulated single-unit recordings 
by 24% while glial encapsulation increased the signal amplitude by 17%, contrary to the 
notion that encapsulation leads to electrical isolation of the recording contacts (except 
when the resistivity of the peri-electrode space is sufficiently high) (Moffitt and 
McIntyre, 2005). Further, the impedance of the peri-electrode space was correlated with 
the amplitude of the low frequency LFPs (2-7 Hz, including theta band), but not the beta 
band LFPs (Yousif et al., 2008b, Rosa et al., 2010, Lempka and McIntyre, 2013). In prior 
work, we studied how changes in the conductivity of the peri-electrode space can 
influence the stimulus artifact in ECAP recordings (Chapter 4), but not the ECAP itself. 
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5.2 Methods 
A computational model was used to calculate ECAPs and LFPs recorded with a 
DBS electrode from a population of model thalamic neurons, as well as evoked 
responses generated by single neural elements. The model is reviewed in detail in 
Chapter 4, and is described here only briefly. The three stage model included: (1) a finite 
element method (FEM) volume conductor model of the DBS electrode implanted within 
the ventral intermediate (Vim) nucleus of the thalamus, (2) multi-compartment cable 
models of thalamocortical neurons and their pre-synaptic inputs, which provided the 
electrical sources for the ECAP or LFP, and (3) application of the reciprocity theorem to 
calculate potentials generated by neuronal transmembrane currents at the DBS 
recording contacts. ECAPs and LFPs were calculated for different electrode 
representations, various electrode geometries, and following inclusion of a peri-
electrode space to represent acute and chronic recording conditions. The monopolar 
symmetric contact configuration (monopolar stimulation contact between two 
symmetrical, bipolar recording contacts) was used to match previous studies (Chapters 
2-4). The model was also modified to explore the spatial selectivity of single-units, 
measured with monopolar or bipolar recording contacts, under various recording 
conditions and with different electrode geometries. 
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5.2.1 FEM volume conductor model 
The first stage used a FEM model developed in COMSOL Script v.1.2 (COMSOL) 
to calculate potentials generated by DBS (Fig. 5.1). The volume conductor included 
geometrical representations of the DBS electrode within a prism-shaped Vim, and both 
were surrounded by adjacent brain tissue represented as a cylinder parallel to the DBS 
electrode and centered at the electrode tip (Birdno et al., 2012). The conductivities of the 
electrode contacts, electrode insulation, and brain tissue were 5×106, 1×10-13, and 30. S/m, 
respectively (Moffitt and McIntyre, 2005, Yousif et al., 2008a). In a subsequent version of 
this model, a 500 μm thick peri-electrode space was introduced around the DBS 
electrode to represent edema (1.7 S/m) or a glial encapsulation layer (0.1 S/m) (Butson et 
al., 2006, Yousif et al., 2008a). The DBS electrode was shifted from its original location 
(Birdno et al., 2012) by 6 mm along its axis in a ventral direction, which more accurately 
represented clinical electrode placement as well as the experimental ECAP shape 
recorded in humans during Vim-DBS (Chapter 4). The dimensions of the electrode 
initially matched that of the Medtronic 3387 clinical electrode, with 1.27 mm diameter, 
1.5 mm contact length, and 1.5 mm contact spacing, and were subsequently varied with 
diameters ranging from 0.5 to 1.5 mm, recording contact lengths of 1 to 2 mm, and 
contact spacings of 0.1 to 2 mm. For the different contact lengths and spacings, the 
electrode tip location was shifted to maintain the same location for the stimulating 
contact, which preserved neural activation across geometries. To calculate potentials 
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generated by monopolar DBS, a 1 V boundary condition was imposed at contact 1, the 
outer boundary of the surrounding cylindrical tissue was grounded, and the model was 
meshed and solved. 
 
Figure 5.1: Computational model used to determine the effects of the electrode 
and peri-electrode tissue properties on recorded neural signals. The FEM geometry of 
a Medtronic 3387 DBS electrode is shown, surrounded by a peri-electrode space 
domain, and implanted in a prism representation of the Vim thalamus. The locations 
of 500 thalamocortical (TC) somata within the Vim are indicated by the dots, and the 
axon positioning is shown for one neuronal unit, which includes a TC neuron and 
pre-synaptic inputs from the cortex (CTx), cerebellum (CER), reticular nucleus (RN), 
and thalamic interneurons (TIN). 
 186 
5.2.2 Multi-compartment cable models 
The potentials from the FEM model were coupled to validated multi-
compartment cable models of neurons implemented in NEURON v7.1 (Hines and 
Carnevale, 2001). The neuron models had appropriate geometrical and ion channel 
representations of thalamocortical (TC) neurons, including the soma, initial segment, 
and dendritic tree (McIntyre et al., 2004a) and their pre-synaptic inputs from the cortex 
(CTx), cerebellum (CER), reticular nucleus (RN), and thalamic interneurons (TIN) 
(Birdno et al., 2012). Interconnections between neural elements included excitatory 
glutamatergic synapses from CTx and CER to TC, inhibitory GABAergic synapses from 
RN and TIN to TC, and excitatory 1:1 synapses from TC and CTx to RN, and from CTx 
and CER to TIN, implemented with virtual terminating axons (Fig. 3.2B) (Birdno et al., 
2012). A single neural unit, defined as one TC cell and its pre-synaptic axonal inputs 
from CTx, CER, RN, and TIN, was repeated 500 times, with TC soma locations randomly 
distributed within Vim (Fig. 5.1). Any neural elements that intersected the DBS electrode 
or peri-electrode space (when present) were removed. The potentials at the FEM mesh 
nodes were interpolated at the compartment locations of all model elements, and 
extracellular stimulation was delivered to the cable models by scaling the potentials by 
the specified DBS amplitude. The stimulation waveform was symmetric and biphasic, 
delivered in a 1 s train with 100 Hz frequency, 50 μs/phase pulse duration, and cathodic-
phase first polarity, with a pre-stimulation period of 0.5 s and simulation time step of 25 
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μs. The resulting transmembrane currents were measured from each model 
compartment as a function of time and served as the electrical sources for ECAP 
calculation. Additionally, transmembrane potentials were measured at the initial 
segment of the TC neuron and at the proximal node of Ranvier of each pre-synaptic 
input for detection of neural activation. LFPs were calculated in a similar manner but 
without delivery of DBS. The intrinsic patterns of activity present in the original model, 
including harmaline bursting of CER inputs and 20 Hz Poisson spiking of CTx inputs 
(Birdno et al., 2012), was introduced in the LFP model, but not the ECAP model. 
5.2.3 Calculation of ECAPs and LFPs using the reciprocity theorem 
The reciprocity theorem was used to calculate the potentials generated by 
neuronal transmembrane currents (Helmholtz, 1853, Moffitt and McIntyre, 2005). This 
approach first required calculation of the reciprocal FEM solution, in which a unit 
current source was placed at the boundary of each recording contact (0 and 2) in turn, 
and the resulting potentials were calculated at each compartmental location. This was 
interpreted as the voltage impressed on each contact for a unit current at a given 
compartmental location, and was adjusted by multiplicative scaling according to the 
actual magnitude and sign of the respective transmembrane current.  The process was 
repeated for the currents at all compartments, and the differential voltage across the two 
contacts was summed at each time step to calculate the ECAP or LFP.  
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5.2.4 ECAP and LFP data processing 
The model-calculated ECAPs and LFPs were post-processed in MATLAB. The 
signal magnitude was scaled by 364 to account for the true cell density in the human 
Vim (65 cells/mm2 in 50 μm sections (Hirai et al., 1989)). The stimulus artifact in the 
ECAP signal was removed by template subtraction (Briaire and Frijns, 2005), in which 
the artifact template was calculated using a subthreshold stimulation pulse (0.01 V), 
scaled to match the artifact generated in the trial of interest, and subtracted. Further, the 
ECAP was band-pass filtered from 10 Hz - 10 kHz with two cascaded first-order 
Butterworth filters and stimulus-triggered averaged over eight responses to replicate the 
processing performed experimentally (Chapters 3 & 4). The LFP was filtered from 2-100 
Hz with a first-order Butterworth filter (Pedrosa et al., 2012). 
ECAP signals were compared across model iterations using calculations of signal 
energy and RMS error (RMSE). ECAP signal energy was calculated by squaring the 
signal and integrating over individual ECAP phases. RMSE was calculated using the 
equation below (van Dijk et al., 2009): 

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The magnitude of LFP signals was calculated as the standard deviation over a 2.5 
s duration waveform and compared across model iterations. 
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5.2.5 Single-unit recordings  
The thalamic population model was modified to enable calculation of evoked 
responses generated by a single local cell (TC neuron) or passing axon (60 node, 2 μm 
diameter MRG model (McIntyre et al., 2002)) positioned near a single monopolar 
recording contact 0 or two bipolar contacts (0+/2-). The axons of both elements were 
parallel to the electrode, and the lateral distance to the electrode boundary varied from 
0.125 to 10 mm. The TC soma was centered lengthwise on contact 0 for both monopolar 
and bipolar recordings. Similarly, the center node of the passing axon was centered on 
contact 0 for monopolar recording or contact 1 for bipolar recording. The elements were 
activated by applying a suprathreshold depolarizing intracellular stimulation pulse with 
100 nA amplitude and 50 μs duration at the TC soma or most ventral node of the 
passing axon. ECAPs were calculated as before, by coupling the multi-compartment 
cable models and reciprocal FEM approach. The stimulus artifact was removed using 
the template subtraction method, with the template calculated using a hyperpolarizing 
intracellular stimulation pulse of equal magnitude. Finally, signal energy was calculated 
by squaring the signal and integrating over the first 5 ms. 
5.3 Results 
Computer simulation was used to calculate how the ECAP and LFP generated by 
a population of model thalamic neurons, or the evoked response measured from single 
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neural elements, were affected by the presence of the electrode, the geometry of the 
electrode, and changes in the composition of the peri-electrode space. 
5.3.1 ECAP and LFP signal waveforms 
The ECAP waveform recorded from the population model was similar to that 
from clinical recordings (Chapter 4), with a small, initial positive (P1) phase, followed by 
a large negative (N1) phase, secondary positive (P2) phase, and large, secondary 
negative (N2) phase (Fig. 5.2A). Cerebellar afferents generated the dominant 
contribution to all phases of the model ECAP, although contributions from cortical 
inputs reduced the magnitude of P1, N1, and N2 through destructive interference and 
shifted P2 to more positive voltages. The remaining elements had negligible 
contributions. 
The LFP signal recorded with DBS off oscillated at a fundamental frequency of 
7.2 Hz, in the high theta band (Figs. 5.2B,C). This was similar to recordings made in 
humans with ET (Kane et al., 2009, Pedrosa et al., 2012).  
5.3.2 Effect of the presence of the DBS electrode 
We analyzed how ECAPs and LFPs were altered by the presence of the electrode 
(Medtronic 3387 dimensions) by changing the conductivity of the recording contacts to 
that of the insulating shaft in the reciprocal FEM solution (insulating contact model). 
Compared to the original model, in which the recording contacts were highly 
conductive, the insulating contact model resulted in a similar ECAP waveform 
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Figure 5.2: ECAP and LFP signals recorded with the Medtronic 3387 electrode. 
A: Composite ECAP response, and individual contributions from activation of CTx 
and CER inputs, with 3 V DBS. The average ECAP and single responses are shown in 
the bold and light traces, respectively, and phases of the ECAP are labeled. B: LFP 
signal arising from intrinsic network activity. The LFP magnitude (standard 
deviation) was 37.04 μV. C: FFT power spectrum of LFP signal from (B), with peak 
frequency at 7.2 Hz. 
(RMSE=6.9%) with a 3.7% and 13.1% reduction in N1 and N2 phase energy, respectively, 
indicating that the presence of the recording contacts had a negligible effect on the 
ECAP (Fig. 5.3A). Similarly, the LFP magnitude was reduced by only 5.1% when the  
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Figure 5.3: A: ECAP responses for different electrode representations in the 
reciprocal FEM model. The DBS amplitude was 3 V for the original and insulating 
contact models, and 35 V for the point electrode model. B: Neural activation for the 
conditions tested in (A), shown as a percentage of each type of element (TC, CTx, 
CER, RN, and TIN) that fired an action potential in a given 0.1 ms bin following DBS 
pulses. C: Signal energy of each phase from the ECAP responses in (A). 
highly conductive recording contacts were absent (insulating contact), as compared to the 
original model. In the point electrode model, the DBS electrode was replaced by zero area 
point electrodes at the center of the original locations of the stimulating and recording 
contacts. The DBS amplitude was increased from 3 V to 35 V to maintain similar neural 
activation, with a difference of 1.1% in total neural activation within the first 0.2 ms of 
the DBS pulse (Fig. 5.3B). There was a large difference between the ECAPs from the 
original and point electrode models (RMSE=74.1%), with the latter have increased ECAP 
 193 
phases energies in P1 (340.4%) and P2 (14.9%), but with the N2 phase reduced by 98.0% 
(Fig. 5.3A,C). 
5.3.3 Effect of electrode geometry 
The signals generated by a single TC local cell and a single passing axon during 
action potential propagation past the two bipolar recording contacts are shown in Fig. 
5.4A. A residual stimulus artifact was measured from the passing axon, observed as the 
initial positive deflection, and was not included in the calculation of signal energy. The 
maximum peak-to-peak signal amplitudes measured with bipolar recording contacts 
from the local cell and passing axon with a Medtronic 3387 electrode were 0.21 μV and 
0.32 μV, respectively, and decreased as the electrode to element lateral distance 
increased (Figs. 5.4B-D). ECAP energy was negligible (≥2 orders of magnitude smaller 
than the greatest ECAP energy observed) at electrode to element distances beyond ~1 
mm. Additionally, the ECAP energy recorded from elements stimulated with a sub-
threshold pulse (~40 nA) was 2-3 orders of magnitude smaller than that from excited 
neural elements for a given electrode to element distance.  
For both the local cell and the passing axon, signal energy increased with smaller 
electrode diameters (Fig. 5.4B) or shorter contact lengths (Fig. 5.4C). Further, smaller 
contacts were more spatially sensitive, producing steeper reductions in signal energy as 
the electrode to element distance increased, whereas there was less relative decline in 
signal energy over distance with the larger contacts. Compared to the original design,  
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Figure 5.4: Single-unit responses measured from a local cell or passing axon 
with bipolar recording contacts across electrode designs. A: The evoked response at 
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various lateral distances between the neural element and electrode using the 
dimensions of the Medtronic 3387 electrode. B-D: Signal energy versus lateral 
distance across electrode diameters (B), contact lengths (C), and contact spacings (D).  
using the smallest contact diameter (500 μm) increased recording selectivity for the local 
cell over the passing axon (ECAP energy ratio of 1.09 at a cell distance of 0.125 mm), 
whereas the largest diameter (1500 μm) was more selective for the passing axon (ratio of 
0.52). Similar trends between electrode geometry and signal energy were observed using 
a monopolar recording configuration (data not shown). Contact-to-contact distances 
smaller than that of the Medtronic 3387 electrode reduced the energy of the recorded 
response, whereas larger spacings had an ambiguous effect dependent on element type 
(Fig. 5.4D). Smaller contact spacings also reduced contributions from more distant 
neurons, based on the faster reduction in signal energy at longer cell distances.  
The effects of contact diameter and length on the ECAP were phase-dependent, as 
expected from the neural element specific effects observed in the single-unit analysis. 
Reducing the diameter from 1270 μm (Medtronic 3387) to 500 μm increased N1 and P2 
phase energy by 32.1% and 109.9%, respectively, and decreased N2 phase energy by 
71.2%, whereas increasing the diameter to 1500 μm increased the energy of the N1 phase 
(158.2%) and reduced only the N2 phase (-69.8%) (Figs. 5.5A, 5.6A). The larger diameter 
electrode also distorted the typical ECAP waveform (Fig. 5.5A), greatly reducing the P1 
and P2 peaks to below 0 mV. DBS amplitude was adjusted to maintain similar activation 
across the diameters tested, and there was only a difference of 8.1% in total neural  
 196 
 
 
Figure 5.5: ECAP responses across electrode geometries, including electrode 
diameters (A), recording contact lengths (B), and contact spacings (C). The initial 
negative and positive peaks of the ECAP with a 100 μm contact spacing in (C) 
corresponded to a residual stimulus artifact. DBS amplitude was 3 V for all electrode 
designs except with diameters of 500 or 1500 μm, for which DBS amplitude was 
increased to 3.5 V. D: Neural activation for the three electrode diameters tested. Data 
presentation is similar to Fig. 5.3B. 
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Figure 5.6: Signal energy of each phase from the ECAP responses in Fig. 5.5 
across different electrode geometries, including electrode diameters (A), recording 
contact lengths (B), and contact spacings (C). 
activation within the first 0.2 ms of the DBS pulse (Fig. 5.5D). Nevertheless, differences 
in neural activation across contact diameters remained, and this may have contributed to 
ECAP distortion. Reducing the contact length from 1500 µm to 1000 µm increased N1 
energy by 21.3% but decreased N2 energy by 24.0%, whereas increasing the contact 
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length to 2000 µm decreased N1 (-35.4%) and increased N2 (23.0%) phase energies (Figs. 
5.5B, 5.6B). Lastly, a shorter inter-contact spacing of 100 μm (originally 1500 μm) 
reduced the overall ECAP, particularly the N1 (-85.8%) and N2 (-97.6%) phases, whereas 
increasing the spacing to 2000 μm increased N2 energy by 75.5% (Figs. 5.5C, 5.6C). 
Local field potentials were also recorded with different geometries. The LFP 
amplitude was relatively stable across the geometries tested (≤10% change compared to 
the Medtronic 3387 design), except for a large increase (24%) when the diameter was 
reduced to 500 μm and decrease (-34%) when the contact spacing was reduced to 100 
μm. 
5.3.4 Effect of recording conditions 
We investigated the effect of acute edema or chronic glial encapsulation on the 
recorded signal by introducing a 500 μm thick peri-electrode space with the appropriate 
conductivity. Edema or glial encapsulation decreased or increased signal energy, 
respectively, in bipolar recordings from a single local cell or passing axon, particularly 
when the element was located within the peri-electrode space (Fig. 5.7A). Similar trends 
were observed with measurement from single neural elements with a monopolar 
recording configuration (data not shown). We attempted to maintain a similar extent of 
neural activation in the ECAP model across conditions, with or without representation 
of the peri-electrode space, and there was only a difference of 7.9% in total neural 
activation within the first 0.2 ms (Figs. 5.7B,C). Despite these adjustments, removing  
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Figure 5.7: Neural responses recorded in the original, acute edema, and chronic 
glial encapsulation models. A: Signal energy of single-unit responses versus lateral 
distance of the local cell or passing axon, measured with bipolar recording contacts. B: 
ECAP responses for the original model with and without elements in the peri-
electrode space (PES), and for the edema and glial encapsulation models, with no 
elements in the PES. DBS amplitude was 2 V with neurons in the PES, and 3 V 
otherwise. C: Neural activation for the conditions tested in (B). Data presentation is 
similar to Fig. 5.3B. D: Signal energy of each phase from the ECAP responses in (B). 
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neural elements from the peri-electrode space alone had a large effect on the ECAP, with 
increases in phase energy of P1 (845.5%) and N2 (380.2%), and a reduction in that of N1 
(-99.9%), due to changes in electrode to element distances. Subsequent changes to the 
peri-electrode space conductivity to represent edema caused decreases in the energy of 
all phases (-25.4-87.6%), whereas glial encapsulation increased the energy of all phases 
(7.3-130.9%). 
The composition of the peri-electrode space also had a substantial impact on the 
LFP. Removing neural elements from the peri-electrode space alone reduced the LFP 
magnitude by 31.4%, and acute edema led to further reductions, with a magnitude 
43.3% smaller than that under the original conditions. Conversely, glial encapsulation 
generated only a 27.8% reduction in LFP magnitude, or a 5.2% increase over the 
condition where neural elements were removed from the peri-electrode space, but the 
conductivity was that of the surrounding grey matter. 
5.4 Discussion 
We conducted a systematic investigation of how the presence and geometry of 
the DBS electrode, as well the changing conditions between acute and chronic electrode 
placements, affected recorded evoked (single-unit and ECAP) and intrinsic (LFP) neural 
signals. The highly conductive contacts had a negligible effect on the ECAP (RMSE=6.9%) 
and LFP (5.1% magnitude change), in agreement with prior work (van Dijk et al., 2009). 
Van Dijk and colleagues suggested that this result occurred only if the impedance of the 
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electrode-tissue interface (ETI) was high relative to the effective tissue impedance, 
although we did not include the ETI in our model. The differences in ECAPs recorded 
with the DBS electrode versus a point electrode indicated that spatial averaging across 
the larger contact surface decreased the signal magnitude in a phase-dependent manner 
(RMSE=77.9%). This differed from a previous study, which found small differences in 
single-unit recordings made with a microelectrode compared to those made with a point 
source representation (Moffitt and McIntyre, 2005), but this likely resulted from the 
already small surface area of the microelectrode (400 µm2) compared to the DBS 
macroelectrode (5.98 mm2). 
Smaller contact diameters and lengths increased signal energy in single-unit 
recordings. This increase in signal strength for smaller contact surfaces confirmed 
previous findings (Schoonhoven and De Weerd, 1984, Dimitrova et al., 1999, Moffitt and 
McIntyre, 2005, Lempka et al., 2011, Lempka and McIntyre, 2013), and can be explained 
by considering how recording the full potential generated by a nearby neuron requires 
that the contact area be small compared to the "steepest portion" of the corresponding 
extracellular field (Humphrey and Schmidt, 1990); otherwise, potentials are reduced by 
averaging. Similar trends were observed between ECAP energy and electrode diameter 
or contact length, although with variable effects on different phases of the ECAP. 
Changing electrode diameter also impacts the size of the stimulation contact, which can 
alter neural activation and distort the typical ECAP waveform, and we attempted to 
 202 
mitigate this effect by adjusting DBS amplitude accordingly. In addition, we confirmed 
that smaller recording contacts are more sensitive to signals from nearby neurons, 
whereas larger contacts have more uniform volumes of recording sensitivity. This could 
be used to tune the size of the recorded volume to encompass only the neuronal 
population that is critical to therapeutic effectiveness. Finally, we demonstrated that 
electrodes with diameters smaller than the Medtronic 3387 electrode had increased 
recording selectivity for local cells over passing axons, whereas the opposite was true 
with larger electrode dimensions. Selective recording from cerebellothalamic passing 
axons may be desired, given that their activation during DBS appears critical to effective 
therapy (Coenen et al., 2011, Sandvik et al., 2011, Birdno et al., 2012, Keane et al., 2012), 
as observed in Chapter 4. 
Reducing contact spacing from 1500 μm to 100 μm decreased the ECAP energy, 
particularly the N1 and N2 phases, whereas increasing contact spacing to 2000 μm 
increased the N2 phase. Similarly, shorter contact-to-contact distances reduced 
substantially the LFP signal magnitude. We initially expected that moving the recording 
contacts closer to the stimulating contact would increase ECAP signal strength by 
reducing the distance between activated neurons and recording contacts. However, this 
was more than offset by the reduced contribution from distant neurons associated with 
shorter distances between bipolar recording contacts (Lempka and McIntyre, 2013). 
Monopolar recording will maximize contributions from distant neurons, but even still, it 
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is unlikely that the ECAP would include contributions from all activated neurons. 
Single-unit recordings indicated that neural elements contribute to the ECAP up to 
lateral distances of ~1 mm, whereas the average radius of neural activation could extend 
to ~2.8 mm during clinical DBS, assuming a spherical volume of activation of 91 mm3 
about a monopolar stimulating contact (Frankemolle et al., 2010).  
These results inform electrode design for improved ECAP recording. Reducing 
the recording contact length and electrode diameter, as well as increasing contact 
spacing, can increase the signal magnitude, and the two former changes can also 
increase spatial sensitivity. We envision a novel electrode design that, compared to the 
Medtronic 3387 electrode, has a smaller recording contact length (1000 μm) and 
diameter (500 μm), as well as greater contact spacing (2000 μm). After adjusting 
stimulation voltage to maintain equal neural activation between the Medtronic 3387 
electrode and this design (5.4% difference in the percentage of total neural activation in 
the first 0.2 ms), the ECAPs recorded with the new electrode exhibited greater energy of 
phases P1 (198.8%), N1 (119.3%), and P2 (2170.7%), although N2 was reduced (-63.7%) 
(Fig. 5.8). Moreover, the greater spacing between stimulating and recording contacts in 
the novel electrode reduced the artifact magnitude by 23% compared to the Medtronic 
3387 electrode, calculated using the tissue heterogeneity model methodology (Fig. 4.4), 
but with homogenous conductivity in the peri-electrode space ( 30. S/m). Two potential 
shortcomings of this design are the increase in stimulation voltage requirements, due to 
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the smaller stimulating contact diameter, and increased selectivity for local cells, such as 
thalamocortical neurons, relative to passing axons, such as cerebellothalamic afferents, 
even though the latter may mediate the therapeutic effectiveness of Vim-DBS. 
Additionally, if contacts on the new electrode are to be used for stimulation, there are 
changes in the risks for tissue damage and electrode corrosion. 
 
Figure 5.8: A: ECAPs recorded with the original, Medtronic 3387 electrode and 
the novel electrode with smaller recording contact area and larger contact spacings. 
DBS amplitude was 2.5 V for the original electrode and 3 V for the novel electrode. B: 
Neural activation for the electrodes tested in (A). Data presentation is similar to Fig. 
5.3B. C: Signal energy of each phase from the ECAP responses in (A). 
The ECAP was affected by changes in the composition of the peri-electrode space 
intended to represent recording with acute or chronic placement of the electrode. 
Neuronal cell loss in the peri-electrode space alone had a substantial impact on ECAP 
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and LFP recordings, even with adjustments in stimulation amplitude to maintain similar 
levels of neural activation for the former. Further, acute edema decreased the signal 
energy in single-unit recordings, ECAPs, and LFPs, while chronic glial encapsulation 
had the opposite effect. Similarly, Moffitt and McIntyre found that reductions in current 
density with glial encapsulation were counteracted by increases in resistivity and 
resulted in a net increase in electric potentials, per Ohm's law, while the opposite was 
true for edema (Moffitt and McIntyre, 2005). It is also important to consider how glial 
encapsulation of the electrode can increase the magnitude of the stimulus artifact, 
particularly with impedance imbalances between contacts. The stimulus artifact can 
overlap with and distort the ECAP (Chapter 4), and thereby negate potential increases in 
ECAP amplitude under chronic recording conditions. 
The computational model used in this work provided insight into how 
properties of the electrode and peri-electrode space affect recorded neural activity, but 
there were several limitations. First, geometrical approximations were made for the 
location of the DBS electrode and for the neural fiber trajectories, which could have 
affected neural activation during DBS and the resulting ECAP signal. Second, the model 
did not include representations of the ETI, tissue capacitance, or tissue inhomogeneity, 
which could have influenced both neural activation during DBS (Butson and McIntyre, 
2005, Yousif et al., 2008a, Grant and Lowery, 2010, Lempka et al., 2010, Tracey and 
Williams, 2011) as well as the recorded activity. In a modeling study of beta band LFP 
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recordings made from a DBS electrode, the capacitance of the ETI and bulk brain tissue 
had no significant effect on the signal, although these effects are expected to be 
frequency-dependent (Lempka and McIntyre, 2013). Specifically, tissue capacitance and 
tissue inhomogeneities generate a low-pass filtering effect (Bedard et al., 2004, 2006, 
Buzsaki et al., 2012) that could impact the higher frequency components of the ECAP 
signal. Conversely, the ETI acts as a high-pass filter (Wise and Angell, 1975, Butson and 
McIntyre, 2005), which can affect theta LFP recordings (Yousif et al., 2008b, Rosa et al., 
2010), but should not substantially alter the ECAP. The electrode impedance is related to 
the surface area of the contacts (Butson et al., 2006), meaning that the effects of the ETI 
on the LFP may vary across electrode designs. Third, we did not consider the impact on 
signal fidelity of thermal noise (or other noise sources), which would increase with the 
higher ETI impedance expected for a smaller contact surface area (Dimitrova et al., 1999, 
Lempka et al., 2011). Consequently, both the signal and noise amplitudes may increase 
with the use of smaller electrode diameters or contact lengths, leading to a potentially 
ambiguous effect on the signal-to-noise ratio. 
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6. Conclusions 
Deep brain stimulation (DBS) is an FDA-approved, surgical therapy for 
movement disorders, including essential tremor (ET) and Parkinson's disease (PD), but 
the mechanisms of action remain unclear. The clinical efficacy of DBS depends on 
identifying appropriate stimulation parameters, but programming sessions are time 
consuming, costly, and can result in sub-optimal outcomes. Closed-loop systems could 
provide automatic parameter adjustment to optimize treatment using a neural feedback 
control signal, such as local field potentials (LFPs) or single-unit recordings. 
We hypothesized that the evoked compound action potential (ECAP) could serve 
as a closed-loop feedback signal by providing insight into the element type and extent of 
neural activation in the vicinity of the DBS electrode during stimulation. This was based 
on analogous ECAP recordings from the cochlear nerve that are used to assist 
programming of cochlear implants. The purpose of this dissertation was to determine 
the suitability of the ECAP as a feedback control signal by recording and characterizing 
the signal, using experimental and computational methods. The work includes the first 
ECAP recordings made from the same DBS lead used for stimulation in preclinical and 
clinical studies. We demonstrated that ECAPs: 1) could be measured in the presence of a 
stimulus artifact using our novel recording hardware, 2) provided insight into neural 
activation across a range of stimulation parameters, 3) had characteristics that were 
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correlated to clinical tremor, and 4) were affected by the recording conditions and the 
DBS electrode design. 
6.1 Summary of results 
6.1.1 Instrumentation to record ECAPs during DBS 
The first aim was to develop recording instrumentation that could record ECAPs 
with high fidelity in the presence of a stimulus artifact (Chapter 2). The relatively large 
artifact can saturate recording amplifiers and mask or distort short latency ECAPs. 
Previous techniques to remove the artifact include post-processing (i.e., template 
subtraction) and filtering, but these were inadequate for a closed-loop application, 
where "real time" recording is required. We developed DBS-ECAP instrumentation, 
which combined commercial amplifiers and additional circuit components to reduce the 
artifact. These components included anti-parallel diodes at amplifier inputs to clip 
selectively the artifact, internal amplifier blanking during delivery of each stimulus 
pulse, and a relay disconnecting the stimulating electrodes following each pulse to limit 
capacitive discharge from the electrode-tissue interface (ETI). ECAPs were recorded 
from non-stimulating contacts on the DBS electrode, eliminating the need for additional 
electrodes and ensuring that recording contacts were near the activated neural elements, 
using a differential configuration that reduced common-mode noise. 
We validated the capability of this instrumentation to reduce the artifact and 
enable high fidelity recordings through in vitro and in vivo experiments. In vitro testing 
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performed in a saline tank demonstrated that reduction of the artifact magnitude with 
DBS-ECAP instrumentation enabled an increase in gain by a factor of 1,000-5,000 times 
without saturation, compared to a conventional biopotential amplifier. The recording 
fidelity of mock ECAPs (mECAPs), which were delivered by a pair of microelectrodes 
near the DBS electrode, was increased by the higher gains and reduced temporal overlap 
with the artifact. Sub-millivolt mECAPs with short latencies of only 0.5 ms could be 
recorded with low distortion using clinically-relevant DBS parameters and short, 
symmetric, biphasic pulses. However, longer, asymmetric pulses, such as those used in 
implanted pulse generators (IPGs), precluded recording ECAPs with low distortion 
except at latencies of ≥1 ms. The artifact was smaller when recording contacts were 
symmetrical about a monopolar stimulation contact (monopolar symmetric), thereby 
balancing the potentials generated by stimulation, in comparison to configurations using 
bipolar stimulation or monopolar stimulation with asymmetrical recording contacts 
(monopolar asymmetric). Physiological ECAPs were also recorded in vivo from an 
anesthetized cat, implanted with a mini DBS electrode in the ventrolateral (VL) nucleus 
of the thalamus, without contamination by the artifact. Based on these findings, we used 
the DBS-ECAP instrumentation for all subsequent experimental work in this 
dissertation. 
As well, we developed an electrical circuit equivalent model (PSpice), which 
represented the properties of the electrode and medium, stimulation output, and 
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components of the DBS-ECAP instrumentation, to study the sources of any residual 
stimulus artifact. First, the turn-off delay of the stimulator relay allowed some capacitive 
discharging before the electrodes were completely disconnected, and using a relay with 
a more rapid off time could have further reduced the corresponding third phase of the 
artifact. Second, the larger artifact observed in vivo, particularly in post-mortem 
recordings, compared to in vitro, was presumably generated by tissue inhomogeneities 
between contacts, and by discharging of the tissue capacitance after each pulse.  
6.1.2 Investigating the neural origin of ECAPs  
For the second aim, we characterized the ECAP in vivo across stimulation 
parameters and determined the neural elements contributing to this signal (Chapter 3). 
ECAPs recorded during acute DBS in the VL thalamus of anesthetized cats were 
consistent across experiments, and depended on the stimulation and recording contact 
configuration. For the monopolar symmetric configuration, we observed primary 
positive (P1) and negative (N1) phases, followed by secondary positive (P2) and 
negative (P2) phases, with the latency of secondary phases dependent on electrode 
location. Responses were similar for cathodic- and anodic-phase first polarities, as 
expected with the use of symmetric, biphasic pulses, ECAP signal energy increased with 
larger DBS amplitudes (P<0.0001) and pulse widths (P<0.002), and the signal energy of 
secondary ECAP phases was larger at 10 Hz than 100 Hz DBS (P<0.002). While the ECAP 
waveform shape differed for alternative contact configurations, the effect of stimulation 
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parameters was similar to the monopolar symmetric case. The monopolar asymmetric 
configuration generated a N1'-P1'-N2' waveform, corresponding to action potential 
propagation past each of the two recording contacts, and the waveform recorded with 
the bipolar configuration was highly dependent on electrode location. 
We investigated the neural origin of the ECAP using pharmacological 
interventions and a validated computational model of thalamic DBS. The model was 
extended to enable calculation, using the reciprocity theorem, of the ECAP response 
generated by neuronal transmembrane currents. The experimental and computational 
ECAPs were similar in shape for different contact configurations, and were correlated 
across stimulation parameters for the monopolar symmetric configuration (R=0.80-0.95, 
P<0.002). The model indicated that direct activation of thalamocortical (TC) cells 
produced P1 and direct activation of pre-synaptic inputs produced N1. Moreover, post-
synaptic activation of TC cells and inputs from the reticular nucleus and thalamic 
interneurons generated the secondary phases. This was confirmed by the reduction of 
secondary phases following microinjection of glutamate receptor antagonists 
CNQX/APV, and by the increased secondary phase latency with administration of 
muscimol, a GABAA receptor agonist, which hyperpolarized TC neurons. The model 
also demonstrated that increases in ECAP signal energy with DBS amplitude and pulse 
width resulted from greater neural activation, and the effect of frequency on secondary 
phases likely resulted from increased synchronization of post-synaptic TC activation at 
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10 Hz compared to 100 Hz DBS. Therefore, ECAPs provide information about the 
spatiotemporal activation pattern (based on the timing and polarity of ECAP phases), 
the spatial extent of activation (ECAP magnitude), and types of elements activated (pre- 
or post-synaptic cells).  
The computational model could have been improved in several ways to generate 
ECAP waveforms that were even more similar to experimental recordings. The cat VL 
thalamus was represented using a geometrical approximation based on the human 
ventral intermediate (Vim) nucleus of the thalamus (Birdno et al., 2012). Model accuracy 
may have increased by instead using the true anatomical shape of the cat VL thalamus 
(Jimenez Castellanos, 1949), as well as accurate fiber trajectories and correct electrode 
positioning. Second, inclusion of thalamocortical-corticothalamic reciprocal synaptic 
connections (Hersch and White, 1981, Briggs and Usrey, 2007, Mina et al., 2013) may 
have led to more accurate representation of secondary ECAP phases. A final 
improvement would have been incorporation of the ETI, tissue capacitance, and tissue 
inhomogeneities, which may have filtered the ECAP signal. 
6.1.3 Relationship between ECAP characteristics and tremor during 
thalamic DBS 
For the third aim, we determined the feasibility of recording ECAPs in human 
subjects, investigated the neural origin of this ECAP and the sources of any stimulus 
artifact, and correlated ECAP characteristics with motor symptoms (Chapter 4). 
Experiments were conducted intraoperatively, with external stimulating and recording 
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hardware connected to the subject's implanted DBS brain lead unilaterally. We recorded 
ECAPs and measured tremor using an accelerometer across DBS amplitudes, pulse 
widths, and polarities. This was performed on patients with ET, tremor-dominant PD, or 
fragile-X associated tremor/ataxia syndrome (FXTAS), who were undergoing surgery for 
initial electrode implantation (acute) or replacement of their IPG (chronic).  
There was large subject-to-subject variation in stimulus artifact amplitude, 
especially among the chronically implanted electrodes. This artifact variability was 
consistent with cochlear ECAP measurement (Miller et al., 2008), and was explored 
using the electrical circuit equivalent model from Chapter 2 and a finite element method 
(FEM) volume conductor model that represented the heterogeneous conductivity in the 
peri-electrode space. Both models revealed that the larger stimulus artifacts may have 
been caused by chronic glial encapsulation of the electrode, resulting in imbalances in 
tissue impedance between contacts. While the impedance imbalance was greater in 
chronic experiments compared to acute experiments, a relationship for the former 
between the extent of impedance imbalance and the magnitude of the stimulus artifact 
was not observed. The difference in recording fidelity between acute and chronic 
conditions demonstrates the importance of measuring neural activity at both time points 
within a study, rather than the acute setting alone, by utilizing the IPG replacement 
surgery for intraoperative clinical recordings (Birdno et al., 2008). 
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 Despite the presence of the stimulus artifact, we obtained high fidelity ECAP 
recordings from both acutely- and chronically-implanted electrodes. In recordings 
containing a stimulus artifact, polarity averaging was performed to remove residual 
artifact. When present, ECAPs displayed a consistent waveform with N1-P1-(N2-P2) 
phases (N2 and P2 not always observed). Further, specific ECAP phase characteristics 
varied systematically with stimulation parameters, including non-monotonic 
relationships between ECAP energy and DBS amplitude, and increases in secondary 
phase energy with reductions in frequency from 130 to 10 Hz. With variation in DBS 
amplitude and polarity, increases in the energy of ECAP phases were correlated with 
reductions in tremor at 130 Hz or exacerbation of tremor at 10 Hz across subjects with 
near statistical significance (R=0.6-0.87, P<0.078). Moreover, the energy of secondary 
phases was positively correlated with tremor across DBS frequencies (R=0.69, P<0.061). 
The statistical power of these relationships could have been increased by testing a 
greater number of parameters in a given experiment, performing replicate trials to 
reduce variability, or measuring ECAPs when DBS was applied at other, less 
therapeutically effective contacts. However, the intraoperative setting and patient 
fatigue limited the number of parameters that could be tested. ECAPs can be recorded in 
the clinical setting, and their relationship with tremor suggests that they may provide a 
feedback control signal for automated DBS parameter adjustment. 
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The computational model of thalamic DBS was used to explore the neural origin 
of clinical ECAPs. Shifting the electrode from its original position (Birdno et al., 2012) 
along its axis in the ventral direction resulted in a similar waveform to that recorded 
experimentally, and aligned with targeted clinical electrode placement of contact 0 at the 
ventral border of Vim. The positional dependence could be useful in targeting the Vim 
during implantation or in selecting the optimal contact(s) for stimulation. The model 
also indicated that activation of cerebellothalamic fibers dominated the clinically 
measured ECAP, and given the experimental relationship between ECAP energy and 
tremor, this suggested that excitation of these fibers is critical in DBS therapy, a 
conclusion supported by other studies (Hamel et al., 2007, Herzog et al., 2007, Sandvik et 
al., 2011, Birdno et al., 2012, Keane et al., 2012). The model also helped to explain the 
non-monotonic relationship between ECAP energy and DBS amplitude, in which 
contributions from additional activation of corticothalamic inputs at higher amplitudes 
destructively interfered with the composite ECAP and reduced the apparent signal 
magnitude. 
There are several changes to the clinical protocol that may have improved the 
quality of ECAP recordings. First, the stimulation counter electrode used in IPG 
replacement surgeries was placed externally, and the resulting voltage drop across the 
skin could have reduced voltages in the brain tissue, and therefore, decreased the extent 
of neural activation. Using an internally-placed counter electrode, such as a retractor at 
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the incision site, would have mitigated this voltage drop effect. Second, the impedance 
imbalances between contacts in subjects undergoing IPG replacement surgery may have 
been generated by chronic stimulation at only one of the two recording contacts, since 
stimulation at a contact causes attached proteins and cells to desorb from the surface 
(Lempka et al., 2010). One solution is to select the contact configuration appropriately, 
with the expectation that chronic DBS will reduce the impedance at the clinical 
stimulating contacts, and which may require use of the monopolar asymmetric 
configurations (or alternatives). Another solution is to apply low amplitude DBS 
temporarily at all contacts used for stimulation or recording immediately prior to the 
ECAP recording protocol. This would disrupt the encapsulation layer and thereby 
reduce the overall impedance as well as any imbalances between contacts, and it would 
take approximately 30 minutes for the effect to reach steady state (Lempka et al., 2010). 
A third solution is to perform impedance balancing at the inputs to the differential 
amplifier in the DBS-ECAP instrumentation. Placing an adjustable load, such as a 
potentiometer, at the front-end of this amplifier stage could minimize differences in 
impedance between the stimulation contact and each recording input, and thereby 
reduce the stimulus artifact. 
6.1.4 Influence on the neural signal of recording conditions and 
electrode design 
The fourth aim was to understand better the factors that influence ECAP 
recording, including the physical presence and dimensions of the electrode, as well as 
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changes in the peri-electrode space composition in the transition from acute to chronic 
recording stages (Chapter 5). The computational model from Chapter 4 was used to 
calculate the evoked response from an activated single elements (local cell or passing 
axon), as well as ECAP responses and LFP activity from the thalamic neuronal 
population, across different conditions. The population ECAP and LFP signals were 
unaffected by the presence of the highly conductive recording contacts. Acute edema or 
glial encapsulation in the peri-electrode space decreased or increased, respectively, the 
magnitude of the single-unit response, ECAP signal, and LFP signal response, after 
accounting for neuronal cell loss in the peri-electrode space. On the other hand, we saw 
previously that glial encapsulation can generate impedance imbalances and increase the 
stimulus artifact magnitude, which may negate increases in recording fidelity associated 
with a larger ECAP. 
Reducing the recording contact surface area by reducing diameter or length 
increased the magnitude of the single-unit response, had variable effects on the different 
phases of the ECAP, and in most cases had a small effect on the LFP. Smaller contacts 
increased spatial selectivity for nearby neurons by averaging biopotentials over a 
smaller area, and smaller diameter recording contacts increased selectivity for local cells 
over passing axons, whereas the opposite was true with larger diameters. This indicated 
that larger diameter electrodes would preferentially record from pre-synaptic inputs 
such as cerebellothalamic fibers over TC neurons, and was confirmed when comparing 
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the neural contributions to the ECAPs from preclinical and clinical studies in Chapters 3 
& 4. Shorter spacing between contacts reduced ECAP energy and LFP magnitude due to 
smaller contributions from more distant neurons (Lempka and McIntyre, 2013), whereas 
increasing contact spacing had variable effects on the ECAP phases and a small effect on 
the LFP. An improved electrode for high fidelity ECAP recording would therefore use a 
smaller diameter and recording contact length, and longer contact spacing, which we 
found would increase ECAP signal energy. This study informed recording conditions 
that improved ECAP recording fidelity, and was the first to investigate alternative DBS 
electrode designs for improved neural recording. 
6.2 Clinical relevance of findings 
The work performed in this dissertation supported the use of the ECAP as a 
feedback control signal for automated parameter adjustment, and provided insight into 
the mechanisms of action of DBS. The clinical study performed in Chapter 4 identified 
ECAP signatures of clinical effectiveness, including a correlation between greater phase 
energy and reductions in tremor at 130 Hz, which could be used to adjust DBS 
amplitude or pulse width. Further, secondary phase energy was increased at lower 
frequencies, and was correlated with exacerbation of tremor. This relationship could be 
used to identify the critical DBS frequency that masked pathological firing patterns 
(Kuncel et al., 2007). The relationship between ECAP phase energy and tremor differed 
between subjects, and the absolute phase energy varied by an order of magnitude, 
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suggesting that the threshold ECAP energy value used for parameter selection needs to 
be subject specific and normalized to some maximum energy value. 
Automated selection of stimulation parameters and contacts in clinical 
programming sessions could increase the therapeutic benefit of DBS, reduce side effects, 
and improve battery life. Moreover, periodic parameter adjustments in closed-loop DBS 
systems would maintain optimal settings as the disease progressed or the response to 
DBS changed over time, and proof-of-concept was demonstrated in a computational 
model-based implementation of this system (Appendix A). 
The results from the clinical study also improved our understanding of DBS by 
indicating the type and extent of activation required for therapy. Cerebellothalamic 
afferent inputs were the dominant contributor to clinical ECAPs, and given the 
correlation between ECAP phase energy and tremor, this suggests that activation of 
these elements is critical. This was in agreement with prior work showing that effective 
DBS for ET masked pathological bursting activity from the cerebellum to the thalamus 
(Birdno et al., 2012, Keane et al., 2012), and that targeting these fibers during DBS 
implantation may be more effective than implantation in the Vim proper (Hamel et al., 
2007, Herzog et al., 2007, Sandvik et al., 2011). Given the apparent role of 
cerebellothalamic afferent activation in tremor reduction, novel electrodes or stimulation 
waveforms targeting those neural elements are expected to maximize therapeutic 
outcomes. ECAP measurement also provided insight into whether effective DBS 
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required activation of a specific volume of tissue within the targeted Vim nucleus, 
irrespective of location, or a particular region within the Vim nucleus. Given the 
correlation between ECAP signal energy and tremor, and noting that the former 
provides a measure of the extent of neural activation, we concluded that DBS must 
activate a sufficient volume of tissue for clinical benefit. If it was necessary to activate a 
particular brain region, then increases in ECAP signal energy would not necessarily be 
related to motor symptoms. However, using high DBS amplitudes (i.e., above the 
clinical voltage) that extend activation outside of Vim and into brain regions that 
aggravate tremor, such as the internal capsule, can reduce the effectiveness of tremor, as 
we saw with the non-monotonic relationships between tremor and DBS amplitude. 
6.3 Future directions 
The findings from this dissertation suggest several future research directions to 
pursue, exploring further the electrode location dependency of ECAP characteristics, 
including exploring ECAP recording from other brain targets, clinically validating an 
ECAP-based closed-loop DBS system, and testing in vivo the effect on ECAP recording 
fidelity of different electrode dimensions. 
The focus of this dissertation was on ECAP recording during thalamic DBS, but 
other brain targets are commonly targeted for treatment of movement disorders, 
including the subthalamic nucleus (STN) for PD. The preclinical, clinical, and 
computational modeling studies presented in Chapters 3 & 4 could be extended to 
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ECAP recording during STN-DBS. The experimental setups would be very similar, 
except that clinical assessment of motor symptoms would use an alternating finger 
tapping task (Brocker et al., 2013), which is significantly correlated with UPDRS scores 
in PD, particularly the bradykinesia subscore (Taylor Tavares et al., 2005). Additionally, 
because there is a longer latency before onset or washout of the effects of STN-DBS, 
compared to thalamic DBS, trial lengths should be extended from 2 min to 8 min, with 
DBS off for the first 4 min and on for the next 4 min (Beuter and Titcombe, 2003, Temperli 
et al., 2003). During STN-DBS, one would expect ECAP contributions from local STN 
neurons and pre-synaptic inputs from the GPe and cortex, measured at the ventral 
recording contact, and contributions from projecting axons from the GPi to the 
thalamus, measured at the dorsal recording contact (Miocinovic et al., 2006). Activation 
of fibers in the adjacent internal capsule (IC) could also contribute to the measured 
ECAP signal. A computational model of ECAP recording during STN-DBS could 
determine the neural origin of the signal. We propose using the Miocinovic model 
(Miocinovic et al., 2006), modified with explicit representation of pre-synaptic inputs 
into the STN. This work may help to validate the hypotheses that effective STN-DBS 
requires activation of pre-synaptic cortico-STN afferents (Gradinaru et al., 2009), and 
that side effects are generated by stimulation of the IC (Krack et al., 2002, Tamma et al., 
2002). It would also be useful in investigating the feasibility of using ECAPs for 
automated parameter adjustment in closed-loop STN-DBS. 
 222 
Another extension of this work is to investigate further the electrode location 
dependent character of the ECAP within preclinical in vivo experiments. We observed 
previously that ECAP characteristics varied with electrode location in both the 
preclinical in vivo study (Chapter 3), and the clinical thalamic DBS computational model 
(Chapter 4). For the former, the electrode was fixed in one location for the duration of 
each experiment, and ECAPs were compared across animals in conjunction with 
histological identification of electrode locations. However, to confirm this electrode 
location dependency, ECAPs should be measured within a given cat experiment at 
several locations as the electrode is advanced in a dorsal-to-ventral trajectory. 
An additional potential extension of this work is implementation of a real-time, 
ECAP-based closed-loop DBS system, using the intraoperative clinical setting discussed 
in Chapter 4. This system would provide automated modulation of DBS parameters, 
including amplitude, pulse width, and/or frequency, using a closed-loop controller (i.e., 
proportional-integral-derivative or fuzzy logic (Lin et al., 2012, Gorzelic et al., 2013)) to 
obtain a target ECAP energy value that maximized therapy. An initial assessment of 
correlations between ECAP signal energy and motor symptom responses would need to 
be conducted in each subject to identify this target ECAP value. For safety, the closed-
loop system should have specified maximum values for DBS parameters, with current 
density limited below 30 μC/cm2, in the event that the controller becomes unstable. 
Motor symptom assessment would be conducted periodically to quantify DBS 
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effectiveness, and any side effects noted on a 1-10 scale. Finally, measures of DBS 
effectiveness, side effects, and power usage should be compared between the steady-
state closed-loop parameters and open-loop parameters selected previously by a 
neurologist. 
We assessed the effect of variation in electrode designs on ECAP recording 
fidelity using a computational model in Chapter 5, and in future work these outcomes 
could be validated through an in vivo study. DBS electrodes of various diameters, 
contact lengths, and contact spacings would first need to be fabricated. Using the 
preclinical experimental setup described in Chapters 2 & 3, ECAPs would then be 
recorded from each electrode design in-turn, and compared against that recorded with 
the original design. The same implantation trajectory should be used between each 
tested electrode, with the stereotactic location of the stimulating contact(s) remaining 
constant, to generate equal neural activation between the tested designs. 
6.4 Concluding remarks 
Closed-loop DBS systems could reduce the clinical burden of parameter selection 
and optimize therapeutic outcomes. We hypothesized that the ECAP could provide 
insight into neural activation during DBS and therefore serve as a suitable feedback 
control signal for a closed-loop system. We measured ECAPs in preclinical and clinical 
studies using instrumentation that reduced the stimulus artifact to improve recording 
fidelity, and with a computational model that provided insight into the neural origin of 
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the signal. These represent the first ECAP measurements made during DBS from the 
same brain lead used for stimulation. We provided experimental and computational 
evidence that the ECAP provides insight into the type and extent of neural activation 
following each DBS pulse, varies systemically with stimulation parameters, and is 
correlated with tremor. Moreover, the character of the ECAP and stimulus artifact is 
affected by changes in the composition of the peri-electrode space, and the former varies 
with dimensions of the DBS electrode. Our results support previous findings that 
suggested effective DBS requires activation of cerebellothalamic fibers, and demonstrate 
the feasibility of the ECAP as a potential feedback signal in closed-loop DBS systems. 
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Appendix A: Closed-loop deep brain stimulation based 
on evoked compound action potentials: a simulation 
analysis 
A.1 Introduction 
Deep brain stimulation (DBS) is a FDA-approved therapy for treatment of 
Parkinson's disease, essential tremor, and other movement disorders. DBS systems 
currently operate in an open-loop manner, in which invariant stimulation is delivered 
continuously, and a physician periodically closes the loop by adjusting stimulation 
parameters based on the symptom response and side effects profile. However, this 
methodology requires significant clinical effort (Ondo and Bronte-Stewart, 2005) and 
may not result in optimal settings (Okun et al., 2005, Moro et al., 2006). Alternatively, 
closed-loop DBS systems have been proposed to adjust DBS settings automatically based 
on a recorded neuronal feedback signal.  
Several closed-loop brain stimulation systems have been tested experimentally or 
in simulations. DBS in the globus pallidus interna (GPi), with timing controlled by 
single-unit activity in the motor cortex, ameliorated Parkinsonian symptoms in MPTP-
treated monkeys better than continuous, open-loop, 130 Hz DBS (Rosin et al., 2011). 
Recordings of local field potentials (LFPs) from the hippocampus (HC) in sheep were 
used to detect seizures during HC-DBS and temporarily discontinue stimulation 
(Stanslaski et al., 2012). Similarly, seizures were automatically detected in clinical 
electrocorticogram (ECoG) recordings and triggered high-frequency stimulation, either 
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locally in the cortex or remotely in the anterior thalamus, which reduced the mean 
seizure rate (Kossoff et al., 2004, Fountas et al., 2005, Osorio et al., 2005). A modeling 
study of thalamic DBS demonstrated that an adaptive minimum variance controller of 
stimulation amplitude could more closely restore the recorded LFP spectrum to a 
tremor-free reference spectrum than open-loop DBS (Santaniello et al., 2011). 
Additionally, thalamic fidelity was improved in the Rubin-Terman (RT) network model 
of the basal ganglia (Rubin and Terman, 2004) with subthalamic nucleus (STN) DBS 
proportional to the filtered and time-delayed STN-LFP signal (Guo and Rubin, 2011). 
Finally, a proportional-integral-derivative (PID) closed-loop controller was successfully 
implemented in the RT model, with the amplitude or frequency of GPi-DBS driven by 
estimates of thalamic reliability or synaptic conductances between GPi and thalamus 
(Gorzelic et al., 2013). PID controllers have also be used to regulate muscle force or joint 
angle via stimulation with intramuscular or nerve cuff electrodes in animal models 
(Crago et al., 1980, Lin et al., 2012) and in human upper (Crago et al., 1991, Lemay and 
Crago, 1997) and lower (Chizeck et al., 1985, Abbas and Chizeck, 1991) extremities. 
The objective of this work was to determine the feasibility of closed-loop DBS 
using the evoked compound action potential (ECAP) as the feedback control signal. In 
prior studies, we showed that ECAPs can be recorded during DBS in preclinical and 
clinical studies, are modulated systematically by stimulation parameters, and are 
correlated to clinical motor symptoms (Chapters 2-4). The correlation between ECAP 
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characteristics and motor symptoms served as the basis for a PID controller or its 
variants, including P and PD controllers, for adjustment of DBS amplitude or hybrid 
amplitude/pulse width modulation (Tyler and Durand, 1997, Lin et al., 2012). We 
evaluated in simulation the ability of this system to identify parameters that minimized 
burst-driver band power in thalamocortical neurons, a proxy for clinical effectiveness 
(Birdno et al., 2012), and to adjust stimulation parameters in response to disturbances. 
A.2 Methods 
We implemented in simulation an ECAP-based closed-loop DBS system (Fig. 
A.1) consisting of a P, PD, or PID controller coupled to a DBS parameter modulator. 
Stimulation was delivered to the plant, which was a validated biophysically-based 
population model of thalamic DBS and generated the ECAP responses that were 
subsequently analyzed by the controller.  
The details of the thalamic DBS model have been described in detail in Chapter 
3, and are reviewed briefly. A finite element method (FEM) volume conductor model 
was used to calculate the voltages generated by a three-dimensional geometrical 
representation of a NuMed mini DBS electrode within the cat ventrolateral (VL) nucleus 
of the thalamus, all encompassed in a cylindrical brain tissue volume. The FEM model 
output was coupled to validated biophysical cable models, which included anatomical 
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Figure A.1: Implementation of a closed-loop DBS system in simulation. The 
ECAP signal energy error (EE) was defined as the difference between the target (ET) 
and actual (EA) signal energies. To obtain the latter, ECAPs were measured from a 
thalamic DBS model ("plant"), the stimulus-triggered average (black trace, below) was 
calculated from single ECAP responses (gray traces), the averaged signal was squared, 
and integration was performed over the duration of the signal (black fill), excluding 
the residual stimulus artifact. EE served as the input to the controller, and the 
controller output (EC) was used by the DBS parameter modulator to adjust amplitude 
and/or pulse width. 
and electrical representations of thalamocortical (TC) neurons, pre-synaptic inputs from 
the cortex (CTx), cerebellum (CER), reticular nucleus (RN) and thalamic interneurons 
(TIN), and their synaptic connections. A neural unit was defined as a single TC neuron 
and its corresponding pre-synaptic inputs from the four brain areas, and 500 of these 
units were randomly distributed with TC soma locations confined within the VL 
thalamus. Neural elements that intersected with the electrode or the surrounding 150 
μm thick peri-electrode space were removed. The GABAergic synaptic conductances 
from RN and TIN to TC neurons were varied to generate 50% bursting, 30% regular 
spiking, and 20% random spiking TC neurons (Birdno et al., 2012). Additionally, two 
models were used, designated as healthy and tremor conditions, and were differentiated 
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by intrinsic network activity. Specifically, a 20 Hz Poisson train of spikes was introduced 
to CTX inputs in both healthy and tremor conditions, whereas a 5.8 Hz harmaline burst 
input was introduced to 50% of CER afferents in the tremor condition only. Finally, the 
somatic noise injection present in the original model was removed (Birdno et al., 2012). 
Following an initialization period of 500 ms, symmetric, biphasic, cathodic-phase 
first, voltage-controlled stimulation was applied from DBS contact 1. We recorded the 
transmembrane potential (VM) of all TC somata, and calculated the mean fraction of VM 
power in the burst-driver band (5.8±1 Hz, 0.4 Hz resolution) after removing any DC 
offset. Additionally, the transmembrane currents were measured in the compartments of 
all neural elements to calculate the differential ECAP voltage across DBS recording 
contacts 0 and 2 using the reciprocity theorem (Helmholtz, 1853, Moffitt and McIntyre, 
2005). Subsequent ECAP post-processing steps included stimulus artifact template 
subtraction, in which the template was calculated with a subthreshold voltage in the 
absence of intrinsic network activity with linear detrending, two cascaded filtering 
stages with a 10 Hz - 10 kHz band-pass, and stimulus-triggered averaging over 8 
responses to replicate post-processing performed experimentally (Chapter 3). Finally, 
ECAP signal energy was calculated by squaring the signal and integrating over its 
duration, excluding residual stimulus artifact (Fig. A.1). The simulation time step was 25 
μs. 
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The ECAP signal energy error (EE = ET - EA) was the difference between the user-
specified target signal energy (ET) and the actual signal energy generated in the thalamic 
DBS model (EA) and served as the feedback control signal (Fig. A.1). The target energy 
was selected by quantifying the relationship between ECAP signal energy and the 
fraction of somatic VM power in the burst-driver band. The latter is strongly correlated 
with tremor across DBS conditions (R2=0.81) (Birdno et al., 2012) and was used as a 
proxy for clinical effectiveness. Both ECAP signal energy and burst-driver band power 
were calculated in 2.5 s trials across DBS amplitudes, pulse widths, and frequencies in 
the tremor condition, and burst-driver band power was also calculated with DBS off in 
the healthy and tremor conditions. The target ECAP signal energy was selected such that 
the burst-driver band power was reduced from the elevated level in the tremor condition 
without stimulation to the level in the healthy condition.  
DBS parameters were updated over multiple iterations at a 10 Hz frequency 
using a P, PD, or PID controller. The initial DBS parameter set was 1 V amplitude and 60 
μs pulse width. After each 100 ms iteration, the actual ECAP signal energy and 
corresponding energy error were measured, and the controller output at the at the nth 
iteration (EC(n)) was calculated as:  
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K(i)ETK(n)EK(n)E  (Equation A.1) 
where KP, KI, and KD were the proportional, integral, and derivative gains, and T was the 
sampling period of 100 ms. The gains were determined with the Ziegler-Nichols (Z-N) 
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tuning methodology (Ziegler and Nichols, 1942) in a separate simulation trial. For Z-N 
tuning, KD and KI were set to zero and KP was adjusted to the minimum value (KU) that 
generated oscillations in the controller output with constant amplitude and period (PU). 
Using DBS amplitude modulation alone, oscillations were generated with a period of 
PU=200 ms (two controller iterations) using KU=38. The P and PID controller gains were 
then tuned with Z-N values, and the PD controller gains tuned using Z-N values for the 
PID controller and the integral term removed: 
P controller: KP = 0.5KU; KI = 0; KD = 0     (Equation A.2) 
PD controller: KP = 0.6KU; KI = 0; KD = (KP×PU)/8    (Equation A.3) 
PID controller: KP = 0.6KU; KI = 2KP/PU; KD = (KP×PU)/8   (Equation A.4) 
The DBS parameter modulator used the controller output to adjust the 
stimulation amplitude exclusively, or both amplitude and pulse width in tandem. For 
the former, DBS amplitude was adjusted in direct proportion to EC(n), rounded to the 
nearest 0.1 V (Volkmann et al., 2006), and pulse width was fixed at 60 μs to minimize 
charge (Kuncel and Grill, 2004). For hybrid amplitude and pulse width modulation, we 
compared the power requirements (power ~ voltage2 × pulse width (Kuncel and Grill, 
2004)) for an adjustment of amplitude, again proportional to EC(n), or for an adjustment 
of pulse width by 30 μs, increasing for EC(n) > 0 and decreasing for EC(n) < 0, with a 
lower bound of 60 μs. Whichever adjustment, amplitude or pulse width, minimized 
power was implemented for that controller iteration, although we forced adjustment of 
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amplitude in the first controller iteration due to the low starting voltage value. The 
closed-loop controller ran until EA reached steady state and EE approached zero, after 
which a disturbance was introduced. In one implementation, the percentage of TC 
neurons with bursting behavior was increased from 50% to 100%, as a way to model 
progression of the disease state. For a second disturbance, a glial encapsulation layer 
was introduced in the FEM model by reducing the conductivity of the peri-electrode 
space from that of brain tissue ( 30. S/m) to 0.1 S/m (Butson et al., 2006), representing a 
transition to a chronic implantation condition (Yousif et al., 2008a, Lempka et al., 2010). 
A.3 Results 
An ECAP-based closed-loop DBS system was implemented in simulation to 
automatically identify DBS parameters that minimized TC soma burst-driver band 
power, a proxy for clinical effectiveness. 
The fraction of power in the burst-driver band was calculated from the TC soma 
transmembrane potential, and averaged across the thalamic population. The target 
ECAP energy was selected from the relationship between burst-driver band power and 
ECAP signal energy across stimulation parameters (Fig. A.2A). With stimulation off, the 
mean burst-driver band power was 0.0106 for the healthy condition and 0.0347 for the 
tremor condition. Increasing the amplitude or pulse width of 130 Hz DBS reduced burst-
driver band power, and 5.5 V DBS restored this to the healthy level. Conversely, 10 Hz 
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DBS led to relatively small reductions in burst-driver band power, and did not restore 
the healthy level for the parameters tested.  
 
Figure A.2: Mean fraction of TC somatic VM power in the burst-driver band 
and ECAP responses across stimulation parameters and model conditions. A: 
Relationship between burst-driver band power and ECAP signal energy at 130 Hz and 
10 Hz DBS, with stimulation amplitudes of 0.5-5.5 V (proportional to data point size) 
and pulse widths of 60 μs (open circles) and 90 μs (filled circles). The burst-driver 
band power is shown for the healthy and tremor conditions with DBS off (horizontal 
dashed lines), and the target ECAP signal energy for 130 Hz DBS is indicated (vertical 
dashed line). Linear regressions were calculated between burst-driver band power 
and ECAP signal energy, with only the data points constituting the negative linear 
trend used for 130 Hz DBS. B: Stimulus-triggered average ECAPs for a range of DBS 
amplitudes, with 130 Hz DBS frequency and 60 μs pulse width. C: Stimulus-triggered 
average ECAPs for different combinations of pulse widths and amplitudes, with 130 
Hz DBS frequency. The artifact ("Art") and ECAP phases are labeled in (B) and (C).   
Changes in ECAP signal energy were non-monotonic with increasing DBS 
amplitude; ECAP energy initially increased before declining above 3-4.5 V, depending 
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on the pulse width and frequency (Figs. A.2A,B). Moreover, longer DBS pulse widths 
led to increases in ECAP energy only at low stimulation amplitudes (≤4 V), whereas the 
opposite was true at high stimulation amplitudes (Figs. A.2A,C). Importantly, the 
relationship between burst-driver band power and ECAP signal energy across DBS 
parameters was non-monotonic at 130 Hz, with a negative, linear relationship up to ~4 V 
(R=0.97, P<0.0001), before reversing at higher amplitudes (Fig. A.2A). This relationship 
suggested a target ECAP energy of 0.09 mV2-ms, which corresponded to the 
approximate reversal point of ECAP energy with increasing DBS amplitude, as well as a 
burst-driver band value of 0.0145, or a 83.8% decline from the tremor to the healthy 
conditions. On the other hand, there was a relatively flat, linear, monotonic relationship 
between burst-driver band power and ECAP signal energy at 10 Hz DBS (R=0.96, 
P<0.0001), consistent with the ineffectiveness of low frequency DBS for tremor.  
The relationship between burst-driver power and ECAP energy was also 
explored across DBS frequencies (Fig. A.3). Reductions in burst-driver power were 
significantly correlated (α=0.05) with increasing P1 phase energy (R=0.67, P<0.04), and 
nearly significantly correlated with decreasing N1 phase energy (R=0.61, P<0.06) 
generated by higher DBS frequencies. Conversely, we did not identify linear correlations 
between the burst-driver band and either the energy of the entire ECAP signal or the 
secondary phases.  
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Figure A.3: Relationship between burst-driver band power and ECAP signal 
energy for stimulation frequencies of 10-200 Hz (proportional to data point size and 
labeled). The four sub-plots show ECAP energy over the entire signal, and for P1, N1, 
and secondary phases. DBS amplitude was fixed at 4.5 V and pulse width was fixed at 
60 μs. Data presentation is otherwise similar to Fig. A.2A. 
The closed-loop DBS system was first implemented with a P controller with DBS 
amplitude modulation, and a disturbance was introduced after the system reached 
steady state (Fig. A.4). Prior to the disturbance, the system increased the stimulation 
amplitude automatically from the starting value of 1 V to a steady state value of 
4.73±0.09 V (mean ± SD of iterations 6-30). The rise time to reach 90% of the target ECAP 
energy was 500 ms, equivalent to five controller iterations. ECAP energy eventually  
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Figure A.4: DBS amplitude modulation by a proportional (P) closed-loop 
controller (top) and corresponding ECAP signal energy relative to the target value, 
indicated by the horizontal dashed line (bottom). A disturbance increasing the 
number of TC model neurons exhibiting bursting was introduced at iteration number 
31, and the response to this disturbance was compared with closed-loop DBS 
modulation turned on or off. 
reached the target value at the tenth iteration (1 s real-time), which was followed by a 
small overshoot and then steady state after the 15th iteration. Near the 25th iteration, there 
was a small, intrinsic perturbation of ECAP energy away from steady state, and the 
system made corresponding adjustments of DBS amplitude. The average absolute error 
was 0.0032±0.0025 mV2-ms over iterations 6-30. The number of TC neurons exhibiting 
burst activity was increased at iteration 31, and the closed-loop controller subsequently 
reduced DBS amplitude to 4.60±0.12 V, maintaining ECAP energy error at 0.0033±0.0026 
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mV2-ms. If closed-loop control was suspended, the average absolute error increased to 
0.0061±0.0014 mV2-ms after the disturbance.  
 
Figure A.5: Hybrid adjustment of DBS amplitude (top) and pulse width 
(middle) by a P controller, and corresponding ECAP signal energy value (bottom). 
Data presentation is similar to Fig. A.4, except that a glial encapsulation disturbance 
was introduced, in addition to the disturbance affecting the number of TC model 
neurons exhibiting bursting, at iteration number 31. Pulse width data are overlapping 
for the different conditions tested, and amplitude data are overlapping for the two 
closed-loop off conditions. 
 238 
A P controller for hybrid modulation of DBS amplitude and pulse width 
generated similar results (Fig. A.5). Initial adjustments included rapid increase of the 
pulse width from 60 μs to 120 μs, with relatively small changes in DBS amplitude 
compared to that observed with amplitude modulation alone. The rise time was 500 ms, 
and the target ECAP value was reached by 900 ms, with minimal overshoot. This was 
followed by a reduction in pulse width back to 60 μs and a corresponding increase in 
DBS amplitude to 4.31±0.41 V (iterations 15-30) to restore ECAP energy to the target 
value. The average absolute error was 0.0050±0.0076 mV2-ms over iterations 6-30. After 
increasing the number of bursting TC neurons, the controller increased DBS amplitude 
to 4.70±0.08 V, maintaining the ECAP energy error at 0.0044±0.0030 mV2-ms, and if the 
controller was suspended the error increased to 0.0068±0.0022 mV2-ms. Following 
addition of a glial encapsulation layer in the FEM model, the controller maintained a 
low ECAP energy error of 0.0058±0.0114 mV2-ms by increasing the amplitude to 
6.67±0.56 V, while suspending the controller led to an increase in error to 0.0551±0.0031 
mV2-ms. 
Alternative implementations of the closed-loop system used a PD or PID 
controller for DBS parameter adjustment. With exclusive amplitude modulation, the PD 
controller reached the target ECAP energy value with a rise time of 600 ms and minimal 
overshoot, by increasing DBS amplitude to 4.63±0.13 V (Fig. A.6). The actual ECAP 
energy oscillated about the target value, never reaching steady state, with an average 
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ECAP energy error of 0.0045±0.0025 mV2-ms, which was 40.6% higher than that for the P 
controller with amplitude modulation. Following the introduction of both model 
disturbances, the PD controller maintained a low ECAP energy of 0.0054±0.0110 mV2-ms 
by increasing amplitude to 6.70±0.52 V. 
 
Figure A.6: DBS amplitude modulation by a PD controller. Data presentation 
is similar to Fig. A.4. The glial encapsulation and TC bursting disturbances were both 
introduced at iteration number 31. 
Using a PID controller with DBS amplitude modulation, the system identified an 
amplitude (4.8 V) that generated ECAPs with energy near the target value by just the 
second iteration (Fig. A.7A). However, a subsequent overshoot of the controller output 
produced an excessive DBS amplitude of 6.2 V at the third iteration. As a consequence of 
the non-monotonic relationship between DBS amplitude and ECAP signal energy, the 
overshoot of the former resulted in a reduction of the latter away from the target value.  
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Figure A.7: DBS parameter adjustment and corresponding ECAP signal energy 
with a PID controller, with exclusive amplitude adjustment (A), or hybrid adjustment 
of amplitude and pulse width (B). Data presentation is similar to Fig. A.4. 
The system unsuccessfully tried to compensate by increasing DBS amplitude still 
further, and the trial was terminated due to system instability. An analogous situation 
arose for hybrid amplitude and pulse width modulation, in which overshoot of the PID 
controller output produced an incremental increase in pulse width at the third iteration, 
despite ECAP energy already exceeding the target value at the second iteration (Fig. 
A.7B). The longer pulse width reduced ECAP signal energy, since DBS amplitude was 
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high (4.8 V), and the controller unsuccessfully tried to compensate by increasing pulse 
width still further, after which the trial was terminated due to system instability. 
A.4 Discussion 
We implemented an ECAP-based closed-loop DBS system in simulation and 
demonstrated that a P or PD controller adjusted DBS parameters appropriately before 
and after introduction of disturbances. Conversely, the PID controller was unstable as a 
result of the non-monotonic relationship between DBS parameters and ECAP 
characteristics. Nevertheless, the results of this study suggest that ECAPs could be 
clinically useful in closed-loop DBS systems.  
A.4.1 Relationship between ECAP signal energy and burst-driver 
band power across stimulation parameters 
The relationship between ECAP signal energy and burst-driver band power, 
which was used a proxy for clinical effectiveness, was dependent on the stimulation 
frequency. This relationship was non-monotonic at 130 Hz, and was used to establish a 
target energy that corresponded to an 83.8% reduction in burst-driver band power from 
the tremor condition to the healthy condition. In contrast, the relationship between burst-
driver band power and ECAP signal energy at 10 Hz was relatively flat. Since ECAP 
energy was not a good indicator of clinical effectiveness at low DBS frequencies, we 
fixed DBS frequency at 130 Hz and used ECAP energy to adjust only DBS amplitude 
and/or pulse width. However, we could foresee the use of another ECAP characteristic, 
such as N1 phase energy (Fig. A.3), to identify the critical DBS frequency for symptom 
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reduction (Kuncel et al., 2007). In previous experimental work (Chapter 4), we identified 
a negative linear correlation between tremor and ECAP signal energy at 130 Hz that was 
nearly significant (R=0.6-0.87, P<0.078), and a similar, statistically significant relationship 
was found in this work with amplitudes below ~4 V (R=0.97, P<0.0001). In the 
experimental study, we also found a positive, linear correlation at 10 Hz (R=0.86, 
P<0.068), which differed from the relatively flat but statistically significant relationship 
identified in this work (R=0.96, P<0.0001). The differing results found from this 
simulation and prior clinical results suggest that the burst-driver band power may not 
be perfectly aligned with clinical effectiveness across the stimulation conditions tested. 
We examined further the origin of the non-monotonic relationships between 
ECAP signal energy and DBS amplitude or pulse width. The percentage of neural 
elements activated directly by stimulation increased with higher DBS amplitudes and 
longer pulse widths (data not shown), as expected from the strength-distance and 
strength-duration relationships (Kuncel and Grill, 2004). Since the ECAP reflects the 
extent of neural activation (Chapter 3), it would be expected that ECAP signal energy 
would increase with these DBS parameters. However, we also found that post-synaptic 
activation of neural elements decreased above 3-3.5 V, depending on the pulse width, 
which contributed to a reduction in secondary phase signal energy (Chapter 3), such as 
that of the P2 phase (Fig. A.2B). In addition, destructive interference of ECAP 
contributions from different types of neural elements reduced the size of composite 
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ECAP phases at higher DBS amplitudes and longer pulse widths (Chapter 4). For 
example, there was a larger negative phase contribution from CER inputs at longer 
pulse widths that reduced the P1 phase (Fig. A.2C). These effects resulted in the non-
monotonic relationships between ECAP signal energy and DBS parameters. This finding 
was confirmed by similar non-monotonic relationships found in clinical studies between 
the signal energy of ECAP phases and DBS amplitude (Chapter 4), although this was not 
observed in preclinical studies (Chapter 3), presumably because DBS amplitude was 
limited to ≤3 V. 
A.4.2 Closed-loop control of DBS  
We implemented PID-based controllers for automatic modulation of DBS 
amplitude and/or pulse width to reach and maintain ECAP energy at the target value, 
even in the presence of disturbances. This work successfully demonstrated the 
suitability of P and PD controllers in closed-loop DBS systems. These controller adjusted 
the amplitude and/or pulse width from the initial setting to reach the target ECAP 
energy in ≤1 s real-time, and maintained a relatively low average ECAP energy error 
before and after introduction of disturbances affecting TC bursting, representing 
progression of the disease state, and/or impacting DBS-generated potentials via glial 
encapsulation, representing the transition to the chronic implantation stage. For the 
latter, the controllers increased DBS amplitude by 45-55% to compensate for electrical 
insulation of the stimulating contact by the encapsulation layer. Conversely, for open-
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loop DBS, ECAP energy error was increased by 36-91% after the increase in TC bursting 
and by ~1000% after glial encapsulation. With hybrid amplitude and pulse width 
modulation, the system ultimately selected the lowest pulse width available (60 μs) to 
maximize power efficiency, and so the final parameter set was similar to that observed 
with amplitude modulation alone. The PD controller approached the target ECAP 
energy, but never obtained true steady state before presentation of disturbances, with an 
ECAP energy error 40.6% higher than that of the P controller. This may have resulted 
from non-optimized PD controller gains, which were not defined for Z-N tuning. 
A PID-based controller was selected for this work because it is simple, intuitive, 
and easy to tune. However, the main disadvantage of a PID controller is that it is linear, 
which can result in instabilities when implemented in a non-linear system, as observed 
in this work. Alternative closed-loop controllers that have been tested in neural 
prostheses include an adaptive minimum variance controller (Santaniello et al., 2011) 
and a fuzzy logic controller (Lin et al., 2012), which could offer improved performance 
in our application. Nevertheless, the PID-based closed-loop system implemented in this 
work demonstrated proof-of-principle for the ECAP as a feedback signal. 
A.4.3 Study limitations 
There were several limitations of this work that should be addressed. First, the 
computational model used a representation of the mini DBS electrode within the cat VL 
thalamus, rather than a clinical DBS electrode in the human Vim thalamus, which would 
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more accurately reflect clinical implementation of closed-loop DBS (Chapter 4). 
However, the former was selected because the neural origin of the ECAP was better 
understood through a prior study using pharmacological interventions and 
computational modeling (Chapter 3). Second, the selected target ECAP energy did not 
correspond to a full reduction in the burst-driver band power to the healthy condition, 
which would represent optimal therapy, due to the non-monotonic relationship between 
these two variables. On the other hand, the linear, monotonic correlations observed in 
clinical experiments between ECAP signal energy and motor symptoms suggests that 
target ECAP energy values selected in the clinic could correspond to an optimal 
therapeutic response (Chapter 4). Third, we did not perform additional tuning of PID 
controller gains, beyond using the Z-N methodology, which could have reduced the 
overshoot of the PID controller output (i.e., increasing derivative gain or decreasing 
integral gain). Fourth, the closed-loop controllers did not account for non-monotonicity 
between ECAP signal energy and DBS amplitude or pulse width. 
The closed-loop controller proposed in this work did not account for the possible 
generation of side effects with increasing DBS amplitude and pulse width. As these 
parameters are increased to obtain the target ECAP signal energy, stimulation current 
could leak into adjacent brain areas, such as the ventral caudal (Vc) nucleus of the 
thalamus, and generate paresthesias. In subsequent versions of the controller, ECAP 
energy could be measured from distinct phases that correspond to activation of neural 
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elements that generate therapeutic effects (i.e. cerebellothalamic afferents) or side effects 
(i.e. local cells in the Vc thalamus), for more precise DBS parameter tuning. Moreover, 
clinical implementation of a closed-loop DBS controller would require that the physician 
set maximum limits on DBS parameter values to maintain patient safety. 
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Appendix B: Comparison of local field potential and 
tremor spectrograms 
B.1 Introduction 
Abnormal network oscillations present in movement disorders are reflected in 
local field potentials (LFPs) recorded from the ventral intermediate (Vim) nucleus of 
thalamus in persons with essential tremor (ET) or Parkinson's disease (PD). Previous 
studies have noted intra-thalamic LFP coherence, measured from two recording 
microelectrodes, and LFP-tremor coherence, with tremor measured by EMG or an 
accelerometer, at the tremor frequency (4-8 Hz) and its first harmonic in ET and PD 
(Kane et al., 2009, Pedrosa et al., 2012). This suggested that elevated LFP theta band (4-7 
Hz) power was related to tremulous activity, although coherence between theta LFP and 
tremor was not always observed across subjects (Marsden et al., 2000, Pedrosa et al., 
2012). Alternatively, coherence was reported in all subjects with ET and PD between 
EMG-measured tremor signals and 8-27 Hz LFPs, which encompassed alpha (8-12 Hz) 
and beta (13-35 Hz) bands (Marsden et al., 2000). Holdefer and colleagues confirmed the 
presence of beta band LFPs in Vim in PD and ET (Holdefer et al., 2010). Beta oscillations 
in the basal ganglia appear to reflect an anti-kinetic state and may be a signature of PD 
(Bronte-Stewart et al., 2009), and these oscillations could be propagated to the thalamus 
through functional brain loops (Holdefer et al., 2010). Using linear and non-linear 
causality methods, Tass, et. al. demonstrated bidirectional coupling between both theta 
band and broadband (>2 Hz) LFPs recorded from the thalamus and resting tremor in PD 
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(Tass et al., 2010). The authors suggested that theta band oscillations, and possibly beta 
band oscillations, play an efferent role in generating tremor, with a delay for signal 
propagation of 1-2 tremor cycles. 
The aim of this work was to compare theta and beta band LFPs recorded from 
the DBS brain lead in subjects with ET or PD with the onset and amplitude of tremor. 
These signals were recorded during the intraoperative clinical study described in 
Chapter 4. We investigated whether an increase in theta band power or suppression of 
beta band power preceded the onset of tremor (Wang et al., 2007). These measurements 
were made with each subject holding his or her arm in one of three specified positions, 
which was intended to evoke tremor with different amplitudes and durations. We then 
studied frequency-time spectrograms of LFP and tremor signals for temporal association 
analysis. 
B.2 Methods 
We compared clinical recordings of LFP and tremor signals using frequency-time 
spectrograms. These signals were recorded intraoperatively using the identical 
experimental setup discussed in Chapter 4. Specifically, this protocol was performed in 
subjects EP12B (ET diagnosis), EP12C (PD), EP13A (ET), EP13F (PD), and EP13G (ET), 
and EP13I (ET). Three trials of 1 min length were conducted with DBS off, and at 30 s 
into each trial the subject held his or her arm in one of three specified positions for 20 s, 
and tremor was measured with an accelerometer. For all positions, the arm was held 
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straight out with the elbow fully extended, and either (1) parallel to the ground, (2) at a 
45° angle, or (3) perpendicular to the ground. LFPs were recorded differentially from 
DBS contacts using the DBS-ECAP instrumentation and sampled at 80 kHz. Signals were 
recorded either just when tremor was measured (EP12B and EP12C only) or through the 
entire 60 s trial period. Multitaper spectrograms were constructed from the tremor 
signals, after summing across the three accelerometer axes and detrending with local 
linear regression (2 s window size, 1 s step size), and from LFP signals (down-sampled 
to 10 kHz), using the Chronux analysis toolbox (www.chronux.org) in MATLAB 
(mtspecgramc function: 1 s sliding window, 0.2 s step size, 2 Hz bandwidth). 
B.3 Results 
Frequency-time spectrograms of LFP and tremor were constructed across clinical 
experiments (Fig. B.1). Large tremor power was observed at the fundamental frequency 
and its harmonics for short periods in EP12C (Fig. B.1A), and throughout the entire trial 
in the remaining experiments, including EP13G (Fig. B.1B). The amplitude and duration 
of tremor were similar between different arm positions within a given experiment, with 
the exception of relatively little tremor present in EP13A only when the arm was parallel 
to the ground. In EP12C, we observed short periods of theta and beta LFPs, with close 
temporal association to periods of large tremor (Fig. B.1A). Further, the amplitude of 
tremor matched the relative amount of LFP power. Although theta band LFP activity 
was not observed in the remaining experiments, we did observe beta band LFPs in 
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Figure B.1: Raw LFP signals (entire signal and 1 s zoomed view), LFP 
spectrograms, and tremor spectrograms from subjects (A) EP12C and (B) EP13G. 
Subjects held their arm for 20 s in the position indicated, and tremor and LFP signals 
were measured. There was a rest period of 40 s between each trial (thick black vertical 
lines in each plot), and the measurements made from the three distinct trials were 
merged into the one continuous recording shown. Hotter colors in the spectrograms 
correspond to greater power. 
EP13G (Fig. B.1B) and EP13F. However, there was no obvious association between beta 
activity and changes in tremor over time. Finally, theta and beta band activity was not 
observed in LFPs recorded from subjects EP12B, EP13A, or EP13I.  
 
Figure B.2: LFP spectrogram from subject EP13F, including recordings made 
during rest, movement, and posture. During each 60 s trial, the subject moved his arm 
from a rest position to one of the three designated arm positions at the ~30 s mark, 
and held it in that posture for 20 s. The dashed vertical line marks the start of tremor 
recording, after the subject had already moved to the designated arm position, and the 
solid vertical line marks the end of a trial. 
 Spectrogram analysis was also conducted on the entire LFP signal, which 
included periods of rest, movement to the designated arm position, and posture during 
tremor measurement. We observed a reduction in the low beta band (~13 Hz) during 
movement to the designated arm position, preceding the tremor measurement, in 
subject EP12F (Fig. B.2). However, no differences were detected between the rest and 
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tremor periods. Moreover, we did not observe beta reductions during movement in the 
other three subjects for which LFPs were recorded during the entire trial period. 
B.4 Discussion 
We investigated relationships between LFP activity and the onset and amplitude 
of tremor. High LFP power was observed in the theta and/or beta band in two subjects 
with PD, and in the beta band in one subject with ET, whereas no LFP activity was 
recorded in three other subjects, two with ET and the other with PD. In one subject, beta 
band activity was reduced during movement from rest to the designated arm position, 
similar to observations in the basal ganglia (Cassidy et al., 2002, Levy et al., 2002, Priori 
et al., 2002, Kuhn et al., 2004, Williams et al., 2005). We found a tight temporal 
association between increased theta and beta power and the onset of tremor, and 
between the relative magnitude of LFP and tremor power, in only one subject, EP12C 
(Kane et al., 2009, Holdefer et al., 2010, Pedrosa et al., 2012). The inconsistent association 
between LFP and tremor power across recordings was in agreement with prior work 
(Marsden et al., 2000, Pedrosa et al., 2012). Further, it is difficult to rule out the 
possibility that the LFP activity recorded in EP12C was a motion artifact, given the 
presence of LFP peaks at the tremor frequency and its harmonics. Nevertheless, our 
experimental setup was designed to reduce motion artifact in LFP recordings by using a 
large separation distance between the arm used for tremor measurement and the 
location of the recording reference electrode, which was placed on the contralateral 
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thigh. Therefore, the relationship between LFP activity and tremor was not reproducible 
within the relatively small patient population that we tested, and additional experiments 
may help to elucidate any association between these signals.   
There were several limitations to this work that should be addressed in future 
work. First, we did not generate tremor with sufficiently different amplitudes or 
durations using the three arm positions tested (except in EP13A), which would have 
been valuable in comparing the relative power of LFP and tremor activity. Using 
additional arm orientations, such as holding the hand near the face, or asking the subject 
to perform an action, may have led to greater differences in tremor. Second, coherence 
analysis could be used to quantify the relationship between LFP and tremor, as 
performed previously (Marsden et al., 2000, Kane et al., 2009, Pedrosa et al., 2012). 
However, temporal information is lost with a traditional coherence calculation, and 
time-dependent coherence analysis (Wang et al., 2007) may be more useful for this 
application. 
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Appendix C: Investigating a harmaline tremor model in 
anesthetized cats 
C.1 Introduction 
Our previous preclinical studies of evoked compound action potential (ECAP) 
recording during deep brain stimulation (DBS) lacked a behavioral measure of the 
motor symptom response to stimulation (Chapters 2 & 3). However, identifying 
signatures of therapeutic effectiveness requires quantifying changes in tremor across 
thalamic DBS parameters, and correlating these changes with ECAP characteristics. The 
objective of these experiments was to record simultaneously changes in ECAPs and 
tremor in a cat model of essential tremor (ET). However, we were not able to generate 
consistent tremor despite repeated experiments across a range of conditions. 
Harmaline-induced tremor is a widely accepted preclinical model of tremor 
(Martin et al., 2005) that shares many features with ET in humans (Wilms et al., 1999). 
Specifically, harmaline administration in cats elicits a "fine generalized tremor" at 8-12 
Hz, along with periodic muscle contractions of 1-10 s duration, and is generated by 
rhythmic activation in the olivo-cerebellar system (de Montigny and Lamarre, 1973), 
consistent with the etiology of ET in humans (Deuschl and Elble, 2000). A partial lesion 
of the lateral cerebellar nuclei or superior cerebellar peduncle can lower the tremor 
frequency on the lesioned side to that of ET (6-7 Hz) (Lamarre, 1995). Single-unit 
recordings after harmaline administration showed a rhythmic firing of inferior olive 
neurons (8-12 Hz discharge), which induced a corresponding rhythmic response in 
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climbing fibers and Purkinje cells, and resulted in a bursting firing pattern in the 
fastigial nucleus, reticular formation, and vestibular nuclei (de Montigny and Lamarre, 
1973, Batini et al., 1979, Weiss, 1982). Harmaline may act on GABA receptor-controlled 
gap junctions, enhancing electronic coupling of cells in the inferior olive, and facilitating 
the pacemaker behavior of these neurons (Llinas et al., 1974, Lamarre, 1995). The 
rhythmic activity of the cerebellum is transmitted to downstream spinal motor neurons 
via the reticulospinal and vestibulospinal pathways (Lamarre, 1995), and both the motor 
neurons and muscle tremor activity were shown to be phase-locked to cerebellar activity 
(de Montigny and Lamarre, 1973, Weiss, 1982). Tremor is typically generated 3-10 min 
after harmaline is administered, with the effect lasting for 30 min to 2 hr, and is elicited 
both during rest and during movement (Wilms et al., 1999). 
The objective of this work was to generate harmaline tremor in anesthetized cats. 
In prior studies, cats were usually decerebrated (Villablanca and Riobo, 1970, de 
Montigny and Lamarre, 1973, Weiss, 1982) or awake (Villablanca and Riobo, 1970, Batini 
et al., 1981a) when harmaline was administered. Further, after tremor commenced, 
Flaxedil was used to induce paralysis and eliminate proprioceptive feedback 
(Villablanca and Riobo, 1970, de Montigny and Lamarre, 1973, Batini et al., 1979, Batini 
et al., 1981a, Batini et al., 1981b, Weiss, 1982). Pentobarbital anesthesia was used during 
harmaline treatment in one study (Batini et al., 1979), but large doses of barbiturates can 
block the resulting tremor (Lamarre, 1995). It was necessary to have the animals 
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anesthetized in our acute ECAP recording study, which was performed under non-
sterile, non-survival conditions. Additionally, decerebration could have affected the 
ECAP response by destroying thalamocortical-corticothalamic connections. We tested 
whether harmaline could generate tremor in cats anesthetized with alpha chloralose or 
pentobarbital. 
C.2 Methods 
All animal use and experimental protocols were reviewed and approved by the 
Duke University Institutional Animal Care and Use Committee. We administered 
harmaline in seven anesthetized cats and monitored the animals for any manifestations 
of tremor. Cats were either lying prone or were elevated with limbs hanging free. The 
animals were initially anesthetized with ketamine HCl (35 mg/kg i.m.), and four cats 
were maintained with alpha chloralose (65 mg/kg i.v. supplemented at 15 mg/kg as 
needed), whereas the remaining three cats were maintained with pentobarbital (10 
mg/kg i.v. supplemented at 2-5 mg/kg as needed). There was a latency of at least 12 
hours from when ketamine was administered to harmaline delivery. Harmaline (Sigma-
Aldrich, 51330) or harmaline HCl (Sigma-Aldrich, H1392) were given intravenously at 2-
20 mg/kg, with progressive dosing of 2 or 5 mg/kg increments in some experiments 
(Villablanca and Riobo, 1970, de Montigny and Lamarre, 1973, Batini et al., 1979, Batini 
et al., 1981a, Batini et al., 1981b, Fagni et al., 1982). We waited at least 10 min after each 
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dose of harmaline for a tremor response. A summary of the anesthesia and harmaline 
dosages, as well as the body positioning of the animals, is provided in Table C.1. 
Table C.1: Summary of anesthesia and harmaline dosages, as well as body 
position, across cat experiments. The tremor response following harmaline 
administration is also provided. 
Cat 
Anesthesia 
Dosage 
Harmaline 
Dosage 
Body 
Position 
Tremor Response 
A -chloralose 5 mg/kg harmaline Prone None 
B -chloralose 10 mg/kg harmaline Prone None 
C 
Pentobarbital       
(2 mg/kg suppl.) 
20 mg/kg harmaline        
(5 mg/kg increments) 
Elevated 
Tremor in forelimbs & 
hind limbs and periodic 
muscle contractions 
elicited immediately after 
administration of 20 
mg/kg harmaline 
D -chloralose 20 mg/kg harmaline Elevated None 
E 
Pentobarbital       
(2 mg/kg suppl.) 
20 mg/kg harmaline HCl  
(5 mg/kg increments) 
20 mg/kg harmaline        
(5 mg/kg increments) 
Elevated 
Slight tremor with 15 
mg/kg harmaline HCl 
after 5 min 
F 
Pentobarbital       
(5 mg/kg suppl.) 
10 mg/kg harmaline        
(5 mg/kg increments) 
Elevated 
None; cat died at 1 min 
after administration of 10 
mg/kg harmaline 
G -chloralose 
10 mg/kg harmaline 
(2 mg/kg increments) 
Prone 
Slight tremor with 8 
mg/kg harmaline after 15 
min 
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C.3 Results 
Tremor induction in cats by harmaline administration was inconsistent between 
experiments (Table C.1). A pronounced tremor was generated only in one of the seven 
cats tested (cat C), in which we administered pentobarbital anesthesia and a large dose 
of harmaline (20 mg/kg). This tremor was observed in the cat's free-hanging forelimbs 
and hind limbs for over 15 min, as were periodic muscle contractions of ~10 s duration 
each (de Montigny and Lamarre, 1973). In addition, we observed a slight tremor for 
approximately 5 min in two other animals (cats E and G), one anesthetized with 
pentobarbital and the other with alpha chloralose, after administration of 8-15 mg/kg 
harmaline or harmaline HCl. In the remaining experiments, no tremor response was 
observed. However, cat F died almost immediately after a moderate dose of harmaline 
(10 mg/kg) was delivered. 
C.4 Discussion 
We investigated the induction of tremor by harmaline in anesthetized cats by 
testing different anesthesia regimens, harmaline formulations and dosages, and body 
positions. We generated a pronounced tremor only in cat C, anesthetized with 
pentobarbital, using a large dose of harmaline, consistent with literature (Batini et al., 
1979). However, this was not replicated in other animals, either with pentobarbital or 
alpha chloralose anesthesia, except for a slight tremor in two other experiments with 
either harmaline or harmaline HCl. While the body of cat C was elevated so that the 
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limbs were hanging free, it is unclear if this was critical for observation of tremor. 
Personal communications with Dr. Jaime Villablanca, who had performed similar work 
(Villablanca and Riobo, 1970), suggested that harmaline tremor can only be generated in 
awake or decerebrated cats. The reason for the death of cat F after harmaline 
administration remains unclear. 
There are several other alternative models of tremor in the cat that may be useful 
for our application, although these were developed in unanesthetized animals. First, 
MPTP was shown to generate "tremulousness or shaking of head and extremities" in cats 
(Schneider et al., 1986), and is a good model of Parkinson's disease in primates (Wilms et 
al., 1999). Second, cholinergic drugs, such as carbachol, generated fine head tremor and 
coarse limb tremor with a frequency of 21 Hz (Connor et al., 1966). Third, a lesion in the 
ventromedial tegmentum elicited a 4-8 Hz tremor (Kaelber, 1963). Successful 
identification of a tremor model for use in anesthetized cats would provide a behavioral 
measure of the motor symptom response to DBS, which could be correlated to 
characteristics of recorded ECAPs (or local field potentials) to enable identification of 
signatures of therapeutic effectiveness. 
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